Stock Code: 688363.SH
Sustainability Report
Bloomage Biotechnology Corporation Limited
Bloomage Biotech 2025 Sustainability Report
About This Report
About Bloomage Biotech
Report Introduction
This report is the third Sustainability Report (hereinafter referred to as "this Report") released by Bloomage Biotechnology Bloomage Biotech (SSE Stock Code: 688363), founded in 2000, is a synthetic biology-driven biotechnology company,
Corporation Limited (hereinafter referred to as "Bloomage Biotech", "the Company" or "We") (SSE Stock Code: 688363). committed to leading the global health and beauty industry through scientific and technological innovation.
It discloses information pertinent to our sustainable development and fulfilment of social responsibilities. Bloomage Biotech pioneered the bio-manufacturing of hyaluronic acid, establishing a globally leading position in the
production of carbohydrates and other bioactive substances. With breakthrough technologies in high-end hyaluronic acid
Reporting Scope
research and development, we have become a trusted partner for numerous world-leading universities, research
This Report covers Bloomage Biotechnology Corporation Limited and its subsidiaries. Unless otherwise stated, the institutions, hospitals, and Fortune 500 companies. Guided by a vision of pure scientific exploration, we are deeply involved
reporting scope is consistent with that of the Annual Report. The reporting period of this Report covers the period from in cutting-edge research in glycobiology and cell biology.
January 1, 2025 to December 31, 2025. To ensure continuity, integrity and comparability, certain content extends beyond
Building on this foundation, we continue to deepen our research into bioactive substances closely related to human health,
the aforementioned reporting period, with detailed explanations provided within the Report.
focusing on three key areas - extracellular matrix (ECM), intercellular communication, and intracellular health. We are
Basis of Compilation accelerating the translation of the life science findings and technologies into innovative solutions for anti-aging intervention
This Report follows the Guidelines No. 14 of Shanghai Stock Exchange for Self-Regulation of Listed Companies— and tissue regeneration.
Sustainability Report (Trial), with reference to the GRI Sustainability Reporting Standards (hereinafter referred to as the These breakthroughs are supported by our globally leading synthetic biology and biomanufacturing platform and its pilot-
"GRI Standards") issued by the Global Sustainability Standards Board, the IFRS S1 General Requirements for Disclosure scale conversion facilities. This platform has become a key industry infrastructure, not only driving our own R&D and
of Sustainability-related Financial Information, the IFRS S2 Climate-Related Disclosures, the United Nations Sustainable innovation but also providing transformation support for global research institutions and industry partners, from laboratory
Development Goals (SDGs), the Ten Principles of the UN Global Compact (UNGC) ("the Ten Principles of the UNGC"), research to commercial application.
key topics for CDP ratings and themes assessed by EcoVadis. This Report contains a detailed index in the appendix for
Currently, we offer comprehensive solutions across our four major business segments - raw materials, pharmaceuticals &
readers' quick reference.
medical aesthetics, skin science, and nutritional science. Our portfolio of brands includes BIOHYALUX, QuadHA,
Data Sources MedRepair, Bio-MESO, Agualuna, and Bloomage Health.
The information presented in this Report is sourced from Bloomage Biotech's internal official documents, statistical reports, Upholding our corporate mission of "Let every life be alive", we integrate scientific excellence, industrial scale, and a global
third-party surveys, and relevant public sources. Financial data are derived from the Company's Annual Report. Unless perspective to continuously advance the future of life sciences, bringing health and beauty to the world.
otherwise stated, all monetary amounts are denominated in Chinese Renminbi (CNY).
Board Statement
This Report has been reviewed and approved by the Board of Directors of Bloomage Biotech. The Board hereby affirms
that this Report contains no falsifications or misleading statements, and takes full responsibility for the truthfulness, Chairwoman and General Manager's Message
accuracy, and completeness of its contents. 2025 marks the 25th anniversary of Bloomage Biotechnology Corporation Limited ("Bloomage Biotech"). Reflecting on our
Report Release development journey, we have always been convinced that corporate vitality stems from sustained scientific and
This Report is published in both Simplified Chinese and English. In the event of any inconsistency, the Simplified Chinese technological innovation capabilities, as well as sound and forward-looking operational capabilities. Amid profound global
realignments and continuous industrial transformation, our ability to advance steadily is fundamentally rooted in our
version shall prevail.
unwavering commitment to the mission of "Let every life be alive". We gain insights into global trends with a global vision,
Electronic copies of this Report in both languages can be accessed on the websites of the Company and the Shanghai while deeply rooted in the Chinese market, steadily advancing toward our goal of becoming "an endogenous growth
Stock Exchange: enterprise with ESG at its core". As a participant of the United Nations Global Compact (UNGC) and a signatory to the
https://www.bloomagebiotech.com/ Women's Empowerment Principles (WEPs), we actively integrate globally recognized sustainability tenets into our strategy
and operations. Therefore, sustainable development serves as a vital pathway for us to align with the tides of the times and
http://www.sse.com.cn/
reshape our core competitiveness.
Feedback As a biotechnology and biomanufacturing enterprise driven by synthetic biotechnology, Bloomage Biotech remains
For inquiries or feedback regarding this Report and its contents, you are welcome to contact us through the following committed to embedding the philosophy of sustainable development into its corporate strategy and operations. We promote
contacts: technological innovation and green value creation, continuously contributing to the improved public health and quality of
Office address: 33/F, Building D, Bloomage International Center, No. A6, Jianguomenwai Street, Beijing, China life. To foster the overall progress of the industry, we established an open pilot-scale platform for synthetic biology. This
platform not only serves our internal innovation needs but also opens its doors to external research institutions and industry
E-mail address: esg@bloomagebiotech.com
partners, providing critical infrastructure for the commercialization of research outcomes. By sharing this key industrialized
infrastructure, we have provided essential support for commercializing R&D outcomes across the industry, facilitated
synergistic collaboration within the industrial chain, and bolstered the continuous enhancement of China's biomanufacturing
capabilities.
In 2025, our practices in the field of sustainability received widespread recognition. We were honored with 12 awards,
including the "2025 Best Practice Case of Sustainable Development for Listed Companies" by the China Association for
Public Companies and the "China Top 100 ESG Listed Companies" at the 19th China Listed Companies Value Forum.
Furthermore, the Carbon Disclosure Project (CDP) awarded us ratings of A- for Climate Change and A for Water Security,
both representing leadership-level performance. Additionally, our EcoVadis rating was elevated to the Silver Medal level.
While garnering these honors, we actively amplified our voice as an industry leader, sharing the "Bloomage Experience"
with the world. I personally traveled to Geneva to attend the International Cooperation Seminar on Sustainable Brand
Building, sharing insights on transforming sustainability concepts into endogenous growth drivers. Furthermore, at the 25th
Anniversary Commemoration of the United Nations Global Compact, I emphasized that sustainability must be integrated
throughout the entire organizational chain, from Management to frontline employees. Additionally, our executive
representatives attended the 2025 China Fragrance and Cosmetics Industry Sustainable Development (ESG) Forum to
Bloomage Biotech 2025 Sustainability Report
deliver keynote speeches and share our management practices. These recognitions provide positive feedback for our footprint, several key products have seen a significant decrease compared with the base year, and the effectiveness of
continued integration of ESG and business strategy, reinforcing our confidence in long-term steady growth. renewable energy application has gradually become evident.
Pursuing a governance system featuring compliance assurance and digital empowerment We have integrated low-carbon requirements into the early stages of product R&D and process design, steadily advancing
toward the goal of "reducing total carbon emissions by 50% by 2030 compared to 2023". Regarding the circular economy,
High-quality development must be founded on a robust and effective corporate governance framework. At Bloomage
we have purchased FSC-certified eco-friendly paper to upgrade our green packaging system. Moreover, we have
Biotech, we view corporate governance as an endogenous driver for the long-term growth of corporate value. This year,
normalized the year-round operation of the BIOHYALUX Single-use Empty Tube Recycling Program, facilitating the
we fully upgraded our ESG management system by releasing the Sustainable Development Management Policy and the
efficient conversion of waste packaging into renewable resources. In 2025, we recycled a total of 21,276,700 disposable
ESG Management System. These documents cover key sustainability topics, defining development principles, strategic
empty tubes from the BIOHYALUX brand and 3,852,700 of other brands, promoting packaging recycling and public
vision, and management requirements. We also established and disclosed specific targets covering carbon reduction,
engagement in low-carbon practices. Furthermore, we embedded sustainability into our corporate culture by organizing the
waste management, supplier ESG management, and compliance & business ethics. By integrating key ESG indicators into
the organizational performance evaluation system, we achieved deep integration of sustainability goals with daily first "carbon neutrality" anniversary celebration, fulfilling our green responsibilities with tangible actions to safeguard a
operations. Besides, our Beijing Headquarters and Jinan Production Base were certified to ISO 37301 Compliance sustainable future.
Management System and accepted annual surveillance audits. Furthermore, we commissioned third-party audits for the Adopting a people-centric approach to create long-term value with society
ISO 37001 Anti-bribery Management System to ensure continuous system operation & optimization. We also conducted a We adhere to a people-oriented development philosophy, continuously refining a diverse, equitable, and inclusive talent
systematic audit of business ethics standards covering major business areas. To better demonstrate our practices, development system. We offer employees competitive career paths and growth opportunities while refining multi-channel
philosophy and achievements to the public in a more transparent manner, the Sustainability section was launched as an promotion mechanisms to stimulate organizational vitality and innovation potential. Regarding employee well-being, we not
independent module on our new official website. These achievements and actions further strengthen our confidence in only offer comprehensive statutory and supplementary benefits but also safeguard employee rights through digital
aligning ESG with business strategy and supporting long-term steady growth. communication channels and democratic management mechanisms, creating a supportive and resilient organizational
Concurrently, we continuously refined the collaborative mechanism for risk control, compliance management, and internal atmosphere. Safety and health are our solemn commitments to employees. We continuously optimize our Environmental,
audit. By embedding compliance requirements into the entire process of business decision-making and execution, we Health, and Safety (EHS) management system, with production bases in Jinan, Tianjin, and Dongying certified to ISO
further solidified the institutional foundation for business ethics and standardized operations. Regarding stakeholder 45001. In terms of social responsibility, 2025 marked the fifteenth year of our "In Cloud" public welfare campaign. Over the
management, we maintained an open, transparent, and responsible attitude, engaging in continuous communication with past fifteen years, we have prioritized both cultural heritage and industrial empowerment. Leveraging synthetic
shareholders, employees, customers, suppliers, partners, and the public to foster long-term, stable, and trust-based biotechnology to tap into the potential of unique resources in remote regions, we have transformed scientific achievements
relationships. Furthermore, embracing the digital wave, we actively explored the application of AI technology to enhance into high value-added industries that benefit the populace, contributing to rural revitalization with technological strength and
operational efficiency and empower employees. Leveraging intelligent technology, we enhanced transparent governance demonstrating the warmth of corporate responsibility.
and rational decision-making, thereby providing a solid governance foundation for sustainable development. Looking ahead, we will continue to prioritize technological innovation, underpinned by synthetic biotechnology. We remain
Driving innovation with synthetic biology and upholding the bottom line of product quality dedicated to the long-term track of aging intervention and life health, seeking certain growth amidst an uncertain
environment. With firm resolve, we will drive the synergistic evolution of ESG and business strategies, striving for the mutual
Innovation is the foundation of our development, underpinned by synthetic biotechnology as our core driving force. Adhering
enhancement of corporate, social, and environmental values, and contributing lasting strength to human health and
to a vision of scientific exploration, we delve into the frontiers of glycobiology and cell biology. We focus on three key R&D
directions - extracellular matrix (ECM), intercellular communication, and intracellular mechanisms. Leveraging a world- sustainable development.
leading synthetic biology and biomanufacturing platform, we accelerate the transformation of research findings into
products and systematic solutions, providing essential support for global research and industry partners in bridging the gap
from laboratory to commercialization.
In 2025, we intensified R&D investment to refine an innovation system that spans basic research, pilot conversion, and
industrialization, thereby driving synergistic development across raw materials, medical terminals, skin science, and
nutritional science. Leveraging our globally leading pilot conversion platform for synthetic biology, we achieved
technological breakthroughs in core substances such as Polydeoxyribonucleotide (PDRN), Micro-crosslinked Hyaluronic
Acid (Micro-crosslinked HA), and Non-animal Chondroitin Sulfate (Non-animal CS). From the extracellular matrix (ECM) to
intracellular energy metabolism and intercellular communication, we continuously optimized our R&D layout regarding
aging intervention mechanisms. While pursuing innovation, we upheld the principle that quality remains paramount. This
year, our hyaluronic acid raw material plant passed the on-site audit for current Good Manufacturing Practice (cGMP) from
U.S. Food and Drug Administration (FDA) with "zero defects", demonstrating our enduring commitment to quality
management and product responsibility.
Building upon stringent quality management, we integrated sustainable supply chain management into its product
responsibility system and established the Supplier ESG Management System 1.0. We promoted the signing of the Supplier
Code of Conduct and conducted ESG operational training. We also established carbon data collection mechanisms and
distributed ESG self-assessment questionnaires (covering greenhouse gas, labor, human rights, environmental, and
governance dimensions) to suppliers. With these actions, we extended sustainability requirements to the upstream supply
chain. Moreover, recognized for exceptional low-carbon transition practices, we received the "Pioneer Supplier in Carbon
Reduction" award from clients, marking substantive recognition of our sustainability capabilities by core customers.
Adhering to green and low-carbon operations to promote circular and symbiotic development
Facing the long-term global challenges of climate change and resource constraints, we have deeply integrated green and
low-carbon philosophies into our overall corporate development. Following the first full value-chain greenhouse gas
accounting and verification in accordance with international standards in 2024, we continued to advance full value-chain
carbon accounting and verification in 2025. By continuously improving data quality and management capabilities, we
solidified the practical foundation for comprehensive carbon management. Driven by synthetic biotechnology, we replaced
traditional energy-intensive and highly polluting production methods with advanced biomanufacturing, thereby enhancing
resource efficiency at the source. During the reporting period, we achieved phased progress in its low-carbon transition. In
terms of carbon emissions, our key production bases have achieved a significant reduction. Regarding product carbon
Bloomage Biotech 2025 Sustainability Report
Composition of the Board of Directors Convocation of Three Types of Meetings
Shareholders' Meetings: 2 sessions
The Board consists of 9 directors, including 3 independent Board Meetings: 8 sessions
directors and 2 female directors. Special Meetings of Independent Directors and Specialized
Committee Meetings: 14 sessions
Corporate Governance and Sustainable During the year, the Company organized multiple special training sessions for directors and senior management. The
curriculum covered key areas such as independent directors' performance of duties, Audit Committee supervision,
Development compliant disclosure of annual reports, and corporate governance practices, continuously reinforcing the compliance
awareness and governance capabilities of the core management team.
A robust governance system serves as the cornerstone of an enterprise's enduring success. In 2025, Bloomage Biotech
continued to optimize its corporate governance and sustainable development management framework, while Sustainable Development Management System
simultaneously optimizing and upgrading its risk control, compliance, and audit systems. By strengthening compliant
operations, business ethics, and information security management, we continuously refined our governance mechanisms Sustainable Development Management Framework
and enhanced operational resilience. In this way, we safeguarded the fundamental rights and interests of stakeholders,
Bloomage Biotech has established an ESG governance structure and management mechanism characterized by top-level
and steadily increased the overall corporate value.
leadership and tiered implementation. This mechanism empowers the Company with the capability to advance ESG
management practices through multi-faceted, multi-form, and multi-departmental collaboration.
Corporate Governance
In strict accordance with the Company Law of the People's Republic of China and the latest regulatory requirements of the The Board of Directors is responsible for overseeing and coordinating all ESG-related matters.
China Securities Regulatory Commission and the stock exchanges, Bloomage Biotech continuously improves its corporate It reviews and approves relevant recommendations from the ESG Committee, ensuring that the
Board of Directors
governance system. During the year, the Company revised its Articles of Association in accordance with the Guidelines for Company implements sustainable development principles from top to bottom while integrating
the Articles of Association of Listed Companies and other regulations. Concurrently, it revised over 20 internal management ESG management into business decision-making processes
policies, including the Rules of Procedure for General Meeting of Shareholders, the Rules of Procedure for the Board of An ESG Committee is established under the Board of Directors, with Independent Director Yao
Directors, and the Working System for Independent Directors. Additionally, it abolished the policies related to the Board of Yang serving as Chairman. The committee operates under the supervision of the Board of
Supervisors in accordance with the law. It also ensured that the corporate governance structure remained consistent and ESG Committee
Directors. Aiming to achieve high-quality sustainable development, it is responsible for
effectively aligned with the latest laws and regulations. deliberating on ESG-related matters and reporting to the Board.
The Company continues to deepen the fiduciary duties of directors and executives by explicitly defining conflict of interest The ESG Management Department is responsible for the Company's ESG management,
prevention mechanisms in the Articles of Association. It strictly prohibits the misuse of authority for improper gains and including tasks of building the ESG management system, assessing ESG risks, formulating
refines regulatory requirements concerning commercial bribery, related-party transactions, and horizontal competition. ESG Management ESG strategic plans, driving the implementation of key ESG projects, evaluating and optimizing
Valuing the supervisory, checks-and-balances, and advisory functions of independent directors, it improves relevant Department key ESG indicators, and managing ESG communication and information disclosure. The
provisions in the Articles of Association to enhance their performance capabilities and fully leverage their roles. Meanwhile, department reports annually to the ESG Committee on work achievements and future plans,
it continuously optimizes standardized information disclosure processes, elevating governance transparency and operating under its guidance and supervision.
compliance standards in all aspects.
ESG Working Groups have been established across all business lines, production bases, and
The Company has established a corporate governance structure comprising the General Meeting of Shareholders, the ESG Working Group functional departments, with dedicated teams and designated personnel responsible for
Board of Directors, and the senior management, characterized by clearly defined powers and responsibilities, and coordinating and implementing ESG-related tasks.
standardized operations. The distinct yet collaborative roles of these governing bodies provide a solid guarantee for the
science-based formulation and compliant execution of major decisions, as well as the improvement of operational quality
and efficiency. The General Meeting of Shareholders, composed of all shareholders, serves as the supreme authority In 2025, both the Board of Directors and the ESG Committee each reviewed ESG matters once, while the Chairwoman
responsible for deliberating and approving major corporate matters. The Board of Directors acts as the core governance and General Managerreviewed these matters once. The review covered major achievements regarding the ESG
body, exercising core functions of strategic decision-making and supervisory management. The senior management is management system, sustainability strategy, low-carbon transition planning, supplier ESG management system, ESG
responsible for organizing and implementing specific production and operational activities. During the year, the Company digital management, sustainable corporate culture development, and information disclosure. Meanwhile, the Management
successfully completed the reform of the Board of Supervisors system. To be specific, it integrated the original functions of reviewed and approved the 2025 Annual Plan for Key ESG Projects, covering supplier ESG management, life cycle
the Board of Supervisors into the Audit Committee, Remuneration and Assessment Committee, and Special Meetings of assessment (LCA) management for products, organizational capacity building for sustainable development, and ESG
Independent Directors, all under the Board of Directors, thereby streamlining the governance structure and enhancing management system optimization.
operational efficiency.
The Board of Directors has established six specialized committees - the Strategy Committee, Audit Committee, Nomination Sustainability Strategy
Committee, Remuneration and Assessment Committee, Environmental, Social and Governance (ESG) Committee, and In 2025, the Company upgraded its sustainable development policy framework in all fronts and officially released the
Risk Management Committee. These committees assume supervisory, evaluative, and advisory functions in their Sustainable Development Management Policy and the ESG Management System. These policies cover key sustainable
respective fields, systematically supporting the Board in scientific decision-making and effective governance to ensure the development topics, defining development principles, strategic visions, and management requirements to continuously
standardized and efficient operation of the corporate governance mechanism. enhance operational resilience and innovation capabilities, as well as the adaptability to future market changes. At the
implementation level, the Company integrated key ESG indicators into the organizational performance assessment system,
The Company places high importance on the diversity of the Board's composition. When confirming director candidates,
driving the deep alignment of sustainable development goals with daily operations. This year, the achievement rate of
multiple factors are considered on all fronts, including gender, age, cultural and educational background, professional
relevant targets reached 100%, effectively validating the effectiveness of strategic execution.
experience, skills, and knowledge structure. In 2025, the Company re-elected the new Board of Directors and appointed
the senior management. In this case, the Board members selected possess profound backgrounds in diverse fields with Guided by its strategy, the Company deeply practiced a high-quality development model that balances diverse interests,
complementary professional capabilities, facilitating more rational, comprehensive, and forward-looking decisions in an integrates green concepts, and enhances social welfare. We continued to focus on three core pillars - sustainable
increasingly complex and volatile market environment. operations, sustainable society, and sustainable products. Centered on six key areas - corporate governance, ESG risk
Bloomage Biotech 2025 Sustainability Report
management, sustainable innovation, environmental impact management, employee rights protection, and social During the year, the Company organized eight special sharing sessions centered on ESG concepts, policies, industry
empowerment & public welfare, we steadfastly implemented various management indicators and targets. The Company trends, and professional skills. These sessions covered over 20 departments across the front, middle, and back offices,
consistently adhered to a systematic, evidence-based, and rational approach, dedicated to strengthening operational attracting nearly 400 participants. Concurrently, we innovated our communication approaches by launching four themed
resilience and continuously elevating the capacity for future development. campaigns on our internal platform, "Little Horn", aligning with occasions such as World Earth Day, International Day for
Biological Diversity, World Environment Day, and World Food Day. These initiatives continuously advocated green office
practices and low-carbon lifestyles.
We continuously optimize corporate governance and ESG risk management, identifying,
In terms of cultural practice, the Company held its first-ever carbon neutrality anniversary celebration. A total of 99
assessing, and managing key risks. We establish a sound, transparent, and equitable
Sustainable Operations employees participated in small-sum donations to help offset the 82 tons of carbon emissions generated by the event.
corporate governance mechanism to support the Company's long-term and sound
operation. Additionally, we collaborated with our brand, BIOHYALUX, on an empty tube recycling program to create eco-friendly
souvenirs, vividly integrating sustainability into our corporate culture and achieving a synergy between concept
We focus on innovation to develop more efficient and environmentally friendly dissemination and practical action.
technologies and products. We optimize procurement, production, and other processes
Sustainable Products In terms of digital management, the Company successfully launched the ESG Data Management Platform 2.0 this year.
to reduce emissions, energy consumption, and resource consumption, achieving
sustainability across the product lifecycle. This upgrade enhanced capabilities ranging from data collection, verification, and analysis to report generation on all fronts,
effectively strengthening the precision of ESG management and the efficiency of decision support.
We prioritize employees' rights and interests and strive to create a diverse, inclusive,
and equitable working environment. We engage in social empowerment and public Sustainability Performance Management
Sustainable Society
welfare activities, leveraging technology and resources to create greater value for
society. In 2025, Bloomage Biotech continued to consolidate the long-term mechanism linking ESG performance to compensation,
ensuring the effective extension of the sustainability strategy from top-level design to the execution level. Throughout the
year, the Company integrated ESG Key Performance Indicators (KPIs) into the organizational performance assessment
system. These indicators were incorporated into the annual personal performance commitments of the senior management,
Bloomage Biotech Sustainable Development Framework
heads of core functional departments, and personnel in key positions, maintaining the established weight of ESG indicators
in the comprehensive assessment. Assessment results were directly linked to annual performance ratings and served as
a key basis for salary adjustments and bonus distribution. This clear incentive and constraint mechanism actively drives
the Management to fulfill their sustainable development responsibilities.
Stakeholder Engagement and Double Materiality Assessment
Stakeholder Engagement
Bloomage Biotech places high importance on the ESG concerns of all stakeholders and listens to the opinions and
suggestions of regulatory bodies, shareholders, employees, clients, partners, communities, and other parties. Through
normalized communication, the Company fosters internal, external understanding and consensus, integrating key
expectations into business management and strategic decision-making processes. Furthermore, it regularly discloses
progress through channels such as annual reports, continuously enhancing information transparency and stakeholder trust.
Stakeholder Engagement Mechanism of Bloomage Biotech
Stakeholders Expectations and Demands Engagement and Response
·Compliant operations
·Supervision and inspection
·Tax compliance
·Daily management
Government and Regulatory Agencies ·Economic development
·Meetings and exchanges
·Anti-corruption ·
·Public consultation
·Product responsibility
·General Meeting of Shareholders
·Corporate governance
·Investor exchange meeting
As a member of the Supplier Ethical Data Exchange (Sedex), the Company benchmarks against internationally recognized ·Risk management
·Information disclosure
responsible supply chain standards. We conduct Sedex Members Ethical Trade Audits (SMETA) or equivalent audits and ·Shareholders' rights and interests
Shareholders and Investors ·Field investigations
improvement activities based on business needs. These activities aim to enhance the management level and transparency ·ESG performance
·Teleconferencing
of the supply chain in terms of labor and human rights, health and safety, business ethics, environment and other aspects. ·Business ethics
·Email and online engagement
·Information transparency
Sustainability Culture Development platforms
The Company is dedicated to enhancing employees' awareness and practical capabilities regarding sustainable ·Employee rights protection ·Employee roundtables
development. We formulated and implemented annual plans for ESG training and corporate culture, integrating ESG ·Employee compensation and benefits ·Staff training
concepts into specialized training to ensure that employees at all levels understand and fulfill relevant requirements. To Employees
·Employee training and development ·Employee satisfaction surveys
establish a long-term learning mechanism, we launched an online ESG knowledge base this year, providing all staff access ·Employee safety and health ·Performance assessments
to core ESG documents and creating a digital resource platform for ready access and learning. Additionally, the corporate
website was revamped to feature a "Sustainability" section, showcasing our philosophy, actions, and performance in ·Product responsibility ·Client satisfaction surveys
environmental, social, and governance aspects, thereby improving the efficiency and transparency of internal, external Clients and Consumers ·Excellent services ·Customer service hotlines
ESG information communication. ·Client Privacy Protection ·Social media platforms
Bloomage Biotech 2025 Sustainability Report
Stakeholders Expectations and Demands Engagement and Response Based on the principles of "Double Materiality", Bloomage Biotech assessed 26 ESG issues, identifying 24 issues with
impact materiality and 2 issues with financial materiality, thereby determining the key content of this Report.
·Client follow-up
·Honorable fulfillment of contracts
·Supplier assessments
·Sustainable procurement
·Supplier training
Suppliers and Partners ·Green products
·Supplier meetings and exchanges
·Product responsibility
·Strategic cooperation
·Intellectual property protection
·Public welfare and charity undertakings ·Public welfare activities
·Environmental protection ·Community events
Communities
·Rural revitalization ·Media communication
·Community development ·Public consultation
·Scientific and technological innovation ·Industry exchanges
Industry Associations and Chambers of
·Industry development ·Formulation of industry standards
Commerce
·Product responsibility ·Field visits
·Product responsibility ·Press conference
·ESG performance ·Social media platforms
Media
·Response to climate change ·Public opinion monitoring
·Business performance ·Field interviews
·University-enterprise cooperation
·Scientific research innovation
Universities and Research Institutes ·Academic research
·Talent development
·Technology cooperation
Double Materiality Assessment
Double Materiality Matrix of Bloomage Biotech
In 2025, Bloomage Biotech conducted a double materiality assessment in accordance with the Guidelines No. 14 of
Impact Materiality
Shanghai Stock Exchange for Self-Regulation of Listed Companies—Sustainability Report (Trial) (hereinafter referred to
as the "Guidelines"), relevant international standards, and mainstream information disclosure frameworks. The specific Employee Rights and Interests
Environmental Compliance
assessment steps are as follows: Employee Development
Management
Occupational Health and Safety
Assessment Process of Double Materiality Issues Water Management
Responsible Marketing Response to Climate Change and
Corporate Governance
Bloomage Biotech referenced international standards and disclosure Customer Service Energy Management
Compliance and Risk Management
frameworks, capital market rating indicators, peer performance, national Industrial Cooperation and Development Product Quality
Business Ethics
Step 1 Identification of Material Issues policies, and its business development. As a result, 24 sustainable Pollutant and Waste Management
Intellectual Property Protection
development issues were identified, which formed a repository for material Supplier Management
Information Security
issues. R&D Innovation
Impact Materiality: Internal and external stakeholders were invited to assess Product Environmental Impact
the materiality through online questionnaires. The questionnaire survey Environmental Permits and Certifications
covered 10 categories of stakeholders, including the management team, Circular Economy
employees, government or regulatory agencies, shareholders or investors, Biodiversity
Medium
clients or consumers, suppliers or partners, universities or research Ethics in Technology
Step 2 Survey on Material Issues institutions, industry associations or chambers of commerce, the public, and Rural Revitalization and Social Contributions
sustainable development industry experts. Anti-Unfair Competition
Due Diligence Investigation
Financial Materiality: Interviews were conducted with the management
team to evaluate financial materiality of each issue from various dimensions, Unimportant Important Financial Materiality
including impact on costs and revenues, industry context, business mode,
Environment Issues Social Issues Governance Issues
operational features, and key concerns of investors.
Ranking Material Issues: Survey data and interview results were analyzed
to perform a comprehensive quantitative assessment. Issues were ranked Financially Material Issues
based on two dimensions: "materiality to the Company's financial For those financially material issues identified, we have summarized their impact areas along with associated potential
Step 3 Analysis of Material Issues performance" and "materiality to economic, social, and environmental
risks and opportunities, as well as their potential financial impacts. In accordance with the Guidelines from the Shanghai
impacts"
Stock Exchange, we have disclosed relevant management measures and progress within this Report.
Review of Material Issues: External experts provided feedback on the
identified material issues and their rankings. Subsequently, the management
team reviewed these findings
Bloomage Biotech 2025 Sustainability Report
Response to Climate Change and Energy Management Product Quality
Impact Areas Upstream value chain; company operations; downstream value chain ·Operating Cost Savings: Through stability studies and the optimization of formulations and
packaging technologies, the Company aims to improve logistics compatibility and warehouse
Physical Risks:
turnover efficiency while ensuring product quality and safety. This reduces hidden costs such as
·Extreme weather events (such as typhoons, rainstorms, and floods) may damage
breakage and return & exchange, thereby lowering logistics and warehousing expenditures.
production facilities and infrastructure, and disrupt supply chains and logistics, thereby Potential Opportunities
·Market Premium and Share: Higher levels of quality stability and product experience help
resulting in production suspension losses, asset impairment, and a decline in operating
revenue. strengthen brand reputation and customer loyalty, enhancing market competitiveness and
·Long-term temperature rise and climate anomalies may drive up energy demand for cooling premium pricing capabilities. This supports entry into high-barrier channels and expansion into
new markets.
and exacerbate water scarcity and intake difficulties, leading to increased operating costs
related to energy and water resources. Risks:
Potential Risks Transition Risks: ·Increased investments in quality control, testing & verification, and compliance may drive up
·Domestic and international carbon pricing and climate regulatory policies are becoming operation and management costs.
increasingly stringent, potentially driving up carbon emission compliance costs and export- ·Major quality incidents may lead to inventory write-offs and asset impairment, as well as non-
related expenses. operating expenses such as recalls, compensation, and penalties.
·Clients are continuously raising the entry barriers for low-carbon products and green supply Potential Financial Impacts Opportunities:
chains. If the transition to energy structure adjustment and emission reduction lags behind, the ·Quality improvements and process/packaging optimization are expected to reduce operating
Company may face risks such as order loss, market share decline, and weakened costs associated with rework & repair, complaint handling, returns & exchanges, and logistics &
competitiveness. warehousing.
·Enhanced brand and channel capabilities can drive sales growth and market expansion,
·Energy Security: Optimize the energy mix and increase the utilization of renewable energy promoting an increase in operating revenue.
to reduce dependence on fossil fuels, thereby mitigating operational risks arising from energy
Please refer to the "Innovation-Driven Development and Product Responsibility Management"
price fluctuations and changes in supply policies. More Management Content
section and the ESG Key Performance Tables.
·Cost Reduction and Efficiency Improvement: Leverage process improvements and
digitalized energy efficiency management to enhance energy utilization efficiency, reducing Key Honors in Sustainable Development
energy consumption per unit of product and energy costs.
Potential Opportunities In 2025, the Company maintained communication and collaboration with stakeholders including the government, clients,
·Revenue Growth: Develop climate-resilient products and low-carbon raw materials to
capital markets, industry associations, research institutions, and the media, jointly promoting the positive development of
respond to green consumption trends and premium demands, cultivating new business growth
the industry and society.
drivers.
·Value Drive: Meet customer requirements for low-carbon and green supply chains, deepen International Commitments and Participation
collaboration on emission reduction and green procurement, and consolidate market share ·Bloomage Biotech officially joined the United Nations Global Compact (UNGC) in 2025.
while enhancing differentiated competitive advantages. ·Bloomage Biotech continued participation as a global signatory of the UN Women's Empowerment Principles (WEPs).
Risks： Improvement in International Ratings
·Asset impairment or losses related to production suspension. ·EcoVadis: Awarded the Sustainability Silver Medal, with a comprehensive score ranking in the top 13% of global
·Low-carbon technology R&D and equipment upgrades will increase capital expenditure. assessed companies, achieving a leap from Bronze to Silver Medal.
Procuring green power or renewable energy and adjusting the power structure may ·CDP: The CDP Climate Change rating upgraded from B to A- and Water Security rating upgraded from A- to A, both
temporarily drive up energy unit prices and related operating costs, while also increasing reaching the global leadership level.
Potential Financial Impacts operational expenses such as carbon management. Honors Related to Sustainable Development
Opportunities： The Company received recognition in multiple authoritative selections, garnering a total of 12 ESG and sustainability-
·Through energy efficiency improvements, process optimization, and digital management, the related honors in 2025, including the following:
Company aims to reduce energy consumption and operating costs. ·Selected as the "2025 Best Practice Case of Sustainable Development for Listed Companies" by the China Association
·Enhanced capabilities in low-carbon products and green supply chains can drive order for Public Companies
acquisition and market expansion, promoting operating revenue growth. ·Named in the "China Top 100 ESG Listed Companies" at the 19th China Listed Companies Value Forum
Please refer to the "Green Operations and Climate Response" section and the ESG Key ·Won the 3rd Guoxin Cup · ESG Golden Bull Award
More Management Content
Performance Tables.
Case: Bloomage Biotech Attends UNGC Annual Meeting and Shares Chinese Approach to ESG Governance
On December 2, 2025, Bloomage Biotech was invited to attend the 25th Anniversary Commemoration of the United Nations
Global Compact (UNGC). At the roundtable forum themed "Beyond Social Responsibility: Driving Corporate Resilient Growth
Product Quality
with Sustainable Leadership", Zhao Yan, Chairwoman and General Manager, shared the Company's practical experience and
Impact Areas Company operations; downstream value chain governance philosophy in sustainable development with global attendees. Her speech focused on topics such as ESG
governance framework development, strategic integration pathways, and sustainable leadership.
·Increased Compliance Costs: With the continuous tightening of domestic and international
regulatory requirements for pharmaceuticals, medical devices and cosmetics, the Company may
face increased investments in product safety assessments, testing and verification, registration
and filing, as well as quality system maintenance, which will in turn drive up R&D and
Potential Risks
compliance costs.
·Recall and Compensation Risks: Major quality incidents could trigger product recalls, returns
and exchanges, compensation claims, and penalties. This would lead to inventory write-offs and
losses in channels and customers, resulting in cash outflows and brand asset impairment.
Bloomage Biotech 2025 Sustainability Report
nature and applicability of the institutional framework.
During the year, the Company integrated the functions of legal affairs, risk management, audit & supervision, and
compliance management, establishing the new Risk Control, Compliance, and Audit Center. Through the integration of
functions, it built a risk prevention & control and compliance management system that features "comprehensive coverage,
clear responsibilities, and efficient coordination". This initiative achieved resource sharing among risk control, compliance
operations, and audit supervision, thereby improving the overall efficiency of the risk management system.
Bloomage Biotech was invited to attend the UNGC's 25th Anniversary Commemoration
Case: Bloomage Biotech Signs the "Creating Sustainable Brands" Vision Initiative
On September 4, 2025, Bloomage Biotech participated in the High-Level Dialogue on "Building Sustainable Business and
Brands". The event was jointly organized by the United Nations Conference on Trade and Development (UNCTAD), the United
Nations Forum on Sustainability Standards, and the China Association for Standardization in Geneva. As one of the first Compliance Management
signatories, the Company officially signed the "Creating Sustainable Brands" Vision Initiative (also known as the "Geneva Vision Bloomage Biotech consistently views compliance management as a vital safeguard for steady corporate operations. In
Initiative"), further enhancing its global influence and recognition as a responsible Chinese brand. accordance with laws and regulations applicable to the places of operation and industry regulatory standards, it advances
the establishment of a compliance management system, the cultivation of a compliance culture, and full-process
Investor Rights Protection compliance control in all aspects. This comprehensive approach prevents operational compliance risks and ensures the
sustained, sound development of all business operations.
Bloomage Biotech consistently upholds the principles of "authenticity, accuracy, completeness, timeliness, and fairness" in
information disclosure, viewing transparent and efficient investor relations management as a crucial component of Compliance Management System
corporate governance. This year, the Company revised its Information Disclosure Management System and Investor Aiming to continuously strengthen compliant operations, prevent major penalties, and empower business development,
Relations Management System, optimizing disclosure and communication standards to effectively safeguard the legitimate Bloomage Biotech has constructed a standardized, normative, intelligent, and efficient compliance management system.
rights and interests of investors and other stakeholders. The Company upholds the philosophy of "law-abiding compliance and integrity" among all employees and continuously
conducts compliance awareness activities to promote effective implementation.
To protect investors' rights to information and participation, the Company has established a multi-level, regular investor
communication system and maintained frequent interactions. In 2025, we successfully held three high-quality earnings In terms of institutional development, the Company has formulated and updated relevant policy documents centering on
presentation meetings via online interaction on the SSE e-Interaction Platform. Additionally, through a combination of online the core requirements of the compliance management system. It has also refined departmental responsibilities in line with
and offline channels, we hosted nearly 100 investor research activities and conference exchanges. Key communication the latest organizational structure to ensure that policies are executable and aligned with business scenarios. Furthermore,
mechanisms include, but are not limited to the following: it integrated specific compliance and anti-bribery policies to form a comprehensive institutional framework, achieving
synergistic alignment between these two core policy categories.
• Regular and Thematic Exchanges: We organized annual, semi-annual, and third-quarter earnings presentation
meetings to provide timely interpretation of operating results and strategic layouts. Regarding management system certification, the Company has obtained ISO 37301 Compliance Management System
• One-to-Many and One-to-One Communication: We actively participated in brokerage strategy conferences and certification and accepts regular annual surveillance audits. Currently, the operational sites certified under this management
maintained efficient communication with investment institutions and analysts through on-site research and system cover the Beijing Headquarters and the Jinan Production Base, ensuring the continuous and effective operation of
conference calls. our compliance management system across major operational bases.
• Normalized Interactive Platforms: We made efficient use of the SSE e-Interaction Platform, the special email On the foundation of refined compliance management system, we aim to continuously strengthen lawful compliance
address for investor relations, roadshows and other channels to respond to investor inquiries in a timely and management capabilities and prevent regulatory penalty cases. We are dedicated to building daily management capabilities,
standardized manner. translating compliance requirements into internal management & control measures and standards. Furthermore, leveraging
artificial intelligence tools, we integrate management requirements with operational workflows to promote compliance in
Key Performance Table for Investor Rights Protection in 2025 daily operations and decision-making processes.
Total announcements released throughout the year: 109 (comprising 52 announcement texts and 57 attachments) More Efforts in Compliance Culture Development
Earnings briefings held during the year: 3 The Company upholds the philosophy of "law-abiding compliance and integrity" among all employees and normalizes
compliance training and awareness activities. We have built a compliance training matrix that covers all staff, focuses on
Investor exchange activities launched (including roadshows, reverse roadshows, and strategy conference participation):
key areas, and integrates internal and external coordination. By designing differentiated training content tailored to different
Nearly 100
positions and risk scenarios, we have continuously enhanced employees' compliance awareness and execution capabilities.
In terms of internal employee training, the Company implements precise, stratified, and categorized education. For all
employees (including new hires), it launches general compliance training sessions centered on the Compliance (Anti-
Compliance and Internal Control Risk Management Bribery) Management Regulations and the Employee Compliance and Anti-Bribery Handbook to popularize compliance
policies and personal codes of conduct. Notably, new employees receive training within 30 days of onboarding to strictly
Bloomage Biotech consistently upholds laws and regulations, adheres to lawful operations and tax compliance, and actively enforce the "entry gate", serving as the "first lesson in compliance reinforcement" of their career and solidifying their
fulfills its corporate citizenship responsibilities. This year, the Company improved its governance structure, sound foundation in compliance cognition. For personnel in key positions in important areas such as marketing, engineering, and
institutional system, deepened risk prevention and control, and promoted integrity culture. By introducing the Internal Audit procurement, we conduct special risk prevention training on topics such as "advertising and publicity, contract risk control
System and optimizing the Internal Control Management System, it further refined the professional, digital compliance management, and common disputes in engineering and equipment procurement", with typical cases combined. This
management framework. Existing regulations were categorized into three major types - "compliance management system, initiative aims to prevent compliance risks on the business front line and resolve practical issues.
anti-bribery management system, and comprehensive compliance and anti-bribery system", enhancing the systematic
Regarding the development of an external compliance ecosystem, the Company extends compliance management to
Bloomage Biotech 2025 Sustainability Report
partners, actively conveying Bloomage Biotech's compliance values and cooperation consensus to suppliers, distributors,
and other business associates. For instance, led by business departments, the Company conducts due diligence
investigations on key business partners and guides them to operate in compliance with laws by signing compliance
The Company continuously strengthens the collaborative operational mechanism of the "Three Lines of Defense". Each
agreements or requiring compliance commitments, thereby jointly building a clean, transparent, compliant cooperation
department collaborates according to its designated responsibilities to build a multi-tiered, cohesive, and mutually
ecosystem.
constrained operational mechanism, ensuring continuous monitoring and management of various risks.
To ensure the effective implementation of the compliance culture, the Company has formulated the Implementation
Measures for Compliance Training and the Implementation Measures for Compliance Performance. Compliance training
and examination results are incorporated into the performance assessment system of all business departments and As the first line of defense in risk management, business/operation departments are
First Line of Defense:
individual employees, with clear reward and penalty measures implemented. Simultaneously, the Company has utilized required to proactively identify, assess, control, and report risks within their scope of
Business/Operation
multiple channels, such as the intranet, social media, and meetings, to promote the culture and organized all employees to responsibilities during daily operations, implementing risk prevention and control
Departments
sign the Compliance Commitment Letter. This year, the signing rate of employees reached 100% for the Compliance measures within specific business processes.
Commitment Letter. As the second line of defense for risk management, the department is responsible for
Second Line of Defense: Risk
In 2025, Bloomage Biotech conducted 9 special compliance training sessions, achieving a 100% training coverage rate for organizing group-wide risk management, daily monitoring, and rectification follow-ups. Its
Control and Compliance
personnel in key positions. Throughout the year, the online Training on Code of Conduct for Employee Compliance (Anti- tasks include establishing risk management systems, defining risk rating criteria, and
Department
Bribery) remained available to build a strong ideological defense for integrity in operations among all employees. Regarding driving the digital risk management.
professional capability enhancement, we provided in-depth empowerment to core staff in legal affairs, audit and supervision, As the third line of defense for risk management, the department, under the supervision of
and business lines, improving the professional ability of key personnel to identify risks and translate compliance obligations Third Line of Defense: Audit the Audit Committee of the Board, conducts reviews and evaluations of the Group's risk
into practice. and Supervision Department management status, and periodically reports the review results and rectification
Key Performance recommendations to the Audit Committee.
Special compliance training sessions held: 9
Training coverage rate for personnel in key positions: 100% Risk Identification and Assessment
Signing rate of Compliance Commitment Letter by employees: 100% The Company has established a risk identification mechanism covering the entire business process. In 2025, we led all
departments in conducting regular business risk assessments and updating the Risk Management Matrix. During the
process, we strictly followed a closed-loop process ranging from risk identification and assessment to the formulation of
Internal Control and Risk Management control measures and continuous monitoring. We focused on identifying core risk factors in key areas such as strategic
target decomposition & achievement, partner management, brand reputation maintenance, customer churn, and
Bloomage Biotech is dedicated to building a resilient internal control and risk prevention & control system to cope with the
technological iteration, laying the foundation for subsequent risk responses. This year, we held risk management activities
increasingly complex business environment and external challenges, ensuring the steady achievement of strategic
across the entire business scope and formulated special response measures for major risk items.
objectives.
To deepen the closed-loop risk management, the Company initiated a program on "Matching and Integrating Compliance
Internal Control and Risk Management System Obligations and Internal Control Standards" this year. This program facilitates the translation of external compliance
In 2025, the Company publicly disclosed the Rules of Procedure for the Risk Management Committee, optimizing the requirements into internal, manageable, and traceable risk control points, thereby achieving the goal of proactive risk and
deliberative rules to strengthen the Board of Directors' functions in the overall decision-making and supervision of major compliance management.
risks. In the same year, we launched an upgrade of the risk control system. While clarifying the management structure and
To enhance the efficiency and foresight of risk management, the Company actively advanced the development of a digital,
responsibilities, we optimized communication mechanisms and appointed a Risk and Compliance Liaison in secondary
intelligent risk control system, focusing on elevating the level of refinement and intelligence in risk management. In terms
business departments to effectively strengthen the implementation of various tasks. Regarding system documentation, we
of top-level planning, we formulated a digital and intelligent risk control blueprint, promoting the structuring of business
issued the Internal Control Management System and three process documents. To be specific, the three documents are
rules and the effective accumulation of risk data. We also achieved intelligent scenario applications for compliance and risk
the Establishment of Internal Controls, Policies, and Procedures, the Execution and Monitoring of Internal Control Policies
control in multiple key business areas. As to tool application, we independently developed and launched a tool for intelligent
and Procedures, and the Processes for Reporting Internal Control and Compliance Matters, detailing specific requirements
contract risk review. Utilizing AI models to automatically identify and analyze contract terms and partner qualifications, the
for the execution and monitoring of internal controls. tool can provide revision suggestions, significantly improving the efficiency of legal review and the accuracy of risk
identification. Furthermore, we deployed AI Compliance Assistants in areas such as quality, regulatory affairs, and safety
& compliance. These assistants enable intelligent interpretation of regulatory requirements, comparison of new and old
versions, and intelligent Q&A. They provide business departments with real-time and precise compliance guidance,
enhancing the proactivity and response capability of risk prevention and control.
Risk Management and Response
To address major risks, the Company established a robust risk reporting mechanism. By regularly collecting documents
such as the Quarterly Risk Monitoring Report, Annual Risk Management Report, and Risk Management Matrix, we tracked
potential risks and incidents. To enhance control efficiency, we built an automated collection platform to achieve online
summary and centralized management of risk events, significantly improving the efficiency of information aggregation and
traceability.
Regarding risk management, the Company established a risk early warning mechanism, identified Key Risk Indicators
(KRIs) in critical business areas, and launched these indicators in the digital mechanism. We prioritized the clear
visualization and management of operation-related indicators to enable effective early warnings of risks. During process
control, we continuously monitored business workflows to promptly alert on potential operational risks, and proactively
initiated special audits for identified high-risk areas, driving the optimization of process rules and control tools. Addressing
specific risk points identified during monitoring and audits, we strictly implemented a rectification tracking mechanism. This
involved not only proposing requirements for scenario-based rule refinement but also promoting the formulation or revision
Risk Management Structure of Bloomage Biotech of corresponding management systems. In this way, these actions ensured the effective implementation of every risk control
Bloomage Biotech 2025 Sustainability Report
measure and the formation of a complete management cycle comprising identification, early warning, control, and Bloomage Biotech achieved 100% coverage in employee declarations for conflict
institutionalization. of interest.
In terms of risk response, each business unit organized the systematic formulation of special emergency response plans The Company strictly standardizes the exchange of gifts and business hospitality
in accordance with our Emergency Management Measures. For major or severe emergency events, a group-wide in commercial activities. It prohibits the offering or acceptance of any gifts, cash,
Emergency Response Leadership Team led by General Manager was established to coordinate command efforts. This or entertainment that may compromise the impartiality of business decisions.
team formulated specific response plans and established corresponding reward and penalty schemes to ensure orderly Management of Gifts and Hospitality
Strict due diligence and approval procedures are implemented for charitable
emergency responses and the fulfillment of responsibilities. donations and sponsorship activities to prevent them from being used for bribery
purposes.
Development of Risk Management Culture
In terms of development of risk management culture, the Company has established a tiered training mechanism and held The Company extends compliance requirements to the upstream and
special training sessions for directors, supervisors, senior management, managers at all levels, and operational execution downstream of the value chain. It conducts anti-bribery due diligence on key
personnel in a targeted manner. The training sessions adopted a model combining course learning with project practices, third-party business partners, such as suppliers and distributors. Furthermore,
to enhance the risk control competency and practical capabilities of all employees. In 2025, the Company launched a total Business Partner Management compliance commitment letters contain clauses on good-faith cooperation,
of 16 special training sessions on risk management, achieving a 100% coverage rate for risk management personnel and financial compliance, and anti-commercial bribery. These letters have been
incorporated into all procurement contracts to strengthen third-party risk
department heads.
constraints.
The Company incorporates anti-unfair competition into its compliance
Business Ethics management system. Through institutional development and specialized
Bloomage Biotech strictly complies with the laws and regulations applicable to its places of operation, including the Anti- controls, it effectively mitigates risks associated with unfair competition, including
Anti-Unfair Competition false advertising, commercial disparagement, trade secret infringement, and
Monopoly Law of the People's Republic of China, the Anti-Unfair Competition Law of the People's Republic of China, and
monopolistic practices. In 2025, Bloomage Biotech had no lawsuits or major
the Anti-Money Laundering Law of the People's Republic of China. Upholding the principle of integrity, it maintains a "zero
administrative penalties resulting from its own unfair competition practices,
tolerance" stance toward corruption, fraud, and other violations. This year, the Company continued to refine its anti-bribery
ensuring overall compliance in market practices.
management system, solidifying the foundation for compliant operations through improved regulations, risk controls, and
the cultivation of a culture of integrity.
Anti-Bribery Integrity Culture Development
To regulate the conduct of group-wide employees and business partners, the Company formulated and revised the Anti- The Company has established a normalized integrity training system to continuously enhance employees' integrity
Bribery Management System, the Code of Anti-Bribery Conduct, and the Due Diligence Management Regulations in awareness with methods such as case promotion and online learning, covering all employees. We have held targeted
accordance with requirements of the anti-bribery management system. We also issued the Conflict of Interest Management training sessions for core management personnel and high-risk business departments such as sales and procurement,
System for Employees to clarify behavioral guidelines regarding anti-corruption, anti-fraud, and conflict of interest combining specific job responsibilities with practical cases. Integrity training is incorporated as a mandatory component of
management. All our employees have been required to sign the confirmation form for the Code of Professional Ethics, new employee orientation. New employees are required to sign both the Labor Contract and the Anti-Bribery Compliance
imposing corresponding penalties ranging from verbal warnings and written warnings to termination of employment for Commitment upon joining, ensuring that they master basic anti-bribery requirements before assuming their posts. In 2025,
violations of relevant professional ethics regulations. the Company conducted six special inspections on integrity in operations and reviewed key processes through various
audits. Additionally, two company-wide integrity awareness sessions were conducted, covering compliance requirements,
This year, the Company integrated anti-bribery management into its overall compliance system. It refined the anti-bribery
management responsibilities, and risk cases. These sessions reached all core managers, totaling over 1,000 participants.
responsibilities of each department based on the latest organizational structure, establishing a comprehensive institutional
framework supported by "specific and general regulations". In conjunction with the integrated series of compliance Key Performance
management system frameworks this year, it formulated the Management Regulations for Employee Business Conduct Number of concluded embezzlement lawsuits filed against Bloomage Biotech or its employees: 0
and the Employee Disciplinary Management Regulations. These documents clarify requirements for employees regarding
Number of company-wide anti-bribery risk assessments conducted: 1
anti-bribery and anti-corruption across internal business, external business, and personal conduct. They also detail
penalties for violations of relevant business conduct, guiding employees to build an open and transparent business Number of special anti-bribery training sessions for the management team and employees: 2
environment together with the Company. Training coverage rate for personnel in key positions: 100%
The Company has established an anti-bribery governance structure with the Board of Directors as the supreme leading Percentage of directors receiving anti-commercial bribery and anti-corruption training: 100%
body overseeing the overall picture, the General Manager as the primary person in charge, and the Chief Compliance Percentage of the management team receiving anti-commercial bribery and anti-corruption training: 100%
Officer authorized to assume full responsibility. We have entrusted a third-party certification body annually to conduct an
Percentage of employees receiving anti-commercial bribery and anti-corruption training: 100%
audit of the ISO 37001 Anti-Bribery Management System to ensure continuous and effective system operation. This year,
we conducted one systematic review of business ethics standards, achieving 100% coverage in business audits.
Regular Assessment of Commercial Bribery Risks
The Company remains steadfast in its commitment to upholding high standards of business ethics. It prioritizes the The Company has established a rational and systematic system for assessing commercial bribery risks. Centered on key
prevention of corruption, bribery, unfair competition, conflicts of interest, and other fraudulent activities. To this end, it processes such as partner admission, business agreement signing, third-party management, sponsorship & donations,
continuously strengthens its business ethics system, enhances its complaint and reporting mechanism, and rigorously and expense reimbursement, it has regularly identified, analyzed, evaluated, and addressed risks to dynamically manage
oversees matters related to business ethics, such as integrity in operations, anti-corruption initiatives, and complaint potential corruption and bribery risks. A comprehensive assessment has been conducted at least annually. In response to
handling. This comprehensive approach ensures that any form of corruption and unfair competition is avoided. Maintaining early warning signs such as regulatory policy changes, whistleblower reports, or industry risk incidents, the Company has
a "zero tolerance" stance toward all forms of corruption and violations, the Company has formulated clear, strict behavioral immediately initiated targeted assessments to ensure the agility of risk control. In 2025, we conducted one corruption risk
norms and approval procedures for high-risk areas such as product sales, recruitment, interactions with government and assessment, achieving 100% coverage of all operating sites.
healthcare professionals, and third-party cooperation. By establishing "red lines" for conduct, it embeds anti-fraud
requirements into daily operational processes. Whistleblower Protection Mechanism
Committed to building an honest and transparent business environment, the Company has formulated the Management
The Company requires regular declaration of personal conflicts of interest from
Measures for Compliance Reporting, Investigation and Handling, and established a normalized mechanism for fraud
all employees. Background checks are conducted for new hires, focusing on
Conflicts of Interest prevention, reporting and investigation. We encourage stakeholders, including employees, customers, and suppliers, to
conflicts of interest and bribery records. Strict restrictions apply to hiring
government officials and their relatives to prevent illicit benefit transfer. In 2025, supervise and report violations such as breaches of laws and regulations, fraud, corruption, unfair competition, violations
of business ethics and other violations that may impair our interests. We strictly maintain the confidentiality of whistleblower
Bloomage Biotech 2025 Sustainability Report
information and prohibit any form of retaliation. Personnel with direct interest in the reported matters are required to controllability of external services.
proactively recuse themselves to avoid conflicts of interest, thereby protecting the privacy and safety of whistleblowers and
their close relatives. The Company formulated detailed emergency response
plans for cybersecurity incidents, with the Integrated
We have established multiple complaint and reporting channels, including a hotline, dedicated email, physical mail, and Operation & Digital Center coordinating the handling of
on-site reception. These channels are publicized to all employees, distributors, and suppliers via intranet security events such as system vulnerabilities and cyber-
announcements, contract terms, and brochures. In 2025, adhering to the principle of timely handling, the Company Emergency Response and Security Audit
attacks. Access logs for all application systems were retained
properly addressed all reporting responses and special investigations, achieving a 100% handling rate for reported for a minimum of six months to ensure traceability of
matters. operations and support audits and accountability
determination.
Collect whistle- The Company strictly implemented an annual security
blowing Classify whistle- Analyze and sort Establish an
blowing records out information investigation team training plan, continuously promoting key data security
information
protection points among all employees. Meanwhile, it
established a closed-loop supervision process. To be
Security Awareness Development and Closed-Loop specific, it opened a dedicated reporting mailbox and
Supervision committed to respond to reports of behaviors endangering
The party network security within five working days while maintaining
Reconsider, concerned may strict confidentiality. This process also included appeals and
respond and Handle the
File a record appeal if investigation result
handle reports review stages to enhance the fairness and transparency of
dissatisfied the process.
Whistle-blowing Workflow
Reporting Channels Data and Privacy Security Assurance
E-mail address: jubao@bloomagebiotech.com The Company places high importance on customer privacy protection and data compliance, strictly adhering to the
Tel.: 010-85670099-1503 requirements regarding information collection, use & retention, and individual rights stipulated in its internal Privacy Policy.
For verified reports that recover losses for the Company, we will grant material or honorary rewards to the whistleblowers To ensure standardized and secure data usage, it has established a unified master data standard and governance system.
in accordance with relevant policies, thereby upholding our compliance baseline. It has also built the Group's "Data Lakehouse Integration" architecture, and implemented the "Principle of Least Privilege
Access" to establish refined control mechanisms.
Network Information Security and Data Privacy
The Company compiled the Permissions and Security Operations Manual and the Change
Information security and privacy protection are the fundamental prerequisite for the Company to establish long-term trust and Version Management Manual. These documents cover core processes such as user
and conduct sustainable cooperation with business partners, customers, and employees. In 2025, building upon the Policy Standardization
management, sensitive data desensitization, code change approval, and usage guidelines
continuous improvement of the information security management system, we enhanced our active defense and intelligent for version management tools (Git/SVN).
control capabilities on all fronts by taking robust safeguard measures. This constructed a solid barrier for steady business
operations and the information security of all stakeholders. During the reporting period, Bloomage Biotech had no The Company implemented a strict hierarchical management system for information system
permissions, classified as Top Secret, Confidential, and Secret. This ensures that users are
information security incidents.
Permission Classification granted only the data and functional permissions necessary to fulfill their duties.
Furthermore, passwords for critical systems were stored using non-plaintext secondary
Data Security Management System
encryption to strengthen identity authentication and access control.
The Company strictly complies with laws and regulations such as the Cybersecurity Law of the People's Republic of China.
This year, it officially released and implemented the new version of the Information and Network Security Management The Company established the Indicator Management Center and the Data Asset Ledger
System. This updated the management framework in all aspects to cover the entire process of network construction, Tool Control System. These initiatives implement data permission control at the system control level,
achieving hierarchical and classified management.
operation, and maintenance for the Company and all subsidiaries. We continuously advanced the graded protection system
for network security and fulfilled security protection obligations. We also met relevant compliance requirements such as
annual information security system audits and classified protection assessments. In terms of technical assurance, the Company employs multi-layered technical measures to safeguard network security in
We have established a governance structure with the Information Security Management Committee at our core, all aspects, ranging from infrastructure to application deployment:
implementing the information security management system across five dimensions - organization, management,
technology, training, and supervision. In terms of compliance, we were certified to the ISO 27001 Information Security
Management System in 2025. Additionally, our anti-counterfeiting traceability system and the raw material portal system The Company separated internal and external application deployments, with critical
completed annual re-evaluations, both passing the Level 2 assessment of the National Information Security Classified applications restricted to internal network access only. Physically isolated measures were
Protection, thereby ensuring the security and continuity of business data. applied to systems involving confidential information, and all connected terminals were
Network Isolation and
required to install antivirus software. Furthermore, the Company actively reduced the
The Company has established an information security risk management mechanism covering prevention, monitoring, and Hardening
network attack surface and engaged third-party service providers for network traffic
response, and systematically advances it around three pillars: risk assessment, emergency response, and full-staff monitoring services, utilizing real-time traffic analysis to precisely detect malicious activities
supervision. Key initiatives included the following: and potential security risks.
The Company established a normalized risk assessment Leveraging the Alibaba Cloud Security Center and internal monitoring mechanisms, the
mechanism and conducted regular security reviews of Vulnerability and Encryption
Company implemented dual control over system vulnerabilities. Encryption measures were
network infrastructure and data transmission processes. For Management
Risk Assessment and O&M Monitoring taken for both data transmission and storage to ensure data integrity and confidentiality.
outsourced third-party operation and maintenance services, it
strictly enforced supplier qualification reviews and signed Application Development When introducing technologies such as low-code platforms and Robotic Process
confidentiality agreements to ensure the security and Security Automation (RPA), permission controls were synchronously integrated during the design
Bloomage Biotech 2025 Sustainability Report
phase. For the cloud deployment of Business Intelligence (BI) tools, a full-process
monitoring system was established covering report development, release, and permission
management.
To further enhance the information security awareness of all employees and strengthen its information security
management, the Company invited professional lecturers to produce an online recorded course - Network Security Training
response to the widespread application of artificial intelligence technology, it specifically enhanced safety education within Innovation-Driven Development and Product
this new technological context. To be specific, it organized eight special empowerment training sessions, including AI
Security and Internal Applications, focusing on elevating employees' awareness of AI security risk prevention. These
sessions have ensured that data security baselines are maintained while embracing technological innovation.
Responsibility Management
Bloomage Biotech focuses on four core pillars, "R&D, quality, product services, and supply chain". It is committed to building
Intelligent Technology Empowerment and AI Security a full-process value creation system that spans from source innovation to end-user delivery. It also adheres to an
innovative-driven development approach, leveraging technological advancement to enhance its R&D efficiency and
Bloomage Biotech adheres to a strategy that places equal emphasis on digital drive and security governance, viewing AI industrialization capabilities, while promoting green and low-carbon development and digital-intelligent transformation. With
as a profound transformation in research and production methods. This year, we actively applied AI technologies to responsible products and services, it contributes to the high-quality and sustainable development of the biotechnology
enhance operational efficiency and empower employees. By establishing a standardized and convenient AI service industry.
ecosystem and security norms for technology application, we ensured a balance between technological innovation and
data security.
R&D Innovation
The Company has developed an ecosystem for intelligent office practices and a culture of innovation, establishing an AI
service platform accessible to all employees. Adopting a "local + cloud" dual-engine model, the platform integrates dozens
of the latest domestic and international large models and tools. It provides services such as intelligent data analysis and
R&D Innovation Management
automated workflows, lowering technical barriers and enhancing cross-departmental collaboration efficiency. R&D innovation represents the starting point of Bloomage Biotech's value creation. Through systematic innovation
management, cutting-edge technological breakthroughs, sustainable R&D concepts, rigorous scientific ethics, and open
Case: Bloomage Biotech Holds the First "Smart Bloomage - AI Navigation" AI Innovation Competition with Feishu industry collaboration, the Company continuously strengthens its technological barriers and drives industry advancement.
To further stimulate innovation vitality among all employees, Bloomage Biotech, in partnership with Feishu, hosted the inaugural
Innovation Management System
"Smart Bloomage - AI Navigation" AI Innovation Competition. The event attracted over 70 teams to develop innovative AI
application solutions addressing core business pain points. Through the approach of promoting learning and application through To effectively implement its innovation strategy, Bloomage Biotech has established a tiered and coordinated R&D
competition, the Company sparked an internal upsurge of learning and applying AI, accelerating the overall digital transformation management structure in compliance with relevant laws and regulations, including the Law of the People's Republic of
process. China on Promoting the Application of Scientific and Technological Advances and the Administrative Measures for the
Concurrently, Bloomage Biotech attaches great importance to the application and development of digital-intelligent Safety of Biotechnology Research and Development. By introducing internal policies such as the Management System for
innovation technologies, dedicated to reducing costs and enhancing efficiency with digital means. The Company Grade Evaluation of Raw Material R&D Projects and the Management System for Technical Review of Raw Material R&D
continuously advances system upgrades, digital management of production processes, and automation transformation of Projects, and by optimizing existing policies including the Implementation Rules for the Project-Based Incentive Mechanism
production lines, consolidating the foundation for intelligent manufacturing on all fronts. On this basis, it integrates various of the Skin Science Innovation R&D Center, the Company ensures that its R&D design activities are conducted in a
types of software and hardware facilities to break down data barriers. In this way, it achieves the interconnection and deep standardized, orderly, traceable and regulatable manner throughout key stages such as project initiation, development,
integration of multiple core systems within the industrial park. In this case, key scenarios are included, such as intelligent and review. This system effectively strengthens the governance of scientific achievements and talent incentive standards,
supply chain, intelligent manufacturing, and digital integrated marketing. and has vigorously promoted the efficient transformation of scientific achievements as well as their commercialization and
market application.
Honors Related to Digital-Intelligent Innovation
Bloomage Biotech has received repeated recognition in the field of digital-intelligent innovation, garnering a total of two
sustainable innovation awards in 2025:
• Four scenarios (Digital-Intelligent Lean Management, Quality Traceability & Analysis Improvement, Digital-
Intelligent Supplier Management, and Human-Machine Collaborative Operation) were recognized as Shandong
Provincial Excellent Intelligent Manufacturing Scenarios.
• The Smart Factory for High-end Pharmaceutical Devices and Functional Skincare Products was rated as an
Advanced (Provincial-level) Smart Factory.
While expanding intelligent applications, the Company continuously strengthens data security governance. In 2025, we
updated AI usage norms and data management systems, reinforced the technical protection architecture, and defined
security boundaries for technology applications. A comprehensive defense system was established, covering management
norms, technical protection, operational monitoring, and security culture. It serves to continuously address cybersecurity
challenges and protect the information security of employees, customers, and partners.
R&D Management Structure of Bloomage Biotech
With respect to incentives and research achievements management, we have established scientific standards for the
evaluation of research achievements and talent rewards. During the reporting year, we revised the Patent Incentive
Measures, and optimized the reward mechanism based on both technological innovation results and patent
commercialization performance. We also encouraged team collaboration. These actions further stimulate the company-
Bloomage Biotech 2025 Sustainability Report
wide innovation vitality and enthusiasm for the commercialization of research results, and promote the efficient translation
of scientific achievements and their market applications.
Technology Innovation-Driven Development
During the reporting year, Bloomage Biotech focused on innovation in bioactive substances, advancing technological
upgrades and the restructuring of its R&D system, with the aim of building a full-chain innovation ecosystem spanning from
basic research to market application. Supported by eight major R&D platforms, we further strengthened the collaborative
R&D and green manufacturing of bioactive substances. By leveraging AI technologies, we have achieved functional
integration and intelligent upgrades, continuously making breakthroughs in key technologies while optimizing its patent
portfolio. On this basis, we have established an integrated innovation pathway from scientific research to product
commercialization. Through optimized evaluation and technology transfer mechanisms, we have accelerated the effective
transformation of R&D achievements into commercial products, forming an integrated industry chain spanning bioactive
materials, medical final products, skin science innovation and translational products, and nutrition science innovation and
translational products. In this way, we have significantly enhanced our innovation competitiveness and industry influence.
Bloomage Biotech's Biomanufacturing Pilot-Scale Achievement Transformation Platform Is Among the First to
Case: Bloomage Biotech's Breakthroughs in Innovative PDRN Technology Receive National-level Certification
Bloomage Biotech's invention patent for Specific-Sequence Nucleic Acid Molecules and Their Application as PDRN has been Case: Leading in glycobiology, Bloomage Biotech Wins the AMA Best Ingredient Award
published by the China National Intellectual Property Administration. This technology overcomes the traditional limitations of
In August 2025, Bloomage Biotech participated in the AMA 2025 Aesthetic Medicine Asia Summit & 2nd Aisa Beauty Injection
animal-derived PDRN, and produces multiple confirmed PDRN molecules with defined sequences and proven efficacy, offering
Medical Aesthetics Summit in Chengdu, showcasing eight core products and providing cell-level scientific solutions that support
the cosmetics and pharmaceutical industries new active ingredients for skin care and repair. The technology provides three core
the entire process of plastic and aesthetic medicine. Through breakthroughs in technological innovation and applied research,
advantages, "sequence controllability, safety and non-toxicity, and enhanced efficacy", expanding applications in high-end skin
we received the Best Ingredient Award at the summit. This recognition highlights our core technological strengths in glycobiology
repair and clinical scenarios such as medical wound healing.
and cell engineering, as well as our comprehensive operational capabilities spanning raw-material R&D, process innovation,
Case: Bloomage Biotech's Next-Generation Micro-cross-linked Technology Wins the Science & Technology quality management, global regulatory registration, and technical services.
Innovation Award at the 3rd China Plastic Surgery Innovation and Transformation Competition
Case: Advancing Industry Development Models to Enable High-Quality Development in Biomanufacturing
In the central region finals of the 3rd China Plastic Surgery Innovation and Transformation Competition, Bloomage Biotech won
In August 2025, Bloomage Biotech participated in the academic symposium titled the Economic and Social Value of the
the Science & Technology Innovation Award for its project titled Application and Transformation of Next-Generation Micro-cross-
Hyaluronic Acid Effect. At the symposium, Zhao Yan, Chairwoman and General Manager of Bloomage Biotech, delivered a
linked Hyaluronic Acid Technology in Perioral Skin Anti-Aging. In response to key clinical challenges, the Company leveraged
keynote presentation. Using Bloomage Biotech's development journey as a case study, she provided an in-depth analysis of the
its proprietary micro-cross-linked technology to overcome the difficulties in precise anti-aging treatments, effectively translating
evolving development pathway of China's biomanufacturing industry. She emphasized that companies should achieve
life science research achievements into high-quality products with clinical value.
breakthroughs in manufacturing technologies through applied research and ultimately reinvest the funds from transformation
into both basic and applied research, thus helping enterprises generate new technological breakthroughs in basic and applied
research to achieve transformative growth.
Bloomage Biotech Wins the Science & Technology Innovation Award
Case: Bloomage Biotech's Pilot-Scale Platform Wins the National Five-Star Certification, Setting a Global
Benchmark for Transformation Bloomage Biotech participated in the Academic Symposium on the Hyaluronic Acid Effect
Bloomage Biotech's "Biomanufacturing Pilot-Scale Achievement Transformation Platform" stood out in the selection jointly
released by the Ministry of Industry and Information Technology and the National Development and Reform Commission,
Sustainable Innovation
becoming one of the first national-level certified biomanufacturing pilot-scale platforms in China. The platform has obtained "Five- Bloomage Biotech has established a multi-layered sustainable innovation system spanning ingredients, technologies, and
Star" service certifications in key fields such as cosmetics, food additives, and biopharmaceuticals, fully demonstrating its leading development philosophy, integrating the green and low-carbon principle into the entire value chain from product R&D and
position in the field of biomanufacturing. process innovation to value delivery.
Bloomage Biotech is among the only five companies to receive this honor in the country, signifying that its transformation
Ingredient Sustainability
capabilities in cosmetics, food additives, and biopharmaceuticals have reached the highest national standards. The platform's
the practical application of technology and industry collaboration. process route. Rather than obtaining raw materials through the direct harvesting of rare plants, animals, or marine
organisms, Bloomage Biotech leverages technologies such as metagenomics, metabolomics, and synthetic biology to
identify functional genes from microorganisms, and further applies synthetic biology to construct cell factories, achieving
the large-scale green manufacturing of functional ingredients. This approach not only addresses the difficulties in sourcing
functional ingredients but also reduces its reliance on wild biological resources, and minimizes the harvesting pressure at
the source, thus contributing to ecological protection.
In 2025, the Company achieved several technological breakthroughs in multiple fields by applying synthetic biology,
Bloomage Biotech 2025 Sustainability Report
microbial fermentation, and gene editing technologies. For instance, it realized the large-scale production of Tricholoma Case: Bloomage Biotech's Synthetic Biology Innovation Reduces Reliance on Animal-Derived Sources
matsutake mycelium, eliminating its dependence on wildlife harvesting. It became the first company in China to achieve Through its subsidiary - Bloomage GAG Biotechnology Co., Ltd., Bloomage Biotech is leveraging synthetic biology to drive the
compliant fermentation-based production of sodium chondroitin sulfate, replacing traditional animal-derived extraction. It transformation of heparin production from traditional animal extraction to biomanufacturing. The fully enzymatic synthesis
developed high-purity recombinant collagen (Types III, IV, and VII) and other extracellular matrix (ECM) components. It process developed by the company has increased the anticoagulant activity of heparin to more than ten times that of animal-
realized the green, large-scale production of (S)-equol and other precisely configured bioactive compounds. At the same derived products while establishing a comprehensive non-animal-derived industry chain platform covering glycoengineering
time, it made advances in several key technologies, including multi-targeted delivery, natural preservation, and biomimetic reagents, active pharmaceutical ingredients, and final products. This innovation can reduce the dependence on animal resources
ECM synthesis, while establishing a proprietary intellectual property right portfolio to strengthen the foundation for new and promote the sustainable transformation and technological advancement of the industry.
quality productive force.
Case: Green and Intelligent Manufacturing of Rare Matsutake Active Ingredients
In addition, the Company selected low-toxicity, harmless, and environmentally friendly reagents and materials according to
The Tricholoma matsutake mycelium fermentation lysate filtrate independently developed by Bloomage Biotech has successfully
a strict standard. Several of its bioactive products, including Hyaluronic Acid (HA) and Ergothioneine Pro (EGT Pro), have
completed the new cosmetic ingredient registration with the National Medical Products Administration, with intended uses as a
obtained internationally recognized green certifications, including the COSMetic Organic and Natural Standard (COSMOS) skin-protecting agent and antioxidant. This development overcomes the long-standing reliance on wild harvesting of Tricholoma
and certifications issued by the French ecological certification body Ecocert, ensuring the purity and environmentally matsutake, known as the "king of mushrooms". By applying advanced microbial fermentation technologies and cell lysis
friendly attributes of these raw materials. processes, Bloomage Biotech has successfully addressed the challenges of low yield, instability, and ecological disruption
Technology Sustainability associated with the traditional sourcing methods. The innovation achieves large-scale, standardized production of this rare
natural resource while protecting biodiversity and promoting the sustainable and inclusive utilization of scarce natural resources
Leveraging cutting-edge technologies such as synthetic biology, the Company continuously strengthens its technical through technological advancement.
capabilities to support sustainable innovation. We focus on green manufacturing and biomanufacturing. Through R&D and
improvement work such as production process optimization, process parameter adjustment, and structural modification,
we improve our resource and energy utilization efficiency, and strive to meet the quality and production capacity
requirements while progressively reducing pollutant generation and carbon emission intensity, thereby exploring low-
carbon and sustainable technological pathways.
Relying on the synthetic biology platform, the Company conducts high-throughput
screening and engineering of high-yield microbial strains and promotes green
Efficient Microbial Manufacturing
microbial fermentation processes to achieve efficient and low-pollution
manufacturing of key bioactive substances.
Fermentation-based production methods are adopted to replace traditional
extraction from animal and plant sources, thereby reducing the Company's
Raw Material Source Substitution
reliance on animal-derived materials and rare plant resources while lowering
carbon emissions and wastewater pollution. Bloomage Biotech Completes the NMPA Registration for a New Cosmetic Ingredient
Green technologies such as membrane filtration and enzymatic hydrolysis are Honors for Sustainable Innovation
introduced to replace traditional high-pollution chemical treatment methods. In The Company has received broad recognition through multiple authoritative innovation awards. In 2025, Bloomage Biotech
particular, enzymatic hydrolysis is used instead of acid hydrolysis, which received a total of four sustainable innovation awards, including:
Deep Clean Production Processes
significantly reduces the use of acids and alkalis, helping to establish a clean • Recombinant Type III Collagen and Sodium Surfactin products received the Allē Award from the authoritative journal
production system that converts renewable biomass into high value-added active Cosmetics & Toiletries.
ingredients.
• The hyaluronic acid derivative technology was recognized as one of the Top Ten Technological Advances in China's
Through integrated systems such as high-throughput automated screening, Cosmetics Industry in 2025 by China Association of Fragrance Flavor and Cosmetic Industries.
enzyme transformation and evolution, and AI-based data analysis, the Company
Synergy between AI and high- Philosophy Sustainability
applies AI to design gene sequences and predict molecular structures, helping to
throughput technologies Through institutional guarantee and value-driven communication, the Company promotes the integration of sustainable
accelerate the R&D cycle, improve precision, and reduce the costs of
consumables. development principles throughout the entire value chain of corporate development. From the perspective of management,
it embeds sustainability requirements into its R&D and production processes. During the raw material development stage,
By utilizing both in vitro and in vivo research models to analyze the signaling
an Environment, Health and Safety (EHS) review mechanism is incorporated to ensure that green and safety standards
pathways and targets associated with the action of active substances, the
Deepening Mechanism Research are controlled at the source of the technical route. At the same time, the Company has established a carbon footprint
Company enhances the precision of application solutions while reducing resource
evaluation methodology for active ingredient products. By obtaining carbon footprint certifications, the Company enhances
consumption.
the green index of its products, and uses the evaluation results to guide scientific research and innovation, thereby
The Company continues to enhance its application research platforms and refine systematically advancing the low-carbon product optimization.
the application scenarios of active ingredients in fields such as skincare, food, and
Technology Platform Upgrading From the perspective of consumers, the Company returns to the intrinsic value of products and provides precise and long-
pharmaceuticals, thereby improving the development efficiency and product quality
lasting solutions based on dermatological science. It advocates rational consumption and aims to reduce unnecessary
while reducing redundant R&D investment.
resource consumption. At the same time, through science-based communication, it promotes the green consumption
philosophy and encourages the adoption of healthy and sustainable consumption concepts.
Case: Bloomage Biotech's Registration of Fermentation-Based Pharmaceutical-grade Sodium Chondroitin Sulfate Case: White Tea Hand Care Series of Bloomage Biotech: Caring for Your Hands While Protecting the Planet
The raw material for sodium chondroitin sulfate independently developed by Bloomage Biotech using a fermentation-based Bloomage Biotech consistently integrates sustainable development deeply into product innovation. It has successfully launched
process has successfully completed the master file registration with the Center for Medical Device Evaluation (CMDE) of the the White Tea Aromatic Hand Cream and White Tea Hand Cleanser. In terms of raw materials, the products prioritize naturally
National Medical Products Administration (NMPA), making the Company the first enterprise in China to achieve compliant derived ingredients, with more than 80% of ingredients sourced from natural origins. White tea extract serves as the core active
registration of fermentation-based sodium chondroitin sulfate production. This breakthrough marks a transformation in the ingredient, while the remaining ingredients are carefully selected from plant-based oils, natural moisturizing factors, and
resource sourcing model for sodium chondroitin sulfate production, shifting from traditional animal extraction to microbial biodegradable surfactants. This has reduced its reliance on chemically synthesized ingredients that may pose potential risks to
fermentation-based manufacturing. The innovation reduces the immunogenicity risks and environmental burdens and is the ecological environment and human health, embodying the principles of purity, safety, and sustainability from the source. The
expected to be applied in ophthalmology, orthopedics, and medical aesthetics. entire R&D and production process strictly follows the principles of green chemistry. The Company optimizes its production
Bloomage Biotech 2025 Sustainability Report
processes to reduce energy consumption, adopts environmentally friendly packaging to minimize plastic usage, and ensures ·The Beijing Key Laboratory of Intelligent Carbohydrate Manufacturing and Functional
that production waste is properly treated, achieving environmental friendliness in the entire value chain from raw material
Applications, jointly established by the Company and Peking University, was officially
purchasing and manufacturing to final products. Testing and validation show that the products are gentle and non-irritating to
approved. As Beijing’s first provincial- and ministerial-level key laboratory dedicated to
the skin, and demonstrate good biodegradability in natural environments, which can reduce the potential environmental impacts.
precision manufacturing and applications in carbohydrate science, it fills a gap in specialized
platforms within the Beijing International Center for Science and Technology Innovation. The
Science and Technology Ethics laboratory focuses on three core research directions—carbohydrate biosynthesis, chemical
Deepening University-
The Company strictly upholds the ethical boundaries of scientific research and rigorously complies with applicable synthesis, and functional applications—while actively supporting China’s 15th Five-Year Plan
Enterprise Collaboration
regulations and guidelines, including the Ethical Review Measures for Life Science and Medical Research Involving Human to drive innovation in biomanufacturing technologies and industrial upgrading.
Subjects, the Good Clinical Practice (GCP) for Drug Clinical Trials, and the Declaration of Helsinki. By adhering to the 3R ·The Company continues to deepen collaboration with universities including Jiangnan
principles, "Replace, Reduce, and Refine", it has established the internal specification titled Technical Guidelines for University and Southwest University. Guided by the “Three Reductions and Three Health
Cosmetic Consumer Usage Testing to ensure that both internal and external testing activities are conducted in compliance Initiatives” concept, these partnerships advance both fundamental research and translational
with laws and regulations. From the perspective of governance structure, it has established an ethics management system development of active ingredients in areas such as joint health, lipid metabolism, and gut
with clearly defined roles and responsibilities. The R&D Management Committee is responsible for overseeing the health.
development of technology ethics on the global R&D platform, while the Cosmetic Efficacy Evaluation Ethics Committee
·Together with leading domestic research and medical institutions, the Company has initiated
provides dedicated oversight of relevant evaluation procedures. Leveraging a dynamic risk assessment framework, the
Building Academic the establishment of the Skin Pharmacology Committee under the Chinese Pharmacological
Company continuously evaluates and updates product safety based on the latest developments in toxicology, scientific Platforms Society. This initiative aims to build a comprehensive academic platform spanning the full
assessment methodologies, and regulatory requirements. In 2025, the Company incurred no regulatory penalties related
value chain and to address common challenges in the industry.
to violations of technology ethics standards.
·In 2025, the Company published multiple high-impact SCI papers in fields including
Test Ethics and Clinical Alternative Approaches
functional sugars, flavonoids, and probiotics. Notably, its research team published a study on
Guided by the core principles of science, humanity, and responsibility, Bloomage Biotech continuously explores advanced Research Outputs N-acetylneuraminic acid in npj Science of Food, a Nature portfolio journal. The study
technologies and alternative approaches in the evaluation of product safety and efficacy, aiming to reduce its reliance on systematically elucidates its roles in immune regulation and gut microbiota modulation,
both human and animal testing. The Company has successfully established and applied a series of advanced in vitro model providing robust scientific support for the Company’s proprietary BLOOMNEST product line.
technologies, which are widely used in safety and efficacy evaluations such as skin irritation and phototoxicity assessments.
In addition, it has developed a multidimensional efficacy evaluation system to ensure product safety while continuously Case: Bloomage Biotech Co-Initiates the Establishment of the Skin Pharmacology Committee to Promote
reducing its dependence on traditional testing methods. Collaboration among Industries, Universities and Research Institutes
The Company regards human efficacy and safety verification as a cornerstone of compliance and trust. For finished In November 2025, at the 2025 Academic Conference on Skin Pharmacology and Medical-Engineering Translational Research,
products, we collaborate with qualified clinical testing institutions to conduct rigorous human efficacy tests, ensuring that Bloomage Biotech cooperated with leading domestic research and medical institutions to initiate a proposal for establishing the
all data withstand both scientific and ethical scrutiny. During the clinical trial process, we first assess the feasibility of clinical Skin Pharmacology Committee under the Chinese Pharmacological Society. This initiative aims to build a comprehensive
trial exemption through methods such as comparison with equivalent products. For trials that must be conducted, we strictly academic platform spanning the entire value chain from basic research to clinical validation. Leveraging Bloomage Biotech's
implement informed consent procedures to fully protect the rights and interests of subjects and ensure the scientific rigor research strengths in the Extracellular Matrix (ECM) and anti-aging science, the collaboration focuses on addressing common
of the trials. industry challenges, particularly in efficacy evaluation and delivery technologies.
In terms of animal testing, the Company strictly complies with the Guiding Principles for the Registration Review of Animal
Testing Studies for Medical Devices, and always prioritizes animal welfare and ethical principles. Alternative methods such
as cell-based experiments are adopted first to avoid unnecessary animal testing.When animal testing is indeed required
for product safety assessment, the Company conducts strict screening of partner institutions, prioritizing research
organizations and medical institutions with sound animal ethics review mechanisms. Cooperation agreements clearly
stipulate compliance with nationally and internationally recognized animal ethics principles and relevant regulations, so as
to protect laboratory animal welfare, optimize experimental designs to reduce animal usage, and minimize animal suffering
to the greatest extent.
In 2025, focusing on core functional ingredients and products such as salidroside and hyaluronic acid (HA) derivatives, the
Company established an in vitro acute toxicity evaluation model based on human keratinocytes, reducing or replacing
animal toxicology tests and animal cell tests to ensure animal welfare. In addition, we developed a highly biomimetic in
vitro three-dimensional dermal tissue model to simulate the real skin microenvironment, enabling rapid evaluation of skin
cell responses, biocompatibility and functionality of raw material or product candidates. This model has been pioneeringly
Bloomage Biotech attended the 2025 Academic Conference on Skin Pharmacology and Medical-Engineering
applied in pharmaceutical and medical device R&D projects.
Translational Research
Artificial Intelligence and Information Ethics
Standard Setting
Bloomage Biotech abides by relevant standards on artificial intelligence (AI) ethics and information ethics. In product R&D,
the Company applies AI technologies in a responsible manner. In particular, when adopting generative AI solutions, active ·During the reporting year, the Company participated in the development of several national
human oversight is implemented, and comprehensive evaluation and assessment are conducted on final outputs. In terms and industry standards for sodium hyaluronate. The industry standard developed under the
of information ethics, the Company regards data as a key asset, coordinates the requirements of information confidentiality Company’s leadership, Determination of Sodium Hyaluronate Content in Oral Cleaning and
and integrity, and ensures compliant management and control throughout the entire data lifecycle. Care Products by High-Performance Liquid Chromatography, successfully passed review.
Sodium Hyaluronate Testing
In addition, it actively contributed to the development of national standards including the
Standards
Determination of Sodium Hyaluronate in Food, the Methods for Determining the Purity and
Collaborative Development
Molecular Weight of Sodium Hyaluronate, and the Methods for Determining the Degree of
Bloomage Biotech actively builds an open R&D ecosystem, extensively sharing its technological expertise and industry Modification and Cross-Linking of Cross-Linked Sodium Hyaluronate, providing key
chain resources. In 2025, by deepening industry–university–research collaboration, leading the development of high- methodological support for quality control of related products.
standard industry norms, and expanding its strategic partnerships, the Company broke down industry barriers and, together
with its partners, drove industry-wide innovation. Raw Material and Product ·During the reporting year, the Company led the development of group standards including
Standards the Ectoin for Medical Device and the Sodium Acetylated Hyaluronate for Cosmetic Use. It
Cooperation Among Industries, Universities and Research Institutes
Bloomage Biotech 2025 Sustainability Report
also participated in the formulation of several group standards, such as the DNA Sodium as
a Cosmetic Ingredient and the Guidelines for the Export of Collagen Raw Materials for Use
in Medical Devices. In addition, it also participated in the development of the industry
standard, Recombinant Collagen Dressings, systematically improving the technical
standard framework in these related fields.
·During the reporting year, the Company's brand QuadHA, in collaboration with the Chinese
Frontier Technology Research Hospital Association and other institutions, released the Expert Guidelines on
Guidelines Cellular-Level Anti-Aging, providing technical leadership and normative reference for the
emerging field of cellular-level anti-aging.
Case: Official Release of the Group Standard - Ectoin for Medical Device Developed under the Leadership of
Bloomage Biotech
Keynote Speech Delivered by Professor Shi Haining, Chief Scientist of Functional Foods at Bloomage Biotech
Led by Bloomage Biotech and jointly drafted with multiple industry partners, the group standard - Ectoin for Medical Device
(T/CSBM 0061-2025) was officially released and will come into effect on March 1, 2026. The establishment of this standard aims Case: Bloomage Biotech's Presence at the 35th IFSCC Congress with Nine High-Quality Papers
to address the current inconsistent quality issues of Ectoin (Tetrahydromethylpyrimidine Carboxylic Acid) used in medical
In September 2025, the 35th IFSCC Congress was successfully held at the Palais des Festivals et des Congrès de Cannes.
devices, and to provide a unified industry benchmark to ensure the safety and efficacy of raw materials.
Bloomage Biotech presented nine high-quality research papers at the congress, demonstrating the global scientific influence
and competitiveness of China's beauty and cosmetics research community. At the congress, Bloomage Biotech delivered a
speech on its cutting-edge research titled Ectoin in Addressing Chronic Stress under a 3D Skin Model, and shared its latest
research findings, injecting new scientific momentum into the technological innovation in the cosmetics industry.
Group Standard - Ectoin for Medical Device
Industry Empowerment Bloomage Biotech at the 35th IFSCC Congress
The Company has established strategic partnerships with Xcell, LG Household &
Health Care, and COSMAX NBT in Korea. With a focus on areas such as cell culture Intellectual Property Protection
Expanding Global Collaboration
media, skin longevity, and oral anti-aging agents, they develop products and introduce Bloomage Biotech integrates intellectual property (IP) management into the entire process of product operations
technologies jointly to promote international collaborations and localized applications. management. By establishing clear management policies and objectives, optimizing organizational structures and resource
elements, and strengthening full lifecycle IP management, the Company implements the Plan-Do-Check-Act (PDCA) cycle
The Company actively participates in leading international academic conferences. As
a key contributor to global scientific collaboration and knowledge sharing, it
to build and continuously improve a standardized and effective IP management system. During the reporting year, the
continuously shares its cutting-edge R&D achievements and innovative expertise with Company obtained certification for its intellectual property management system and upgraded the system in accordance
Sharing Innovative Expertise with GB/T 29490-2023 standard.
the global scientific community. Through open and professional academic dialogues, it
transforms innovation into shared scientific consensus that drives the collective The Company strictly complies with the latest laws and regulations. With reference to standards such as the Requirements
advancement of the industry. of Enterprise Compliance Management Systems for Intellectual Property, it has developed and continuously refined the IP
protection management policies and procedures tailored to its business development needs, and effectively implemented
them in its IP management activities. It clearly defines the principles and division of responsibilities for managing various
Case: Bloomage Biotech's Presence at the 2025 International Hyaluronic Acid Conference types of intellectual property rights, including patents, trademarks, copyrights, and trade secrets, and regulates the
In June 2025, Bloomage Biotech participated in the 5th International Hyaluronic Acid Conference hosted by the International processes of IP application and registration, utilization, management, transfer, and protection. In addition, IP management
Society for Hyaluronan Sciences (ISHAS), where it presented a range of scientific research and innovation achievements in the documentation is managed in a scientific and well-organized manner.
field of hyaluronic acid. Professor Shi Haining, Chief Scientist of Functional Foods at Bloomage Biotech, delivered a keynote
speech demonstrating that hyaluronic acid has protective effects on the joint health of physically active populations based on
scientific experimental data, providing theoretical support for the emerging field of sport nutrition. In addition, Dr. Sun Xin, an Strengthening the Evaluation ·The Company formulates the patent portfolio strategies, defines clear portfolio
applied research scientist, introduced a supramolecular hyaluronic acid-ectoin complex (HA-ECT) developed by Bloomage Mechanism before Patent objectives and principles, and designs differentiated filing approaches according to
Biotech. Through molecular design, it can enhance the skin permeability and cellular activity, and help to alleviate skin Application different technical solutions.
inflammation and aging caused by external factors, offering new directions for skincare product development.
·The Company adheres to the principle of "trademarks precede market entry". To be
Enhancing Trademark and Brand specific, it conducts comprehensive searches and analyses prior to product
Development launches, and completes trademark registrations for multiple classes in different
regions to build a trademark portfolio covering key global markets. At the same time,
Bloomage Biotech 2025 Sustainability Report
it strengthens its routine monitoring of the external use of the "Bloomage Biotech" The Company proactively collaborates with external regulatory bodies, certification agencies and customers to conduct
brand. It has also established supporting internal audit specifications to ensure the various audit activities. By establishing an internal quality inspection and audit team, we routinely conduct internal system
lawful and compliant use of brand marks. audits and product tests to ensure management compliance. In 2025, we completed a total of 55 factory inspections by
clients and third-party audits organized by clients, with no major quality risks identified. For general deficiencies identified
·The Company further optimizes its intellectual property data system, and enhances during audits, we developed corrective action plans according to requirements and completed closed-loop processing
Advancing Digital Management its capabilities for rapid data retrieval, multi-dimensional analysis, and real-time timely, ensuring effective operation and continuous improvement of the quality management system.
Upgrades monitoring of critical nodes. Digital tools are leveraged to replace the repetitive
manual work, significantly improving its operational efficiency. Quality Audit Overview
·The Company actively broadens its external communication and collaboration ·For pharmaceutical and medical device: Brazil MDSAP, EU MDR audits, BSI unannounced inspections, etc.
channels and proactively participates in industry standard development and ·For active pharmaceutical ingredient (API): FDA audits, inspections of Ukraine State Administration of Medicines
legislative research. It has participated in activities such as the revision of the ·For personal care: ISO 22716 & GMPC audits and Watsons audits
Guidelines for the Cultivation of High-Value Patents organized by Shandong
Expanding External Collaboration Quality Certifications
and Exchange Provincial National Intellectual Property Protection Center, and legislative research
for the Regulations of Jinan Municipality on the Protection and Promotion of ·ISO 13485 Medical Device Quality Management System Certification
Intellectual Property Rights led by Jinan Municipal Coordination Task Force for ·ISO 9001 Quality Management System Certification
Quality City Development, thereby contributing to the standardized development of ·ISO 22716 & GMPC (US) Certification
the intellectual property sector.
·EFfCI GMP (Good Manufacturing Practice Certification by the European Federation for Cosmetic Ingredients)
The Company has established a mechanism for resolving intellectual property disputes and formed a dedicated emergency
·HACCP System Certification
response team comprising IP professionals, legal personnel, external attorneys, and technical experts. In case of an
intellectual property dispute, the team will conduct investigations, obtain evidence for infringement cases, and take ·FSSC 22000 Food Safety System Certification
differentiated response measures. In 2025, the Company was not subject to any penalties or liabilities arising from ·ISO 22000 Food Safety Management System Certification
infringement of third-party intellectual property rights, nor were there any material IP infringement litigation cases. ·Kosher Certification
In terms of capability development, the Company's IP team maintains a biweekly knowledge-sharing mechanism and ·Halal Certification
delivers annual IP training programs. During the reporting year, a total of seven specialized training sessions covering
patents, trademarks, and copyrights were conducted for business units, with 310 participants in total. These sessions Case: Bloomage Biotech Successfully Passes FDA Audit
effectively enhanced employees' IP awareness and practical competencies. In March 2025, the Company received a notification of compliance following the U.S. Food and Drug Administration (FDA) on-
site cGMP inspection, along with the Establishment Inspection Report (EIR), confirming that the relevant facility passed the on-
Quality Management site GMP audit with "zero-deficiency". As one of the world's primary pharmaceutical regulatory authorities, the FDA conducts
audits covering critical elements such as quality systems and data integrity. This audit was conducted in accordance with
We define quality management as a double materiality issue: it is not only a core focus of the company's sustainable requirements including ICH Q7, covering six major systems (i.e., quality systems, facilities and equipment, materials systems,
development, but also has a material impact on the company's financial performance. The Company strictly adheres to production systems, laboratory systems, packaging and labeling), with additional verification of computerized systems and
national laws, regulations, and technical guidelines, including the Pharmacopoeia of the People's Republic of China, the electronic records integrity. The "zero-deficiency" result of this audit marks that the Company's Good Manufacturing Practice
Guidelines for Self-inspection Verification of Medical Device Registration, and the Technical Guidelines for Cleaning (GMP) system for pharmaceutical production meets international high-standard requirements.
Validation. It continuously implements and refines internal regulatory documents such as the Quality, Food Safety and
HACCP Management Manual and the Product Monitoring and Measurement Control Procedure. By establishing a clearly Strategy
defined, full-process quality management system, it conducts quality and safety controls covering product design and Bloomage Biotech integrates quality management into its corporate strategy, clearly defining a quality strategy centered
development, R&D innovation, manufacturing, warehousing and logistics. on "Customer Centricity, Compliance Competitiveness, and Quality and Inheritance ". By benchmarking against
international advanced standards, it has established a comprehensive quality management system, promotes a culture of
Governance quality across all employees, and consistently delivers products and services with market competitiveness.
Bloomage Biotech has established a three-tiered quality management structure comprising the Board of Directors, Supply Product Lifecycle Quality Assurance
Chain Platform, and Quality Center, employing a vertical management model to implement quality management. The
Bloomage Biotech implements quality control throughout the entire product lifecycle, continuously enhancing its quality
Company conducts management reviews and internal audits in accordance with system requirements to ensure the
management system covering supplier quality, R&D management, production management, product recalls, and other
effective operation of its quality management system. It also cascades quality objectives down to organizational and
processes. The Company conducts comprehensive product safety reviews across all segments of the industrial chain and
individual performance levels, continuously monitoring and evaluating them through key quantitative indicators. This drives
maintains ongoing quality management and supervision of products. During the reporting year, the Company conducted
the implementation of quality responsibilities at every level.
identified after review.. In 2025, none of the Company's products, including pharmaceutical/non-pharmaceutical raw
materials, cosmetics and medical devices, were found non-compliant.
·The Company adheres to internal regulations such as the Material Classification Management
Procedure and the Group Supplier Quality Management Procedure, strictly conducting supplier
Supplier Quality qualification audits, controlling incoming material quality and performing regular quality assessments.
For detailed information on supplier quality management, please refer to the Section "Sustainable
Supply Chain Management".
·Quality Benchmarking: During the product development process, product critical quality attributes
are defined by packaging development engineers, formulation R&D engineers, professional efficacy
R&D Quality evaluation institutions and safety testing organizations to ensure quality and safety are controlled from
the very beginning of product R&D.
·R&D Evaluation: Through formulation design, compatibility studies, and stability testing, the
Bloomage Biotech 2025 Sustainability Report
Company conducts safety assessments and quality reviews during the R&D phase, ensuring that Risk Management
product development is both science-based and quality-controlled. Bloomage Biotech has established a routine mechanism for quality risk identification and communication. The Quality
·Source Control: Leveraging the proprietary R&D technology platform, the Company conducts in- Center is responsible for identifying and analyzing quality-related risks and opportunities, formulating response measures
depth research on the efficacy mechanisms, safety, and stability of various bioactive substances.
to reduce risks to acceptable levels, and ensuring the effective operation of the quality management system. In the
Through rigorous source screening, compositional analysis, purity test and allergenicity assessment of meantime, the Quality Center prepares risk management reports and conducts quarterly quality risk reviews and reports to
raw materials, we strictly enforce quality standards and production compliance at the sourcing stage, achieve dynamic monitoring and rapid response. Each production base formulates and implements the Risk and
ensuring safety, efficacy, and batch stability. Opportunity Control Procedure to identify, assess, control and track improvements related to quality risks and opportunities.
·Process Control: An analytical testing system for product manufacturing has been established to Based on its own business characteristics and industry research findings, the Company conducts a comprehensive
carry out multiple key safety tests, including accelerated stability studies, packaging material identification of quality management risks and opportunities. Following this identification, it performs an integrated
compatibility research, and preservative efficacy test. Through rational risk assessment and multi- assessment focusing primarily on the type, level, potential impact and countermeasures for each risk and opportunity.
dimensional test methods, potential risks such as prohibited ingredients, excessive levels of restricted
substances, and microbial contamination are identified and controlled. All test items are executed in
accordance with national standards, industry regulations and international regulatory requirements, Risk
Risk Type Risk Level Potential Impact Response Measures
Production Quality providing a solid technical foundation for product quality. Description
·Process Standards: We have enhanced process standards by introducing advanced manufacturing
Adjustments in regulations and ·Main functional departments reinforce
technologies and refined process controls to achieve high-efficiency production in sterile compliance requirements may
environments. Through rational raw material compatibility, the synergistic effects of the formulation collection of and evaluation on laws
render products, processes or
system are optimized. Process validation is conducted to comprehensively verify equipment, Regulatory and regulations as required.
High quality systems non-compliant,
production procedures and test methods for commercial manufacturing. requirements ·All departments shall implement strict
leading to increased
·Finished Product Test: A dual testing mechanism is implemented before finished products are rectification costs and process controls in accordance with
launched. On one hand, a comprehensive full-specification test is conducted in accordance with compliance risks. requirements.
product standards to ensure that product quality meets specified requirements. On the other hand,
production and testing records are reviewed to confirm that all deviations have been effectively ·Reinforce communication with
addressed and closed, with no outstanding issues remaining. Products are released only after passing Changes in customer quality customers about formulating quality
this comprehensive evaluation. standards, delivery timelines standards, and unify standards and
Customer and cost expectations may test methods of the two parties.
·Routine Prevention: Based on product positioning, order cycles, and historical demand fluctuation High
demand increase alignment difficulties, ·The Marketing Department enhances
trends, the Company establishes rational safety stock levels, and defines replenishment triggers and elevate delivery risks and communication and interaction with
upper and lower inventory limits, thereby achieving precise replenishment and optimized inventory reduce customer satisfaction. customers to promptly collect and
structure. External Factors understand their needs.
·Emergency Response: An interdepartmental coordination mechanism has been established to
rapidly identify urgent order requirements and conduct comprehensive assessments of the availability Lagging iteration of processes
of finished goods, semi-finished products and packaging materials. By flexibly responding through and equipment may
Daily Operational compromise quality stability ·Develop technology breakthrough
methods such as reallocating available stock and accelerating the conversion of semi-finished
Management Technology High and efficiency, increase costs, and equipment upgrade plans based
products, the Company enhances its response speed. Timely post-event reviews are conducted, and
the findings are simultaneously updated into the production scheduling process. and undermine product on current technical capabilities.
·Continuous Monitoring: After a product is launched, it enters a phase of active monitoring and competitiveness and market
responsiveness.
continuous optimization, and a "Post-marketing Product Safety Monitoring System" is established..
Regular data reviews are conducted, with corresponding adjustments simultaneously made to Industry competition and
·Intensify efforts to explore new
inventory and production plans, thereby achieving a dynamic balance between supply and demand demand fluctuations may
and ensuring efficient resource allocation. markets, assess trends in mature
impact order stability and
Competition Moderate markets and promptly provide the
pricing, increasing operational
·Recall System: The Company has established and improved system documents including the Non- Company with new market
uncertainty and complicating
conformance Control Procedure, the Product Recall Management Procedure and the Medical Device strategy implementation. opportunities.
Recall Management Standard Operating Procedure. These procedures cover the entire chain from risk
identification and rapid response to traceability and disposal, effectively achieving closed-loop Inadequate operation and
management of quality risks. maintenance management of
·Strictly implement equipment
·Traceability System: A digital smart QR code traceability system has been established, recording facilities and equipment may
upgrades and maintenance according
key information at each stage, including raw material warehousing, production, packaging, and Internal Factors Resources Low lead to downtime, deviations,
to the Company's plans to enhance
shipment. This enables point-to-point traceability from the product to its corresponding container. The or quality fluctuations,
equipment stability.
traceability system covers key stages including new product introduction management, supplier increasing production risks and
Product operational costs.
traceability and management, raw and auxiliary material certification, production and manufacturing
Traceability and
control, laboratory management and warehousing and transportation management. Annual forward
Recall
and backward traceability simulation tests are conducted to ensure product traceability throughout its
entire lifecycle, from production through the post-market phase. Opportunity Opportunity Type Description Response Measures
·After-sales System: We participate in return/refund guarantee programs on major e-commerce
Adjustments in the regulatory ·Dynamically monitor laws,
platforms (e.g., Tmall, Douyin, JD.com, Xiaohongshu), while deploying dedicated customer service
environment and policy regulations and regulatory
personnel to proactively collect consumer feedback on product quality, usage methods and skin
Opportunity orientation may create requirements while
concerns to drive continuous improvement of products and services.
Policy opportunities for enhancing intensifying policy learning.
·Recall Drills: At least one simulated recall drill is conducted annually to test and enhance the
the Company's compliance ·All departments strictly
Company's recall capabilities and response speed. No actual recall incidents occurred during the capabilities, product implement relevant work in
reporting year. registration and market accordance with the
Bloomage Biotech 2025 Sustainability Report
Opportunity Opportunity Type Description Response Measures consolidates and shares quality philosophies, standard requirements and exemplary cases to facilitate knowledge transfer.
expansion. Company's rules and The Company conducts annual quality safety training for all employees. During the reporting period, quality and safety
regulations. culture training covered topics including quality and safety laws and regulations, and internal system audit. This training
reached personnel in quality-related positions at the production bases. Through special lectures, industry exchanges, and
Intensified industry professional skills competitions, the Company enhanced employees' quality knowledge and practical abilities,
competition is driving strengthening their capacity for problem analysis and resolution. Besides, it integrated quality awareness, tools and
customers to raise their methods into business units and operational processes, fostering organization-wide participation in quality creation, quality
requirements for quality,
·Actively expand the market control and continuous improvement.
delivery, and compliance
to create new opportunities
Market capabilities. This presents an Case: Bloomage Biotech Quality Month: Improving Quality Through Innovation
opportunity for the Company for development and
transformation. In September 2025, Bloomage Biotech organized Quality Month activities centered on the theme "Improving Quality Through
to acquire new customers
Innovation". During the event, the Company officially released a quality white paper The Ark of Life: Hoisting the Sails toward
and secure higher-value
the Stars and Seas - Exploration, Heritage and Warmth. This paper elaborates on core topics such as quality culture and
business by upgrading its
ecological foundation, competitiveness building, quality improvement and heritage innovation, and the expression of quality
management capabilities.
insights. This fully demonstrates Bloomage Biotech's pursuit of excellence in quality and its implementation pathway.
Introduction of new Simultaneously, Bloomage Biotech released its corporate quality declaration: "Quality is the lifeline of our enterprise, and
·Actively carry out
equipment and processes safeguarding this lifeline is the code of conduct for every employee. Everyone is a creator and guardian of quality". This further
can enhance technological technological research and clarifies quality responsibilities for all employees and strengthens their commitment and accountability. To implement these
Technology equipment modification to principles, the Company prioritized quality safety culture training with full staff participation. Through specialized lectures, case
proficiency, reduce product
costs, and strengthen market continuously guarantee studies, on-the-job practices and other diverse activities, quality concepts were integrated into daily operations, effectively
product quality. enhancing employees' focus on quality compliance and risk prevention.
competitiveness.
Metrics and Targets
Bloomage Biotech has established the operational target of building and implementing a comprehensive quality
management system that covers the "entire process, full chain, and all employees". Building upon this foundation, it sets
quality management goals tailored to its own business characteristics. It also conducts regular management reviews and
evaluations of established product quality and safety targets to ensure they are effectively implemented as planned and
successfully achieved. This year, all its bases met all annual quality targets. The Company had no major liability accidents
related to product and service safety & quality, with no significant quality risks identified.
Medical Devices, Pharmaceutical Raw Materials, Non-
pharmaceutical Raw Materials
Target: Quality White Paper - The Ark of Life: Hoisting the Sails toward the Stars and Seas - Exploration, Heritage and
A customer satisfaction rate of over 93%, and a first-pass Warmth
yield rate of finished products of over 99%.
Progress: Pharmacovigilance and Adverse Reactions
Quality Management Targets Cosmetics Pharmacovigilance
Target: Bloomage Biotech strictly complies with national, local, and international regulations and guidelines related to
On-time delivery rate exceeding 99% and the Operating Procedures for the National System for Monitoring Adverse Events of Medical Devices, thereby
Progress: establishing a pharmacovigilance system covering pharmaceuticals, medical devices and cosmetics. In 2025, it focused
The Company has established a comprehensive pharmaceutical safety management system structure. The Drug Safety
Committee is led and coordinated by the Chairman of the Board, with members including the heads of key functional
To achieve its quality management targets, Bloomage Biotech has developed key implementation pathways and specific departments such as Pharmacovigilance Department, Quality Assurance Department, Production Management
action plans in a systematic and comprehensive way. It has established a product quality assurance system and Department, Marketing and Sales Department, R&D and Innovation Department and Regulatory Compliance Department,
continuously improved its quality safety and culture training content, driving its product quality and safety management ensuring that management efforts cover all aspects of the process. The Drug Safety Committee focuses on its core
level towards industry excellence benchmarks. responsibilities, including the assessment of major safety risks, the management of significant or urgent drug safety
incidents, decision-making on risk control and the monitoring of drug safety. It promotes cross-departmental collaboration
Quality Safety Culture and Training to achieve efficient response and closed-loop management across all stages from R&D and production to the post-
The Company adheres to the principle that "quality is the lifeline of an enterprise", and continuously promotes the marketing phase.
communication and implementation of this quality philosophy. Through initiatives such as "Quality Month," quality
Through dedicated internal audits & self-inspections for pharmacovigilance, product testing, specialized investigations, and
knowledge competitions, and QC group activities, it enhances employees' understanding and engagement with quality
external reviews by clients and regulatory bodies, the Company ensures data integrity and traceability throughout product
requirements and improvement methodologies, transforming quality awareness from regulatory requirements into daily
lifecycles. In 2025, we completed one dedicated internal audit of our pharmacovigilance system and one company-level
practices. Additionally, leveraging platforms including quality culture walls, the Quality White Paper, and internal training, it
Bloomage Biotech 2025 Sustainability Report
GMP self-inspection for pharmaceuticals. We underwent 14 audits related to adverse event monitoring, which were Adverse Reaction Handling Process
conducted as part of official, client, and company-level medical device inspections. Additionally, we completed four self-
inspections and external audits of our cosmetic quality system. These efforts achieved full coverage of critical processes, ·Adverse reaction reports for individual cases are submitted through the regulatory system or
ensuring the compliance and safety of all product categories. internal platforms within the required deadlines, ensuring timely compliance.
To continuously enhance the pharmacovigilance awareness and capabilities of all employees, the Company conducted ·For events assessed as posing potential quality or safety risks, reports are escalated to
diverse training sessions covering pharmacovigilance, medical device vigilance and cosmetic adverse reaction monitoring. higher management through the designated channels.
In 2025, we organized 25 training sessions, including regulatory briefings, policy interpretation, technical courses, and ·Relevant business units lead cross-departmental investigations to comprehensively assess
practical exercises, with a total of 188 participants. potential contributing factors across product usage, storage, transportation, manufacturing,
Investigation and Decision-
Furthermore, the Company actively collaborates with external industrial partners to build a pharmacovigilance collaboration quality control, R&D design and regulatory compliance.
Making
network, empowering employee growth and the sustainable development of the enterprise. In 2025, we engaged in in- ·The investigation findings from all departments are consolidated to assess the nature and
depth cooperation with clients and institutions such as the Jinan Food and Drug Inspection and Testing Center, Jinan scope of impact of the event. Subsequently, corresponding risk control measures (such as
Adverse Drug Reaction Center. Focusing on key topics including cosmetic adverse reaction monitoring, development of product improvement, label revision, or partial recall) are formulated and implemented,
medical device vigilance system, and investigations into the current status of manufacturing enterprises, we conducted thereby achieving closed-loop management.
eight exchange and practice activities. These took various forms, such as enterprise research, joint research projects, and
participation in provincial and municipal pharmacovigilance professional knowledge competitions, thereby promoting the
sharing of pharmacovigilance experience and capability enhancement.
Chemical Ingredient Management
Case: Promoting Learning Through Competition to Build a Robust Pharmacovigilance Knowledge System
Bloomage Biotech has established a chemical ingredient assessment and management system covering the entire process
In the 2025 Jinan City Pharmacovigilance Knowledge Competition in Shandong Province, the team representing the
from raw material access to finished product disclosure. This system balances compliance baselines, risk assessment, and
Pharmacovigilance Center of Bloomage Biotech was awarded the Second Prize for group. Bloomage Biotech is committed to
consumer rights to know and is managed with reference to the "4M" methodology.
strengthening employees' expertise in drug safety and quality standards through learning exchanges and professional
competitions, leveraging contests as educational tools to deepen mastery of pharmacovigilance regulations and practices. The Company continuously refines its chemical ingredient management framework, establishing a framework that includes
compliance-based screening and quantitative risk assessment mechanisms.
Case: Government-Enterprise Collaboration Enhances Cosmetic Safety Monitoring
Compliance-based Screening: It is ensured that raw materials and finished products of Bloomage Biotech comply with
To better implement the Regulations on Supervision and Administration of Cosmetics and the Measures for the Administration regulatory requirements, such as the Safety and Technical Standards for Cosmetics, and that restrictions or substitutions
of Cosmetics Adverse Reaction Monitoring, while promoting corporate safety accountability and monitoring efficacy, Jinan Food
are implemented for ingredients with potential controversy.
and Drug Inspection and Testing Center conducted technical guidance sessions at Bloomage Biotech on June 25, 2025.
Bloomage Biotech introduced its monitoring mechanisms and operational status, focusing on key areas including monitoring Quantitative Risk Assessment: Bloomage Biotech conducts exposure level and risk assessments based on product
system development, personnel allocation, information collection, analysis and evaluation, risk management and control, and usage scenarios. It continuously optimizes formulations to control chemical exposure at a reasonable and as-low-as-
the monitoring of new cosmetic ingredients. Drawing on regulatory requirements and practical experience, experts from the reasonably-practicable level. It also completes necessary human efficacy and safety testing before all products are
center provided guidance and recommendations on strengthening monitoring awareness, optimizing reporting procedures, launched, thereby strengthening the defense line of ingredient management.
improving information collection, and enhancing risk prevention and control capabilities. This exchange further deepened
Furthermore, the Company implements dynamic management of prohibited, restricted and high-risk ingredients, including
government-enterprise collaboration, enabling Bloomage Biotech to refine its monitoring mechanisms and enhance its risk
the following:
identification and response capabilities, thereby continuously ensuring consumer safety in cosmetic use.
Adverse Reaction Management ·The Company conducts mandatory screening for prohibited
The Company places great importance on adverse reaction management for pharmaceuticals, medical devices, and ingredients in accordance with national laws and regulations,
Strict Control of Prohibited and Restricted Ingredients
functional skincare products. It has formulated and issued procedural documents including the Management System for such as the Safety and Technical Standards for Cosmetics,
Reporting and Monitoring of Adverse Drug Reaction, the Control Procedures for Monitoring and Re-evaluation of Adverse to ensure "zero addition" of prohibited substances.
Event of Medical Devices, and the Management Regulations for Monitoring of Cosmetics Adverse Reaction. In the
·For ingredients not legally prohibited but with potential safety
meantime, by integrating these with processes such as customer complaint handling and product recalls, it ensures that
measures including reporting, investigation, customer reassurance, and product disposal for adverse reaction events are risks, the Company establishes specialized assessment and
substitution mechanisms, implementing restrictions
carried out within the required timeframes.
proactively based on industry research advancements and
In 2025, the Company reported 183 adverse drug reactions, 66 adverse events related to medical devices, and 1 adverse Proactive Restriction and Substitution of Controversial
health requirements.
reaction related to cosmetics, continuously enhancing its capacity for quality and safety risk prevention and control. Ingredients
·The Company prioritizes the use of safe, recognized green
ingredients in the industry as substitutes, and reduction of the
use of additives such as preservatives at optimized raw
Adverse Reaction Handling Process
material ratios.
·The Company collects adverse reaction information reported by relevant parties, including
·A dynamic chemical phase-out list management mechanism
medical institutions, distributors, and individual consumers. Relevant internal departments then
has been established. This involves regularly reviewing the
Information Collection and complete adverse reaction feedback forms for individual cases. list of chemicals in use. Based on factors such as updates to
Assessment ·A preliminary assessment is conducted on the authenticity and completeness of the collected the latest laws and regulations, safety risk assessment
information. For cases where information is incomplete or questionable, a follow-up procedure results and advancements in industry technology, it
is initiated to further verify the details. formulates a phased phase-out plan for chemicals that are
Chemical Phase-out Program
high-risk, low-efficiency, or have poor environmental
·Based on the complete information, a report analysis is conducted, with a focus on identifying performance.
serious adverse reaction events and potential risk signals that could lead to significant social ·During the phase-out process, supporting measures such as
Report Analysis and
impact. alternative solution validation, compliant disposal of existing
Submission
·An evaluation is performed on the causality between the adverse reaction and the product, chemicals and employee training are simultaneously
leading to a determination of the causal relationship and risk level. developed to ensure the phase-out is carried out smoothly
Bloomage Biotech 2025 Sustainability Report
and orderly, without impacting production operations or multi-platform manual monitoring system to track live dynamics and public feedback in real time, ensuring that marketing
product safety. activities remain compliant and under control. If any instances of non-compliant marketing are identified, it will promptly
conduct reviews and traceability analysis and establish a record of violations. It will also optimize control processes and
update training content. This continuous improvement of the long-term mechanism reinforces institutional binding force.
The Company provides complete labeling of product ingredients in accordance with regulatory requirements and completes
the necessary filings on regulatory platforms. Consumers can access ingredient information through product packaging Client Privacy Protection
and relevant filing information channels, ensuring their right to know and supporting transparent consumption. Placing great emphasis on the client privacy protection, Bloomage Biotech has constructed a multi-dimensional protection
In terms of internal management, the Company has established comprehensive ingredient safety training and risk control system that integrates institutional constraints, technical safeguards, process controls and third-party management. The
mechanisms. Specialized ingredient safety training is regularly provided for personnel in key positions such as R&D, Company requires employees to strictly manage documents and materials, prohibiting any form of unauthorized disclosure.
production, and quality control, continuously strengthening employees' understanding and execution capabilities regarding For personnel in supervisory roles, their duty of confidentiality is explicitly defined regarding personal information and
regulatory requirements, lists of prohibited and restricted substances, and the management of sensitive ingredients. This privacy accessed during the execution of their duties. They are strictly prohibited from disclosing, selling or unlawfully
year, we successfully organized company-wide training sessions focused on core ingredients such as gradient molecular providing customer information. The Company conducts irregular training on trade secrets and privacy protection to
weight hyaluronic acid (INFIHA) and extracellular matrix (ECM) biomimetic technology. This promoted the management reinforce employees' compliance awareness and accountability requirements.
awareness of ingredient risk across all business areas. Through systematic capacity building, we make sure that all Regarding technology and processes, the Company employs measures such as transmission encryption to ensure the
employees possess standardized capabilities in ingredient identification, assessment, and management, providing a solid confidentiality, integrity and accuracy of sensitive or critical business data during transmission, thereby reducing information
foundation for product safety and compliant operations. leakage risks. Furthermore, it has digitized the approval process for external technical documents, standardizing the
approval pathways for internal access to, borrowing of, and external provision of materials. All B2B cooperation contracts
Customer Service and Rights Protection incorporate confidentiality clauses, prohibiting disclosure of customer information without informed consent. For B2C
consumers (end users), the Company strictly adheres to the Personal Information Protection Law of the People's Republic
Bloomage Biotech adheres to a customer-centric approach, building long-term, mutually trusting relationships through of China and platform rules, implementing the principle of notice and consent, and processing personal information within
responsible marketing, reliable privacy protection, efficient complaint resolution and continuous service optimization. the scope of legality and compliance. For customer data involving third-party collaboration, the Company implements
access reviews and manages confidentiality agreements. For third-party system operation and maintenance services, the
Responsible Marketing Company conducts qualification and credit assessments and signs confidentiality agreements to prevent risks related to
The Company places great emphasis on the scientific accuracy and regulatory compliance of its external communications. external access and data leakage.
It strictly adheres to responsible marketing-related laws and regulations, including the Law of the People's Republic of In 2025, the Company had no customer privacy breaches and received no confirmed complaints regarding infringement of
China on the Protection of Consumer Rights and Interests and the Advertising Law of the People's Republic of China. To customer privacy or data loss. It also had no customer complaints arising from inadequate customer data security
ensure compliance, it has formulated the Code of Conduct for Advertising Release, and the Compliance Guidelines for Live management.
Streaming Promotional Activities, and has revised the Sensitive Term Base for Cosmetics and Daily Chemical Products.
Through these institutional constraints and process controls over marketing and communication activities, it safeguards the Enhancing Customer Service
legitimate rights and interests of consumers on all fronts. In 2025, the Company was not involved in any legal proceedings
related to false marketing claims. Customer Feedback and Complaints
Bloomage Biotech adheres to a customer-centric approach, having established a complaint management system guided
Enhanced Product Information Disclosure by the Group and implemented at its production bases. At the Group level, the Guiding Document for Complaint Handling
The Company has established an open, transparent and verifiable product information disclosure system, implementing Procedures is formulated. Each production base, based on its specific business characteristics, develops its own Customer
information review mechanisms and completing statutory filings to prevent misleading information. Product labels and Complaint Operating Procedures and corresponding management rules, ensuring unified standards and adapted
public documentation disclose information including Chinese name, responsible entity, executive standard number, full implementation.
ingredient list, net content, shelf life, usage instructions and necessary warnings. Additional required information is
The Company has established a customer complaint handling process through its unified online OA system. This process
supplemented according to the product type. The Company concurrently discloses information through its official website
clearly defines the responsible parties and processing standards for each stage, including complaint acceptance,
and e-commerce platforms, and enhances consumers' accurate understanding of product ingredients and usage methods
classification, response, investigation, resolution, and feedback. Access and operations are restricted to authorized
through explanations by R&D experts, science communication content, and customer service consultations. personnel, ensuring processing efficiency while strictly controlling information security. The Company has established a
In 2025, the Company initiated a product label upgrade program, adding internationally recognized certifications such as standardized closed-loop process for complaints, encompassing eight key stages. Through the system, work order routing
COSMOS Natural, NATRUE Certification, and Vegan label. Biodegradability test results and safety assessment data for and timeliness monitoring are achieved, ensuring clear responsibility assignment, explicit processing standards and prompt
key substances (particularly biomacromolecules and polymers) were disclosed to enhance supply chain transparency and and efficient responses at each stage.
verifiability.
Empowering Compliance Marketing Information Inventory product
Complaint In-depth
collection/repor association
In terms of internal management, the Company has established a systematic framework for compliance marketing, confirmation investigation processing
ting
implementing a standardized review process involving multiple departments. It has utilized digital tools for preliminary
reviews and established mandatory review stages at key milestones such as new product launches and efficacy claims.
Through external expert training and regular learning mechanisms (covering key regulatory points, compliance of sensitive
terms, case study reviews, and updates of risk lists), it has continuously enhanced the compliance awareness and practical
Reply to Implementation of Approval of
skills of personnel in key positions such as e-commerce live streaming and operations. This has established a long-term Complaint corrective and disposal
compliance management mechanism integrating four key elements - "institutional constraints, process control, training closure customers preventive actions decisions
empowerment and case study inspiration."
In its external collaborative marketing efforts, the Company has established a risk control mechanism that spans the entire Complaint Closed-Loop Process
process: before, during, and after collaboration. During the contracting phase, the Company incorporates marketing risk
The Company commits to strictly maintaining the confidentiality of complainants and whistleblowers. It publicly discloses
clauses into its contracts and explicitly requires partner agencies and influencers to strictly adhere to all relevant laws,
complaint and reporting channels through avenues such as its official website, product instructions and service agreements,
regulations and platform rules. In the pre-execution phase, the Company conducts rigorous background and access checks
and assesses customer awareness through customer satisfaction surveys. For different types of complaints, it initiates
on potential collaborators, including celebrities, influencers, and streamers. It also provides compliance training to these
differentiated handling processes, forming a closed-loop mechanism with clear classification and defined pathways:
potential partners and strictly reviews all external communication content. During live broadcasts, the Company deploys a
Bloomage Biotech 2025 Sustainability Report
Initiate the quality traceability and corrective and preventive Supplier Admission Management
Product Quality Issues
action mechanism. Bloomage Biotech strictly complies with applicable laws and regulations, including the Law of the People's Republic of
China on Tenders and Bids. It has established a rigorous supplier admission mechanism for supplier selection, and
Transfer to the adverse reaction monitoring and support
Adverse Reactions during Use conducted multi-dimensional evaluations:
process.
Incorporated into the needs assessment and R&D
Experience and Functionality Suggestions
improvement system. ·For new suppliers, the Company collects and reviews their business qualifications and product
documentation, and assesses their quality management systems.
Qualification Review
·For existing suppliers, it conducts on-site, on-line, and written audits to verify the effective
For complex complaints involving multiple stages, the Company has established a cross-departmental joint meeting and operation of their quality systems and regularly updates supplier qualification records.
joint investigation mechanism. It coordinates departments including Quality Department, R&D Department, Production
Department, Regulatory Affairs Department, and Marketing Department to conduct root cause analysis. Through technical ·Through necessary site visits and on-site reviews, the Company verifies the authenticity of
review, batch traceability, and process audits, it develops systematic improvement plans to prevent recurrence of the issue. On-site Review suppliers' production environments and management levels, and selects qualified suppliers for
Besides, it regularly conducts structured analysis of B2B and B2C complaint data, utilizing the results for product inclusion in the annual Qualified Supplier List.
optimization and service standard iteration. In 2025, the Company handled 35 quality-related complaints with a 100% ·In addition to traditional evaluation criteria, the Company also incorporates suppliers' compliance
closed-loop resolution rate. For end user complaints, it enhanced service experience through differentiated response
performance in areas such as environmental management, energy management, occupational
strategies. To be specific, it strengthened communication and emotional support for subjective experience feedback. It ESG Performance health and safety, and labor rights protection into its assessment framework.
implemented escalated responses and transparent tracking for after-sales issues. In 2025, it received 9 end user complaints ·Additional credit is granted to excellent suppliers that have obtained relevant international or
with 100% response and resolution rates.
national management system certifications.
Improvement of Customer Satisfaction
Bloomage Biotech formulated documents including the Operating Procedures for Customer Satisfaction Survey and
Through phased evaluations and ongoing monitoring and verification, the Company ensures that the supplier admission
Analysis, establishing service quality inspection and assessment standards linked to customer service performance, while
process is standardized, consistent, and risk-controlled.
continuously conducting customer service capability training. Through regular online and offline satisfaction surveys, we
evaluate complaint mechanisms, service processes and product experience. Digital tools are leveraged to expand survey
coverage and enhance data analysis capabilities, with results used for product iteration and service optimization. Documentation Trial production
Supplier approval
The Company has built a tiered training system covering internal employees and partner institutions, focusing on review validation
compliance requirements, product knowledge, service process standards, and smart tool applications. Online courses,
offline bootcamps and specialized training improve service professionalism and response efficiency.
Case: Training System Upgrade Enhances Professional Capabilities in Consumer Service
Qualified Supplier
In 2025, Bloomage Biotech upgraded the training system within its Business Unit for Commercialization of Skin Science Sample evaluation Quality agreement
List
Innovations, shifting focus from "knowledge transfer" to "capability building", and transitioning from one-way instruction to
interactive, practice-oriented learning methodologies. Through systematic, sound communication training, the Company
continuously elevates skin consultants' professional competence and communication skills, transforming them from product
presenters to skin health solution providers. This expertise is embedded throughout the service cycle to further enhance
consumer experience. At the same time, for key milestones such as new product launches and employee onboarding, the Supplementation of
Change request and
Company conducts regular training and specialized drills to ensure more accurate content delivery and more professional service. Qualified Supplier
evaluation
List
Case: BIOHYALUX Enhances Customer Satisfaction With a Closed-loop Service System
To continuously improve customer satisfaction and safeguard rights, BIOHYALUX (a Bloomage Biotech brand) optimized its
service system. Focusing on the principles of "faster response, more accurate resolution, more reliable delivery and stronger
protection", it has built a full-process service loop including care outreach, issue handling and feedback-driven improvement.
Small-batch sample
evaluation and On-site review
The team continuously iterates service quality by upgrading the member experience, standardizing service processes, production
strengthening information security and implementing satisfaction surveys and "gray release" test mechanisms. Through the
aforementioned initiatives, the key service indicators for the BIOHYALUX have shown improvement. To be specific, the first-
contact resolution rate for consumer issues increased to 95%. The delivery time has been reduced to within 48 hours. The Supplier Admission Process
complaint rate has been lowered to below 0.05%. Leveraging its excellent service quality and professional capabilities, the
customer service team for Bloomage Biotech's brand BIOHYALUX on the Tmall platform was honored with the "Golden
Dynamic Supplier Management and Evaluation
Wangwang" Customer Service Team awarded by Tmall for its efficient response speed and superior service experience. The Bloomage Biotech places strong emphasis on supplier review and has established a sound supplier evaluation system.
experience score of its Douyin store has consistently remained above 4.9 points. We have formulated the Quality Management Procedures for Group Suppliers and the Management Procedures for
Supplier Quality Review. We have also updated the Supplier Code of Conduct and the Performance Evaluation Form for
Suppliers of Production Materials. We implement a normalized supplier performance evaluation mechanism, conducting
Sustainable Supply Chain Management comprehensive assessments of suppliers in four key dimensions (i.e., quality, cost, delivery, and service). We classify
A stable, responsible, and resilient supply chain is a critical foundation for ensuring the high-quality delivery of innovation suppliers into four categories (i.e., excellent, good, qualified, and unqualified) in terms of assessment results. Based on the
achievements. Bloomage Biotech collaborates closely with upstream and downstream partners to co-create value and evaluation results, differentiated supplier management strategies are applied:
drive collaborative innovation, fostering a transparent, green, and efficient sustainable supply chain ecosystem. ·For suppliers with remarkable performance, the Company allocates greater procurement share and prioritizes them in new
product development, fostering strategic partnerships with them.
Supplier Management and Evaluation ·For underperforming suppliers, targeted performance improvement programs are initiated. Through corrective action notices
The Company has established a full lifecycle supplier management system covering supplier registration and admission, and performance review meetings, suppliers are required to complete root cause analysis and implement corrective measures
merit-based selection, partnership establishment, performance evaluation and management, exit management, and within a defined timeframe.
continuous improvement, thereby enhancing supply chain management transparency.
Bloomage Biotech 2025 Sustainability Report
Supplier Quality Management The Company has established a supplier ESG self-assessment mechanism to dynamically identify and manage the ESG
To continuously ensure product quality and supply chain reliability, the Company has established a systematic, full-lifecycle risks among key suppliers, and facilitate the capability enhancement of suppliers simultaneously. In 2025, the Company
closed-loop supplier quality management system. In addition to defining standards and responsibilities upfront through successfully achieved its annual target of conducting ESG assessments "covering over 20% of the production material
quality agreements, it implements refined management practices in daily operations and dynamic monitoring. Clear and suppliers". At the same time, it attached great importance to the training on ESG management awareness and capacity
quantifiable supplier quality targets are established, including a minimum incoming inspection pass rate of 98% for raw and building for both internal procurement teams and suppliers. During the reporting year, ESG-related training was provided
auxiliary materials and no less than 97% for packaging materials. At the same time, the Company strengthens the full- for internal procurement staff and external suppliers, continuously strengthening the ESG competencies of both internal
process traceability for suppliers and materials and standardizes the inspection and acceptance criteria. During incoming and external personnel.
material inspections, particular attention is given to verifying the consistency between labels, storage conditions, and
Supplier Performance Evaluation and Exit Management
specifications, and the applicable standards and Qualified Supplier List. Where necessary, suppliers are required to issue
The Company provides targeted improvement feedback to suppliers based on the annual performance evaluation results.
formal declarations to ensure material traceability, stable quality, and compliance with production and regulatory
Suppliers with critical non-conformities or rated as "Unqualified" are removed from the Qualified Supplier List. Any future
requirements.
cooperation with these suppliers requires re-assessment through the new supplier admission process, thus establishing a
closed-loop management system that safeguards the overall supply chain quality.
Supplier Quality Management In the reporting year, Bloomage Biotech had a total of 489 production suppliers, distributed by region as follows:
·The Company manages suppliers from the source and implements a classified management system Key Performance
based on the criticality of materials.
Source Control ·Strict review and admission procedures are implemented for key suppliers. ·Mainland China: 480
·The Company defines both parties' responsibilities, technical standards, and liability for breach of ·Hong Kong, Macao, and Taiwan, China: 1
contract through quality agreements, establishing a standardized foundation for ongoing collaboration.
·Overseas countries or regions: 8
·Relying on the annual quality agreements and continuous monitoring mechanisms, all incoming
materials are strictly inspected and accepted.
·Upon detecting any quality deviation, an immediate investigation and feedback process is initiated,
Daily Management Resilience-oriented Supply Chain Risk Management
requiring suppliers to implement corrective and preventive actions.
·Cause-based audits are conducted to verify the effectiveness of corrective measures, ensuring issues Regarding material supply stability as one of the key risks within its supply chain, the Company has established "dual
are fully closed. sourcing" as a core strategy. By developing alternative suppliers, introducing competitive mechanisms, and advancing
domestic substitution, it has reduced its single-source dependency risks and enhanced both the supply chain resilience
·A Qualified Supplier List and an annual audit plan have been established. and the cost control capabilities.
·On-site audits and unannounced spot checks are conducted for key raw material suppliers, and batch- Supplier Risk Management and Mitigation Measures of Bloomage Biotech
by-batch inspections are implemented for critical materials.
·The Company collaboratively develops corrective action plans for identified audit issues, tracks Risk Type Specific Risk Description Response Measures
Quality Audits
progress, and performs follow-up reviews to continuously enhance the supply chain quality ·Cross-functional Collaboration: Front-, mid-, and back-office
management capabilities. departments jointly develop the demand forecasts and
·In 2025, a total of 220 supplier quality audits were completed (including over 160 audits for active procurement plans, and establish an integrated information-
pharmaceutical ingredients and medical devices, and more than 60 audits for personal care materials). sharing and early warning mechanism.
·Classified Management of Materials: Identify critical materials,
Insufficient continuity and implement multi-dimensional classified management, and
Supply Chain ESG Management
stability of material supply establish annual demand forecast and supply plans.
The Company incorporates ESG requirements into its supply chain management. It establishes a supplier ESG Material Stability Risk
directly affect production and
management system, requiring suppliers and their subcontractors to comply with laws and regulations, social responsibility delivery schedules. ·Dynamic Procurement Optimization: Increase procurement
standards, and sustainability commitments. It has defined clear compliance and management requirements from the planning and monitoring frequency for new product demand, and
following five dimensions to ensure that all aspects of the supply chain meet the sustainable development standards: adjust the procurement cycles based on stock levels.
·Strategic Cooperation: Enter into strategic cooperation
Suppliers are required to safeguard employees' legal rights and interests, agreements with key primary packaging material suppliers and
Labor Rights and Human Rights Protection prohibit forced labor and child labor, and provide a fair and dignified establish safety stock.
working environment.
External uncertainties such as
Optimization of Global Supply Chain Layout: Building on existing
Suppliers are required to establish occupational health and safety geopolitical conflicts and
External Environment nodes in the United States, South Korea, and Hong Kong, China,
Health and Safety management systems, prevent workplace accidents, and protect changes in cross-border trade
Risk the Company plans to add new supply chain nodes in Singapore
employees' physical and mental well-being. regulations hinder the cross-
and New Zealand in 2026 to diversify regional risks.
border flow of materials.
Suppliers are required to comply with environmental regulations and
Environmental Responsibility commit to energy conservation, emission reduction, pollution prevention, Dual Sourcing and Domestic Substitution: Take measures like
and resource recycling. Dependence on a single supplier dual sourcing and domestic alternatives for key categories such
may lead to supply disruptions in as film bags, membrane fabrics, paper boxes, and prefilled
Commercial bribery, corruption, and unfair competition are strictly Supply Chain syringe plungers to mitigate supply disruption risks.
Business Ethics the event of capacity fluctuations
prohibited, and suppliers are expected to operate with integrity. Structure Risk
or operational crises of the Strategic Supplier Coordination: Establish long-term strategic
Suppliers are required to establish effective internal management systems supplier. partnerships with core suppliers, share demand forecasts, and
Management System to ensure the continuous and effective implementation of the above ESG promote upstream alignment in delivery mechanisms and
requirements.
strategies.
Bloomage Biotech 2025 Sustainability Report
Optimization of Logistics Solutions: Adopt a combined management system certifications. As a result, we earned international recognition such as EcoVadis Silver Medal, CDP
Long-distance transportation and transportation model of "sea freight for raw materials + air freight Climate Change rating A- and Water Security rating A. Besides, we actively respond to climate change, identify and manage
Delivery and Logistics disruptions in logistics networks for finished goods" to ensure delivery stability. climate-related risks and opportunities, and set greenhouse gas (GHG) emission reduction targets. Following the first full
Risk may delay material delivery and Safety Stock and Alert Threshold Management: Set safety stock value-chain GHG accounting and verification in accordance with international standards in 2024, we continued to advance
impact the production schedules. levels and alert thresholds for high-risk materials, and regularly full value-chain carbon accounting and verification in 2025. By improving data quality and management capabilities, we
review deviations between the inventory plans and actual levels solidified the practical foundation for comprehensive carbon management. Through the deployment of renewable energy,
to balance the supply security and inventory turnover efficiency. the company's key production bases have achieved a reduction in carbon emissions, validating the scientific and practical
feasibility of our low-carbon transition, thereby providing practical support for full value-chain carbon management. In terms
of pollution prevention & control, we strictly implemented national emission standards and strengthened the whole-process
The Company manages its stock through an ERP system and, based on a "one item, one code" approach, achieve full
management of exhaust gases, wastewater, and waste. Meanwhile, we are committed to efficient resource utilization and
lifecycle data recording from production to distribution. This not only provides consumers with anti-counterfeiting and
traceability services, but also enables the Company to quickly identify, trace, and control risks in the event of quality circular economy. To be specific, we continuously reduced our environmental footprint through multiple initiatives such as
concerns or market anomalies. In conjunction with the client feedback mechanism, the Company can promptly initiate the retrofits for energy saving, renewable energy adoption, green packaging, and empty bottle/tube recycling programs, while
Corrective and Preventive Action (CAPA) process, driving continuous improvement of products and services. regularly conducting biodiversity assessments to steadily advance sustainable development.
Sustainable Procurement Practices Environmental Compliance Management
Bloomage Biotech adheres to the principles of sustainable procurement. From the perspectives of low carbon,
environmental protection, and circularity, the Company enhances the sustainability performance of its products through Committed to green manufacturing, Bloomage Biotech follows the management principle of "accident prevention,
collaborative innovation and procurement optimization. It prioritizes suppliers with strong sustainability capabilities, building compliance with regulations, environmental protection, and continuous improvement". It continuously improves its
a sustainable supply chain from the source. It has obtained Forest Stewardship Chain of Custody (FSC-COC) certification, environmental management system to ensure operational compliance and reduce environmental risks and impacts.
enabling it to procure the packaging materials certified by the Forest Stewardship Council (FSC). The certification covers
all external packaging materials for its functional skincare products. Environmental Management System
Strictly following laws and regulations including the Environmental Protection Law of the People's Republic of China and
Supplier Integrity Management the Law of the People's Republic of China on Environmental Impact Assessment, Bloomage Biotech has continuously
To build stable and healthy partnerships, Bloomage Biotech actively safeguards the legitimate rights and interests of both advanced and optimized its ISO 14001 Environmental Management System for operation. In terms of institutional
itself and its partners, practices transparent procurement, and requires suppliers to sign the Anti-Commercial Bribery development, all its production bases have updated multiple environmental protection regulations based on their own
Agreement during the admission stage, maintaining zero tolerance for commercial misconduct. The Company implements specific risks and regulatory requirements. Jinan Production Base added seven regulations including the Management
a supplier negative list and a "one-vote veto" mechanism: Suppliers involved in bid rigging or collusion, violations of Regulation on Legal Disclosure of Environmental Information and the Management Regulation on Hazardous Waste, while
transparent procurement agreements, or major safety or environmental incidents with significant adverse social impact are Dongying Production Base updated 20 environmental management regulations, continuously enhancing lower
blacklisted and permanently disqualified from cooperation. In 2025, all suppliers signed the Company's Anti-Commercial management.
Bribery Agreement, achieving a 100% execution rate. The Company has established a three-tier environmental management network featuring oversight by the headquarters,
primary responsibilities of production bases, and participation by all employees. Its Safety and Environmental Protection
Incorporating green and low-carbon development philosophy into corporate operation management, Bloomage Biotech Management Center coordinates corporate environmental management and supervises all production bases. Each
continuously improves its environmental management system, and drives multiple production bases to obtain international production base, as the executive body, identifies and assesses environmental factors, sets targets, and formulates and
management system certifications. As a result, we earned international recognition such as EcoVadis Silver Medal, CDP implements management plans. Environmental protection personnel are assigned at workshop levels to implement regional
Climate Change rating A- and Water Security rating A. Besides, we actively respond to climate change, identify and manage environmental responsibilities and ensure the execution of measures. In 2025, Hainan Production Base obtained the ISO
climate-related risks and opportunities, and set greenhouse gas (GHG) emission reduction targets. Following the first full 14001 Environmental Management System certification following the production bases in Jinan, Dongying, and Tianjin.
value-chain GHG accounting and verification in accordance with international standards in 2024, we continued to advance As part of its efforts to strictly implement the "three simultaneous" system for environmental protection in construction
full value-chain carbon accounting and verification in 2025. By improving data quality and management capabilities, we projects, the Company conducts environmental impact assessments in accordance with the law throughout the project
solidified the practical foundation for comprehensive carbon management. Through the deployment of renewable energy, construction process, and organizes environmental protection acceptance upon completion, ensuring that new projects
the company's key production bases have achieved a reduction in carbon emissions, validating the scientific rigor and meet environmental compliance requirements from the source.
practical feasibility of our low-carbon transition, thereby providing practical support for full value-chain carbon management.
The Company conducts internal environmental audits at least once a year covering all the operational locations. Non-
In terms of pollution prevention & control, we strictly implemented national emission standards and strengthened the whole-
conformities are identified through personnel interviews, document reviews, and on-site inspections, and internal auditors
process management of exhaust gases, wastewater, and waste. Meanwhile, we are committed to efficient resource
track rectifications until closure. Meanwhile, we actively accept surveillance audits from third-party institutions and ESG
utilization and circular economy. To be specific, we continuously reduced our environmental footprint through multiple
audits of the supply chain from customers, continuously improving resource utilization efficiency and pollution prevention
initiatives such as retrofits for energy saving, renewable energy adoption, green packaging, and empty bottle/tube recycling
& control.
programs, while regularly conducting biodiversity assessments to steadily advance sustainable development.
Environmental Risk Management
The Company prioritizes environmental risk management in environmental compliance management. During the reporting
year, we updated and implemented the Environmental Factor Identification and Evaluation Procedure, further standardizing
the identification, evaluation, and hierarchical control processes of environmental factors. An environmental factor list was
developed across three timeframes, three states, and eight categories, with the effectiveness of control measures for
significant environmental factors regularly assessed.
Green Operation and Climate Response
Incorporating green and low-carbon development philosophy into corporate operation management, Bloomage Biotech
continuously improves its environmental management system, and drives multiple production bases to obtain international
Bloomage Biotech 2025 Sustainability Report
pollution prevention & control practices, standardized management of hazardous waste, and response to environmental
emergencies, enhancing employees' job performance capabilities and compliance awareness.
Index Unit 2025 2024 2023
Number of training sessions on
environmental protection and pollution times 31 53 43
prevention & control
Number of employees trained in
environmental protection and pollution participants 1,604 2,987 3,622
prevention & control
Total hours of training on
environmental protection and pollution hour 926 4,806 3,313
prevention & control
Green Office and Low-Carbon Operations
In response to the national carbon peak and carbon neutrality goals, Bloomage Biotech integrates green and low-carbon
Process for Identifying Environmental Factors The Company has established a comprehensive control mechanism concepts into daily office operations and administration, improving resource utilization efficiency through digital means and
encompassing daily inspections, environmental monitoring, and emergency response. Through regular inspections and fine management to reduce the environmental footprint of operations.
timely maintenance of environmental protection facilities, we ensure their continuous safe and effective operation, reducing
environmental risks in all aspects. Based on this, we conduct environmental monitoring of exhaust gas, wastewater, noise,
and groundwater in strict accordance with the Regulation on the Administration of Permitting of Pollutant Discharges and ·For temperature control, the Company implements the requirements that air
the requirements of the pollutant discharge permit. We disclose relevant information as required by regulations, subjected conditioning temperatures should not be lower than 26°C in summer and not
to supervision from authorities and the public. higher than 23°C in winter. It regularly cleans and maintains air conditioning
Energy Conservation and Fine systems, and gradually applies intelligent temperature control modes.
The Company has established a quantitative evaluation model to comprehensively score environmental factors, which are
Management ·In lighting and equipment management, the Company implements zoned control
then classified into general environmental factors and significant environmental factors for differentiated management. For
and strengthens the "lights off when leaving, equipment powered down" policy. It
significant environmental factors, specialized management plans are developed, specifying responsible persons, capital
cuts off power in non-essential areas during long holidays and arranges dedicated
investment, and completion deadlines, which are incorporated into the annual environmental target assessment. General
personnel for inspections and corrections to reduce energy waste.
environmental factors are managed routinely through standardized operations, specialized training, and daily inspections.
·The Company promotes digital office platforms. It launched an electronic signature
system during the reporting year to achieve a 95% digitalization rate of internal
Impact scope Impact degree Frequency Promotion of Paperless Operations
processes, while advocating for online meetings, electronic reporting, and
paperless approvals.
and Resource Recycling
·For scenarios where paper use is necessary, the Company implements double-
sided printing and secondary use of waste paper, and provides classified recycling
bins in printing areas to enhance resource recycling levels.
Level of social Degree of Regulatory ·The Company manages office waste by rational classification, setting up collection
concern improvability compliance
points for recyclables, hazardous waste, and other waste to improve waste sorting
and standardized handling.
Office Waste Classification and
·The Company actively promotes green initiatives in facilities. For instance, it
Six Dimensions for Evaluating Environmental Factor Impacts Green Facility Upgrades
installed safe and energy-saving solar streetlights on certain sections of roads at
In 2025, all production bases of the Company carried out environmental and safety risk identification and hidden hazard Jinan Production Base, reducing energy consumption while ensuring employees'
investigations on all fronts, covering key areas such as the operation of environmental protection facilities, solid waste travel safety.
management, internal compliance reviews, and the EHS system. For identified problems and hazards, all bases
implemented corrective measures, and completed risk assessments and control plans, forming a closed-loop management The Company is gradually phasing out traditional fuel-powered official vehicles,
system. prioritizing the purchase of new energy hybrid or pure electric vehicles, and adding
charging pile facilities in the parking lot on the campus. It also launches a green
The Company has established a response mechanism for environmental emergencies. All production bases regularly Advocacy of Green Travel
travel initiative for employees, encouraging low-carbon commuting methods such
identify and assess environmental risks, with the Response Plan for Environmental Emergencies, specialized emergency as public transportation and carpooling to collectively reduce carbon footprints
plans, and on-site disposal plans in place. As required by the regulations, all production bases conduct specialized from commuting.
emergency drills at least once a year for scenarios such as exhaust gas leaks, wastewater leaks, and hazardous waste
leaks to enhance emergency response capabilities. In 2025, no production base incurred major administrative penalties ·The Company organized environmental knowledge contests and low-carbon
from ecological and environmental authorities or faced criminal liability due to environmental incidents. lifestyle sharing activities during themed events such as the World Environment
Day and the National Energy Conservation Publicity Week, advocating water
Environmental Protection Culture and Capacity Building conservation, waste classification, and reduced use of disposable products to
Environmental Culture Development
guide employees in adopting green lifestyles through daily practices.
Highly valuing environmental protection and pollution prevention & control, the Company continuously strengthens the ·During the reporting year, the Company successfully held its first-ever carbon
environmental awareness, knowledge, skills, and emergency response capabilities of all employees to effectively fulfill
neutrality anniversary celebration. Through small donations from 99 employees,
corporate environmental responsibilities. During the reporting year, the production bases organized diverse training the event achieved a reduction of 82 tons of carbon dioxide equivalent
sessions and drills on environmental laws and regulations, identification of environmental factors and risk assessment,
Bloomage Biotech 2025 Sustainability Report
Key Strategic Pathways Strategic Initiatives Specific Measures
·Conduct product life cycle assessment (LCA) and product
Response to Climate Change and Energy Management Advance R&D of sustainable carbon footprint management
Product Optimization
products and technology ·Promote sustainable ingredient applications and packaging
To disclose its management and actions in response to climate change in a science-based and effective way, the Company
discloses its climate change risk management system and response progress in terms of governance, strategy, risk innovation
management, and metrics and targets, with reference to the IFRS Sustainability Disclosure Standard S2: Climate-Related ·Conduct GHG (Scope 3) accounting of value chains
Disclosures ("IFRS S2") issued by the International Sustainability Standards Board (ISSB). It continuously explores ·Carry out supplier self-assessment questionnaire surveys
solutions to climate change issues, promoting the implementation of sustainable and low-carbon development goals with Supply Chain Strengthen ESG and carbon
regarding GHG emissions and collect data
measures such as planning of emission reduction pathways, application of energy-saving technologies, and utilization of Optimization management of supply chains
·Promote enhancement in the GHG management capability
renewable energy. across the supply chain
Governance ·Continuously optimize response mechanisms for physical
To ensure effective implementation of its climate change governance efforts from strategic decision-making to execution, risks such as extreme weather, keep improving emergency
the Company has established a climate governance structure led by the Board of Directors, clarifying the respective Enhance climate adaptation response systems for climate change, natural disasters, and
Climate Resilience
capabilities and operational extreme weather events, and strengthen emergency drill
responsibilities of the Board of Directors, the Management, and the execution level to advance the routine climate-related Building
resilience mechanisms and critical facility protection capabilities, so as
risk management.
to effectively enhance climate response capabilities during
Climate Governance Structure of Bloomage Biotech production and operation
·It reviews and makes decisions on major matters related to climate, including climate
Board of Directors strategy, emission reduction targets and pathway planning, and climate-related risk To drive the implementation of climate change strategies, the Company focuses on key strategic pathways including
management, and oversees emission reduction progress. production and operation optimization, product optimization, and supply chain management. With particular emphasis on
ESG Committee under the Board of ·It reviews and oversees the identification and assessment of climate-related risks and critical areas such as reduction of emissions from logistics, it continuously implements concrete actions to enhance the
Directors opportunities, as well as the advancement and completion of key projects. execution efficiency of low-carbon transition and capabilities for guaranteeing continuous operation.
·It is responsible for daily management, policy research, and training regarding
climate issues. It formulates climate strategy pathways and targets, and leads the ·For international orders, the Company actively collaborates with customers to optimize
ESG Management Department Optimizing Transportation
implementation and follow-up of climate-related projects, carbon management, and transportation modes, promoting the shift from air freight to low-carbon alternatives such as
Structure of International
information disclosure. ocean shipping while meeting delivery requirements, thereby reducing carbon footprint in
Logistics
the delivery process.
·It implements climate-related action plans and energy resource management
ESG Working Group requirements in accordance with the Company's climate strategy and targets, and Implementing Multi- ·The Company deepens multi-warehouse collaboration models such as "Fulfillment by
regularly reports on action progress. warehouse Coordination and Cloud Warehouse", shipping goods according to the "proximity principle" to shorten
Proximity-based Distribution transportation distances and reduce energy consumption and emissions
The Company has established a professional working team with expertise, industry experience, and diverse backgrounds, ·The Company uses reusable carriers such as recyclable ice plates and insulated
enhancing their functional competence through regular thematic training to advance the routine and institutionalized Promoting Green Packaging containers in cold chain transportation, gradually replacing disposable packaging materials
operation of key sustainability tasks including climate-related risk management. Meanwhile, ESG performance assessment to reduce waste generated
requirements including climate change have been incorporated into the annual personal performance commitments of ·The Company tests and verifies transportation conditions, and optimizes transportation
departments and relevant senior executives, department heads, and dedicated positions, which are linked to compensation Optimizing Transportation conditions for certain products from "low-temperature cold chain" to "ambient temperature
incentives to enhance execution and implementation effectiveness. Conditions and Modes transportation" while ensuring the quality of such products and compliance requirements,
thereby reducing energy consumption and carbon emissions in transportation
Strategy
Bloomage Biotech has formulated a climate change strategy which has been incorporated into its sustainability strategy,
advancing work related to low-carbon transition and climate resilience in all aspects. In terms of low-carbon transition, we Risk Management
focus on three pathways (i.e., production and operation optimization, product optimization, and supply chain optimization)
Bloomage Biotech has established a routine risk transmission mechanism, incorporating climate-related risk management
to promote improvements in energy and resource efficiency, product life cycle assessment (LCA) management, and value
into the corporate risk management system. Upon review and under the guidance of the Board of Directors and the ESG
chain carbon management. In terms of climate resilience, we improve mechanisms for addressing physical risks such as
Committee thereunder, the ESG Management Department leads the identification and assessment of climate-related risks
extreme weather to enhance our capabilities for guaranteeing continuous operation.
and opportunities, formulates response plans, and coordinates functional teams such as production, procurement, energy,
Key Strategic Pathways and Measures of Bloomage Biotech for Addressing Climate Change and finance teams to implement them. The Company evaluates and reports on risks on a quarterly basis to ensure that
Key Strategic Pathways Strategic Initiatives Specific Measures potential risks can be identified and addressed in a timely manner.
·Establish budgets dedicated for GHG management, and Bloomage Biotech manages climate-related risks and opportunities through the following process:
conduct GHG accounting and third-party verification
·Continuously advance technological upgrades for energy
Production and Improve energy and resource ·Identification: Based on its production and operation
saving and energy efficiency improvements
Operation Optimization use efficiency in production actualities, the Company systematically identifies climate-
·Deploy renewable energy facilities
related risks and opportunities and produces a list, taking
·Participate in trading of green electricity in the market account of industry trends, domestic and international policy
·Sustain efforts in low-carbon culture development landscapes, and best practices as a benchmark.
Bloomage Biotech 2025 Sustainability Report
·Assessment: The Company assesses the applicability and Risk Risk
Risk Level Time Horizon Potential Impact Response Measures
importance of risks and opportunities based on its business Type Description
operations, and comprehensively analyzes them in terms of compensation due to breach plans during flood seasons and
the probability of occurrence, business impact, financial of contract and decreased typhoon periods.
impact, and reputational impact to determine risk levels and customer satisfaction. ·Evaluate and purchase
material opportunities. ·Extreme weather deteriorates insurance such as property
·Monitoring: The Company continuously engages with warehousing conditions, insurance to transfer potential
stakeholders, and regularly reviews and updates assessment causing inventory devaluation financial loss risks.
results to ensure that risks, opportunities, and response losses.
measures align with the Company's actualities. ·Rising cooling loads increase ·Develop the Preparedness
·Response: The Company develops and implements electricity consumption and Plan to Respond to Natural
response plans based on identification and assessment energy costs. Disasters, and conduct regular
results, including but not limited to low-carbon transition ·Increased temperature drills for continuous
plans and adaptation measures approved by the control pressure in improvement of the emergency
Management, and tracks the progress and effectiveness of warehousing and response mechanism.
their implementation. transportation elevates risks ·Implement online
Extreme to raw material/product quality temperature/humidity
Moderate Short/medium/long may cause scrap losses and monitoring with out-of-limit
heat
Bloomage Biotech systematically identifies climate-related risks and opportunities, taking account of business actualities term revenue impacts. alerts for warehousing and
and industry trends. On one hand, we incorporate climate-related physical risks and transition risks into business planning ·Higher fire protection transportation, and improve
and supply chain management, and continuously strengthen our capability against risks in key areas, thus enhancing our demands and safety risks cold chain/insulation
capability for guaranteeing continuous operation. On the other hand, we seize green transition opportunities, and implement under elevated temperatures measures.
measures such as clean energy substitution, energy conservation and efficiency improvement, process optimization, and necessitate increased safety ·Strengthen fire prevention
green manufacturing to reduce carbon emissions and improve resource utilization efficiency. We assess various climate- management investments and measures and maintain
related risks and opportunities in terms of the time horizon (short term, medium term, and long term), affected value chain operation and maintenance firefighting facilities
segment, likelihood and level of risk, and potential impact on business and finance, providing a basis for subsequent costs. periodically.
strategic choices, resource allocation, and development of action plans. The assessment results for the reporting year ·An external flood causes
indicate that current climate change-related risks are generally controllable and are not expected to have a material adverse abnormal water inflow or
impact on our financial position, operating results, and cash flow for the next year. ·Develop the Preparedness
backflow, heightening an
Plan to Respond to Natural
Physical Risks operational risk and
Disasters, and conduct regular
compliance pressure of the
drills for continuous
wastewater system,
improvement of the emergency
Risk Risk potentially triggering
Risk Level Time Horizon Potential Impact Response Measures response mechanism.
Type Description regulatory scrutiny and
River flood Low Short/medium/long ·Regularly inspect and
reputational impacts.
·Equipment and infrastructure term reinforce flood barriers and
·Equipment and infrastructure
may be damaged, leading to drainage facilities, and verify
may be damaged, leading to
decreased production ·Revise and implement drainage capacity in key areas
decreased production
efficiency and additional regulations such as the during flood seasons to ensure
efficiency and additional
capital expenditures for Preparedness Plan to steady operation under high-
capital expenditures for
equipment repair and Respond to Natural Disasters load conditions.
equipment repair and
replacement. and the Response Plan for replacement.
·The short-term pressure on Environmental Emergencies,
wastewater treatment regularly organize flood ·Continuously optimize
increases, the effluent prevention and environmental production processes and
Extreme Short/medium/long deploy water-saving
Acute High discharge volume and water emergency drills, and improve ·Prolonged droughts may
precipitation term equipment, significantly
Risks pollution risks are elevated, the response mechanism for Primarily medium- restrict production water
and the production stability is faster response. improving water resource
to-long term quotas, directly affecting
affected. ·Optimize drainage facilities Water recycling rates.
Moderate (possibly short capacity utilization and
·Regional waterlogging and within the factory, install shut- scarcity ·Enhance water metering and
term during a revenue.
road disruptions may cause off valves for discharge outlets, drought year) ·Rising water prices lead to performance management,
Chronic optimize production scheduling
logistics obstructions and and increase stockpiles of increased production costs.
Risks and peak-valley water usage,
delays in raw material critical flood prevention
arrivals, affecting production supplies. and improve water efficiency
continuity and order per unit output.
fulfillment. ·During site selection for new
·The risk of seawater intrusion
·Logistics and supply chain ·Supply chain resilience: projects or improvement of
Sea-level facing the production bases in
Tropical disruptions may lead to failure Establish a pool of diversified existing facilities, thoroughly
Moderate Short/medium/long Low Long term coastal areas potentially
cyclone in on-time order delivery, logistics suppliers and rise assess the risk of sea-level
term causes devaluation of land
potentially resulting in dynamically adjust logistics rise and elevate design
and fixed assets.
protection standards.
Bloomage Biotech 2025 Sustainability Report
Risk Risk Type Risk/Opportunity Description Potential Impact Response Measures
Risk Level Time Horizon Potential Impact Response Measures
Type Description
qualification/scoring may
·Damage to coastal ports may ·Regularly update climate impact bid success and order
permanently alter logistics exposure assessments for acquisition.
routes and increase operational locations in coastal
·Insufficient information
transportation costs. areas and dynamically adjust
long-term asset allocation disclosure or
strategies. underperformance may
increase financing costs or
·Disclose climate information with
affect financing availability.
high quality by referencing
Our analysis is based on two Shared Socioeconomic Pathways (SSPs) from the Intergovernmental Panel on Climate ·Failure to fulfill
international standards such as
Change (IPCC), namely, SSP1-1.9 (low carbon emissions scenario) and SSP2-4.5 (high carbon emissions scenario), as environmental ISSB, actively responding to
detailed in the table below: responsibilities will damage
Stakeholders' concerns from the capital market.
Reputation the brand image and affect
concerns ·Establish carbon offset
consumers' loyalty.
procurement and utilization
Type Risk/Opportunity Description Potential Impact Response Measures ·If emission reduction
strategies, and strengthen due
progress falls short of
·Inclusion in the carbon diligence of suppliers and cost
expectations, fulfillment of management.
trading market, or intensified commitments to voluntary
carbon constraints within the emission reduction may
industry, could lead to higher increase carbon offset
·Closely monitor the global market
costs related to allowance procurement costs.
environment and changes in
procurement and regulatory
carbon-related laws, regulations, ·Actively apply for national and
compliance.
and policies; continuously conduct ·Energy conservation and
·The introduction of stricter local green manufacturing and
GHG inventories, verification, and
policies and regulations by emission reduction subsidies, technical transformation projects.
carbon footprint management of
Higher carbon China to mitigate climate Policy Incentive policy as well as technical ·Evaluate and phase in increased
products; track changes in
Policy & prices and stricter change increases corporate transformation rewards are usage of renewable energy such
domestic and international carbon
regulation compliance compliance pressure and granted. as distributed photovoltaic and
policies and standards; and
requirements related litigation risks. biogas power.
improve compliance contingency
·Export products may be plans. ·Proactively expand green
subject to accounting, ·Strengthen internal management, ·Instruments like green credit
financing channels to provide
declaration, and potential and sustainability-linked
establish low-carbon transition financial support for low-carbon
costs from border carbon loans are utilized to access
targets and plans, and implement transition.
mechanisms such as CBAM a series of actions. low-cost funding.
Green finance and ·Conduct ongoing life cycle
in the future, which could Opportunity Market ·Low-carbon product
demand assessments (LCA) of products,
weaken the competitiveness certification may enhance the
of product prices or promote third-party certification,
Transition rate of bid success, secure
compress profit margins. and facilitate both customer
Risks potential premiums or more
communication and practical
·Low-carbon technology ·Establish dedicated R&D funds to favorable cooperation terms.
application.
transformation requires evaluate and introduce applicable
substantial upfront capital low-carbon technologies. ·Deploy high-efficiency production
investment. ·Reduce energy and water equipment and energy
·Collaborate with research
Low-carbon Cost reduction and consumption costs per unit management systems to enhance
Technology ·Uncertainties in technology institutions and industry partners
technology iteration Technology efficiency product through industrial energy and water efficiency,
pathways and investment to advance the verification and
improvement energy-saving technologies continuously reducing energy and
payback periods may lead to scaled application of technologies
and resource recycling. water consumption per unit
cost pressures and such as green processes and bio-
product.
competitive risks. manufacturing.
·Climate factors may affect
·Strengthen ESG audits of
the supply stability of bio- Metrics and Targets
suppliers and establish a pool of
based raw materials and
diversified suppliers to mitigate the As part of its efforts to implement the concept of green manufacturing, Bloomage Biotech continuously improves its
drive up prices, increasing
volatility of raw material prices. environmental management system, optimizes product design and production processes, and enhances resource
Supply chain and procurement costs and
Market ·Incorporate low-carbon and utilization efficiency to reduce resource consumption and pollutant emissions.
demand fluctuations delivery uncertainties.
· Failure to meet ESG sustainability requirements into
R&D and product design to Emission Performance
performance or disclosure
expand the supply of low-carbon GHG Emissions of Bloomage Biotech1
requirements of key
products and solutions.
customers for Indicator Unit 2025 2024 2023
The scope of statistics for Scope 1 and Scope 2 GHG emission data includes all wholly-owned operational production bases of Bloomage
Biotech located within China. The GHG emissions include emissions from natural gas consumption, diesel fuel, gasoline, fugitive methane from operations, business trips, and transportation and distribution of sold products. The accounting was conducted in accordance with the
wastewater, refrigerant charge, fire extinguishers, purchased electricity, and purchased heat. Scope 3 data include emissions from purchased requirements set forth in the GHG Protocol: A Corporate Accounting and Reporting Standard as well as the ISO 14064-1:2018 Greenhouse
Bloomage Biotech 2025 Sustainability Report
GHG Emissions of Bloomage Biotech1 Low-Carbon Transformation and Energy Management
Location- Energy Management System Improvement
tCO2e 103,971.11 113,510.99 100,902.09
Total GHG emissions (Scopes 1+2) based
Bloomage Biotech continues to strengthen energy management with the core goal of continuously improving operational
Market-based tCO2e 97,392.40 109,785.94 /
energy efficiency. Through energy planning, daily management, and energy-saving improvement measures, we
Scope 1 emissions tCO2e 25,904.30 37,412.27 43,554.73 consistently enhance energy utilization efficiency. We have established an Energy Management Leading Group and a
Location- multi-level energy management structure to promote the systematic implementation of energy management efforts. Each
tCO2e 78,066.81 76,098.72 57,347.36
Scope 2 emissions based production base of Bloomage Biotech has established a comprehensive whole-process energy management network
Market-based tCO2e 71,488.11 72,373.66 / covering all staff. Led by the management team and coordinated by the engineering equipment department, this network
involves relevant departments, workshops, and teams, covering all critical areas and main scenarios of energy usage. Each
Location- tCO2e/CNY 1 million
GHG emissions per unit of revenue based revenue
(Scopes1+2) characteristics, and ensures effective achievement of the objectives through process tracking and collaborative execution.
tCO2e/CNY 1 million
Market-based 23.19 20.44 / During the reporting year, our Jinan Production Base and Tianjin Production Base obtained ISO 50001 Energy
revenue
Management System certification.
Scope 3 emissions tCO2e 91,546.37 183,852.39 /
Referring to national standards and internal management requirements, the Company has established and continuously
improved its energy management system. Documents such as the Energy Management Manual and the Energy
The Company has established GHG emission reduction targets, and commissions qualified third-party institutions to Management Review Control Procedure have been developed to enhance energy management from such aspects as
conduct carbon verifications every year. The Company implements measures such as utilization of clean energy, promotion technical specifications, management execution, and performance evaluation.
of energy-saving technologies and process improvements to continuously reduce GHG emissions.
·Strive to reduce total company-wide GHG emissions (Scopes 1 + 2) by 50% by 2030 compared to ·Establish an energy measurement and statistics system to
Target
that in 2023. regulate the procurement, warehousing, and circulation
·During the reporting period, the Company saw the continued increase in the usage of renewable Energy Measurement and Statistics management of measuring instruments.
·Conduct regular energy measurements, and establish and
energy and gradual expansion of its coverage. With the implementation of retrofits for energy
saving and energy efficiency enhancement measures, carbon emissions at multiple main maintain energy measurement registers.
Progress
production bases, including the Jinan Production Base, shown a downward trend. Meanwhile, the ·Continuously monitor energy consumption in workshops,
Company completed life cycle assessments (LCA) of key products, with the carbon footprints of
and make comparative analysis with historical data for the
these key products showing significant reductions compared to 2023.
same period, issuing timely alerts for out-of-limit data.
Energy Alert Mechanism
·Promote workshops to identify major energy uses,
Case: Bloomage Biotech Successfully Holds Its First-ever Carbon Neutrality Anniversary Celebration
influencing factors, and key variables to optimize energy
On August 1, 2025, the first 2025 Carbon Neutrality Anniversary Celebration of Bloomage Biotech themed with "United, We management.
Break Through" was successfully held in Jinan. The Company integrated carbon management throughout the event cycle with
reference to relevant guidelines. ·Conduct energy reviews through thematic interviews, on-site
Preparation phase: It developed a low-carbon plan for the event, and launched a low-carbon action initiative, as well as a small investigations, and statistical evaluations, covering unit
donation campaign for the carbon neutrality anniversary. A total of 99 employees participated in the event, with 82 tons of carbon energy utilization status, energy types and sources, energy
Energy Review Control
dioxide equivalent reduced. management, and metering equipment.
·Analyze energy-saving potential and propose improvement
Execution phase: It implemented multiple emission reduction measures, including procuring low-carbon materials, promoting
"high-speed rail instead of flights" and public transportation, encouraging the "Clean Plate Campaign", and bringing personal suggestions in terms of structure process, and management.
water bottles, thereby reducing event-related emissions. ·Prohibit the use of equipment explicitly eliminated by
Closing phase: It compiled data on energy consumption and business travel, completed carbon emission accounting and national decrees and prioritize the selection of energy-
offsetting, and obtained a carbon neutrality certificate issued by a third-party institution, achieving the goal of hosting a green efficient products.
event. Energy-consuming Equipment Management
·Regularly maintain equipment and optimize their debugging
to ensure long-term steady and efficient operation of the
system, maximizing equipment performance.
·Launch regular energy conservation awareness campaigns
Energy Conservation Awareness Training to enhance employees' energy-saving awareness and job-
specific energy conservation capabilities.
Identification and Management of Energy Risks
Bloomage Biotech has established a risk identification and response mechanism covering the entire energy management
process, systematically identifying and analyzing internal and external factors involved in energy management. External
factors mainly include laws and regulations related to energy and energy conservation, energy efficiency standards and
policy requirements, as well as energy price fluctuations and energy supply situations. Internal factors mainly include
production organization methods, operational status of key energy-consuming equipment and utility systems, metering and
Gases—Part 1: Specification with Guidance at the Organization Level for Quantification and Reporting of Greenhouse Gas Emissions or nutritional science innovation and transformation business. Meanwhile, the Company is implementing low-carbon supply chain management,
Removals. During the reporting period, the total Scope 3 greenhouse gas (GHG) emissions decreased year-on-year, mainly due to the which has also contributed to the reduction in relevant greenhouse gas emissions. "/" indicates not applicable.
systematic structural optimization carried out by the Company around its dermatological science innovation and transformation business and
Bloomage Biotech 2025 Sustainability Report
measures for risks and opportunities, and continuously tracks and updates compliance requirements as the minimum consumption reduction management across procurement, transportation, production, and operation. During the reporting
requirements for energy management. year, we continuously enhanced scientific, fine energy utilization by focusing on key areas such as equipment energy
In terms of risk identification methods, the Company conducts dynamic assessments based on on-site inspections and efficiency, transportation efficiency improvement, and energy consumption monitoring. All our production bases prioritized
energy consumption/efficiency data analysis. By comparing energy consumption data, equipment operating parameters, the deployment of energy-efficient equipment during equipment replacement and procurement, preferred electric forklifts
and energy efficiency indicators, it identifies key high-energy-consuming equipment and main areas of energy consumption, and manual hydraulic vehicles in logistics operations, and improved the transportation efficiency of raw materials, auxiliary
monitors abnormal fluctuations, and assesses the potential of improvement for energy saving and potential risks. Key risk materials, and finished products through hoists and Automated Guided Vehicles (AGVs).
types of focus include production security risks caused by fluctuations in energy supply or utilities; inefficient energy Energy Conservation and Consumption Reduction Measures at Production Bases of Bloomage Biotech (Selected)
consumption risks due to equipment aging, insufficient maintenance, or inadequate process optimization (such as
Production Bases Specific Measures
equipment idling, insufficient waste heat utilization, or leaks); management and settlement risks arising from inaccurate
metering; and waste risks resulting from inadequate management of non-production energy use. ·It implemented projects including AI-controlled air
In risk response, the Company establishes operation and maintenance standards for main energy-using processes, conditioning systems, cooling tower retrofits for energy
Jinan Production Base
implements spot check and preventive maintenance mechanisms for key equipment, and continuously verifies the saving, and air compressor networking to enhance energy
effectiveness of measures through on-site inspections, data tracking, and performance monitoring. In response to peak efficiency.
loads or supply constraints of electricity and steam, it optimizes its scheduling with peak-shifting arrangements based on ·It optimized and retrofitted production equipment by
its production plans, and appropriately adjusts operating parameters of key equipment to reduce load and improve interconnecting underutilized or repetitive equipment.
efficiency without compromising product quality and process requirements. Through the above management and technical Tianjin Production Base ·It optimized parameter settings of production equipment
measures, it continuously reduces energy waste and improves energy utilization efficiency while ensuring production based on production requirements to improve operational
stability. efficiency of equipment.
Energy Use ·It conducted regular preventive maintenance and repairs on
equipment to reduce failure rates and energy consumption.
Chaohu Production Base ·It continuously monitored energy performance parameters
Energy Use of Bloomage Biotech2
and operational indicators of main energy-consuming
Index Unit 2025 2024 2023 equipment to ensure rational energy use.
Natural gas cubic meter 10,060,451 13,073,453 15,686,836
Gasoline litre 24,018 30,112 21,706 Optimization of Energy Structure
Diesel oil litre 8,871 7,934 8,939 Bloomage Biotech accelerates the transformation of its energy structure and continuously increases the consumption of
Purchased heat from fossil renewable energy. By constructing distributed photovoltaic (PV) systems and biogas power generation facilities, and
GJ 282,215.92 245,503.80 174,331.73 gradually introducing purchased renewable electricity and biomass heat, the Company has continuously promoted the
fuel
replacement of traditional energy sources with clean energy, achieving an equivalent emission reduction of approximately
Purchased heat from
GJ 119,107.91 153,263.05 38,282.69 28,224.33 tonnes of carbon dioxide equivalent (tCO₂e) in 2025.
biomass fuel
Total electricity consumption kWh 90,152,911 94,746,874 70,453,123
Renewable Energy Consumption of Bloomage Biotech 3
Purchased electricity
kWh 65,968,824 77,625,771 66,931,210
(thermal power) Index Unit 2025 2024 2023
Purchased renewable
kWh 21,220,592 13,375,618 /
electricity Purchased renewable
kWh 21,220,592 13,375,618 /
electricity
Total self-generated
kWh 2,963,495 3,745,485 3,521,913
renewable electricity
tons of standard
Total energy consumption 38,312.93 42,734.83 36,811.37 Total self-generated
coal Renewable electricity kWh 2,963,495 3,745,485 3,521,913
renewable electricity
Including: Clean energy tons of standard
consumption coal
tons of standard • Photovoltaic power
Total energy consumption kWh 2,277,254 2,312,192 2,401,725
coal /CNY 1 9.12 7.96 6.06 generation
intensity
million revenue
Energy Conservation and Consumption Reduction Initiatives
Production bases of Bloomage Biotech analyze their energy consumption, tap into the potential of energy saving, and
continuously advance energy efficiency improvement measures. The Company implements energy conservation and
The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. During the reporting
period, energy structure adjustments and impacts from production and operational activities resulted in significant fluctuations in multiple retrospective adjustments of relevant data for 2023 and 2024 in accordance with the unified caliber for 2025. "/" indicates not applicable.
indicators such as natural gas and gasoline. And the Company optimized the accounting caliber of total energy consumption. Based on the The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. During the reporting
statistics of the original fossil fuel consumption within the production and operation boundary, the Company additionally included the period, energy structure adjustments and impacts from production and operations and external supply of heat from biomass fuel led to
significant fluctuations in multiple indicators such as renewable electricity and heat. "/" indicates not applicable.
Bloomage Biotech 2025 Sustainability Report
Renewable Energy Consumption of Bloomage Biotech 3 effectiveness of exhaust gas collection and treatment
·Enclose key units including equalization tanks, sumps, sludge thickening tanks, and aeration
tanks to centrally collect and treat generated gases, reducing odor dispersion
Tianjin Production Base:
• Biogas power kWh 686,241 1,433,293 1,120,188
·Comprehensively inspect and seal all tanks and openings in wastewater areas to prevent
generation
exhaust gas and odor diffusion
Purchased heat from
Renewable heat GJ 119,107.91 153,263.05 38,282.69
biomass fuel
Exhaust Gas Emissions of Bloomage Biotech 4
Index Unit 2025 2024 2023
Pollutant Emissions and Waste Management Sulfur oxides ton 2.05 1.75 2.32
Nitrogen oxides ton 3.91 6.22 7.46
Bloomage Biotech strictly complies with pollutant prevention and control laws and regulations such as the Law of the
People's Republic of China on the Prevention and Control of Atmospheric Pollution, the Law of the People's Republic of Volatile organic compounds ton 1.66 3.05 3.30
China on Prevention and Control of Water Pollution, the Law of the People's Republic of China on the Prevention and
Control of Noise Pollution, and the Law of the People's Republic of China on the Prevention and Control of Environment
Pollution by Solid Wastes. The Company strengthens source prevention and process control in terms of exhaust gas, Wastewater
wastewater, noise, and waste release management, continuously improving pollution prevention and control capabilities.
It dynamically improves its internal control standards for pollutant emissions in accordance with national, local, and industry Bloomage Biotech actively implements national laws and regulations on wastewater management, continuously enhancing
regulatory requirements, ensuring traceable emission management, controllable processes, and compliant results. its capabilities for risk prevention and control of water environment. The Company has established and updated the
Wastewater Discharge Management Policy, specifying compliance requirements for wastewater pollutant discharge
Exhaust Gas monitoring, licensed emissions, supervision of compliant discharges, and abnormality handling.
Bloomage Biotech requires all production bases to strictly comply with laws, regulations, and standards on exhaust gas The Company has established a wastewater discharge and treatment management system covering the entire process,
emissions. During the reporting year, the Company updated its Exhaust Gas Management Policy to monitor exhaust gas with the Safety and Environmental Protection Management Center serving as the supervisory body and wastewater
emissions at all production bases. The Company has established a governance structure with the Safety and Environmental production and management departments as the implementing bodies. This system covers risk identification, preventive
Protection Management Center as the supervisory body and exhaust gas generation and management departments as the measures, emergency response, and follow-up management, ensuring continuous and steady compliance of wastewater
implementing bodies. It advances exhaust gas control through source reduction and end-of-pipe treatment, striving to discharge while progressively enhancing the standardization and precision of water environment management, with the
achieve a 100% compliance rate for exhaust gas emissions. In terms of treatment measures, the Company employs goal of achieving a 100% compliance rate of wastewater discharge.
processes such as dust removal, desulfurization, denitrification, isolation, water spray, and alkali spray based on exhaust For risk identification and prevention, the Company manages by classification and regularly monitors conventional
gas characteristics. Dedicated personnel are assigned for daily operation and maintenance of environmental protection wastewater (such as domestic sewage, canteen wastewater, concentrated discharge from pure water preparation, and
facilities, and qualified third-party institutions are regularly commissioned to test the emissions. During the reporting year, backwash wastewater) and accident-related wastewater (including firefighting water and chemical/hazardous waste leaks).
all exhaust gas prevention facilities maintained steady operation. Control of conventional wastewater is strengthened with measures like diversion of rainwater and sewage, pretreatment,
Meanwhile, the Company promotes the enhancement of exhaust gas treatment capabilities and source reduction. The and operational process management. Source control measures such as anti-corrosion, anti-seepage, diversion, and leak
efforts include the following: upgrading exhaust gas treatment facilities in factory areas, and standardizing multiple collection are implemented in hazardous waste storage areas and chemical storage zones, with pollution treatment facilities
unorganized emission points for organized collection; optimizing some treatment processes from single methods to and pipeline networks regularly inspected. In case of potential non-compliant discharge or emergencies, the Company
combined processes to improve treatment capacity and operational effectiveness; retrofitting internal floating roofs on the constructs or improves facilities such as emergency ponds and main rainwater discharge interceptors, while developing
alcohol tank farms at some production bases to reduce the volatilization of volatile organic compounds (VOCs) at the corresponding wastewater pollution contingency plans and organizing drills. It implements measures like diking, emergency
source and minimize pollutant emissions. collection, external monitoring coordination, and compliant disposal during the incidents. After the incidents, it keeps track
of and monitors them to drive closed-loop rectification of hidden risks.
Exhaust Gas Emission Reduction Measures of Bloomage Biotech (Selected)
Regarding facility deployment and operational management, the Company's main production bases have self-built
Exhaust Gas Xiangtan Production Base: Monitor emissions of the base for VOCs, particulate matter, wastewater treatment systems where industrial wastewater is treated to meet standards before discharge. For bases
Monitoring nitrogen oxides, sulfur dioxide, particulate matter, and smoke blackness on an annual basis connected to wastewater treatment systems of the industrial parks, pretreatment and discharge controls are implemented
Xiangtan Production Base: according to park requirements, with ongoing coordination and communication maintained with the parks. The Company
·Discharge exhaust gases through 15-meter-high exhaust stacks to improve exhaust gas implements a multi-tiered monitoring mechanism of "online monitoring + routine testing + third-party verification", and
collection efficiency commissions qualified third-party institutions for scheduled routine monitoring, creating multiple safeguards to ensure
·Operate in Class 10,000 or higher cleanrooms to enhance the effectiveness of exhaust gas steady effluent compliance and long-term system operation.
Exhaust Gas purification All production bases monitor wastewater quality following the process of "sampling—testing—verification and reporting—
Purification ·Operate within Class II biological safety cabinets, with exhaust gases filtered through ULPA abnormality handling", focusing on such indicators as Chemical Oxygen Demand (COD), Ammonia Nitrogen (NH3-N), and
filters and sterilized by UV lamps, supported by AHU purification air conditioning systems to Suspended Solids (SS). Test results are documented and promptly reported to the Safety and Environmental Protection
prevent exhaust gas leakage Department for discharge compliance assessment and operation control. In case of abnormal fluctuations, retesting, root
Tianjin Production Base: Require all departments to replace activated carbon according to cause analysis, and corrective actions are initiated per internal protocols, with treatment processes and operational
scheduled intervals to ensure the efficiency of exhaust gas purification parameters adjusted when necessary to prevent non-compliant discharge risks. In case of non-compliant discharge risks
Jinan Production Base: arising at the bases connected to wastewater treatment systems of the industrial parks, such bases promptly coordinate
Odor Treatment with the parks to take interception measures under emergency procedures, diverting wastewater to emergency facilities
·Dredge and maintain biofilter beds in wastewater treatment workshops to improve the
within the parks for further compliant treatment before discharge, minimizing the impact on the external environment.
The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. The Company
monitors, collects, and treats air pollutant emissions in compliance with regulatory requirements, including emissions such as particulate matter protection facilities and adjustments in production and operations resulted in significant fluctuations in most pollutant emission data.
Bloomage Biotech 2025 Sustainability Report
While strengthening compliant discharge, the Company promotes wastewater resource utilization. Reclaimable water register management.
streams (such as steam condensate) are reused to improve water utilization efficiency. Synergies with downstream
treatment facilities are explored to comprehensively utilize certain high-concentration waste liquids (e.g., as carbon sources
in treatment processes), reducing source treatment loads and enhancing resource recovery while ensuring compliance. Management Phase Solid Waste Hazardous Waste
As an enterprise engaged in the manufacturing of pharmaceutical-grade products, related products (hyaluronic acid and ·Recycle cleaning solutions to reduce chemical
·Optimize production processes, improve product
its derivatives) may enter wastewater treatment systems during container cleaning and other processes before discharge. consumption and lower hazardous waste
quality and yield, and reduce solid waste
Test results show compliance with discharge regulations. Given the non-toxic nature of the products, lack of bioactivity, generation.
generation.
and suitability as food ingredients, they pose no substantive negative impact on the environment or human health. Source Reduction ·Strengthen pollution prevention requirements in
·Reduce the moisture content and yield of sludge
production scheduling, and ensure simultaneous
through process optimization to decrease solid
operation of treatment facilities and main
Wastewater Discharge of Bloomage Biotech 5 waste generation.
facilities to reduce process risks.
Index Unit 2025 2024 2023 ·Define classification standards based on the
Total volume of wastewater Directory of National Hazardous Wastes and
discharged
Classification and collect non-hazardous waste by waste by classification to avoid mixed storage.
Chemical oxygen demand ton 86.53 102.52 54.01 classification (general solid waste, domestic
Ammonia nitrogen ton 1.11 0.80 2.03 waste, and food waste).
Total phosphorus ton 1.28 1.04 0.79 ·Categorize general industrial solid waste into
recyclable waste and other industrial solid waste. ·Establish dedicated hazardous waste storage
Total nitrogen ton 8.64 11.23 10.10 Recyclable waste is centrally processed by the
rooms with zoned areas for items such as
waste repository of the Company, while other
laboratory heavy metal waste liquids, general
industrial solid waste is stored in storage sites for
waste liquids, waste reagent bottles, spent
Noise general solid waste.
activated carbon, and waste engine oil.
·Post graphic symbols of environmental
In strict compliance with noise management laws and regulations, and referring to national and local standards such as the Standardized ·Storage rooms must maintain cool ventilation,
Storage protection indicating corresponding solid waste
Emission Standard for Industrial Enterprises Noise at Boundary, Bloomage Biotech ensures that production noise meets comply with safety regulations, remain isolated
categories, and store waste by classification and
environmental emission standards, reducing and preventing noise pollution and hazards. We implement measures such from ignition sources, and be subject to
zone.
as sound insulation, vibration reduction, noise reduction, and sound absorption for production equipment to lower noise management by assigned personnel.
·Strictly enforce storage site requirements to
emissions, proactively select low-noise equipment, and optimize the layout of high-noise equipment. Besides, we formulate ·Prevent contact or mixing of incompatible
ensure environmental protection standards
noise monitoring plans and detect noise every year. hazardous wastes, and strictly prohibit open-air
regarding solid waste, including "prevention of
storage.
scattering, loss, leakage, and rain exposure",
Waste prohibiting open-air storage.
Upholding the green development concept, Bloomage Biotech implements comprehensive waste control and resource
·Entrust units with corresponding qualifications
utilization at all production bases. We have established internal regulations including the General Industrial Solid Waste
Management Policy and the Hazardous Waste Management Policy to ensure the traceability and tracking of, and for transportation and disposal, and verify the
business licenses, environmental impact ·Entrust units with hazardous waste business
accountability for waste. Following the principle of "prevention first, combined with control" and the "three simultaneous"
Compliant assessment documents, pollution discharge permits and hazardous goods transportation
provisions, the Company has established a hierarchical waste management system with the Safety and Environmental
Transportation and permits, and other qualifications of the disposal qualifications for transportation and disposal.
Protection Management Center as the supervisory body and waste generation and management departments as the
Disposal units. ·Standardize inbound/outbound records and
implementing bodies. This system, which covers general industrial solid waste, domestic waste, and hazardous waste,
·Domestic waste is transported by units with handover management.
defines supervision and daily management responsibilities, enabling standardized full-process waste control.
clearance capacity to locations designated by
In 2025, Jinan Production Base of the Company promoted a pilot project for general solid waste reduction, and set waste the government to prevent random dumping.
reduction targets. By implementing measures for key process optimization, including extending blowing time to reduce the
moisture content of filter residue and improving dehydration processes to decrease the moisture content and yield of sludge, ·Implement the information-based register
·Implement the transfer manifest system, and
we achieved and exceeded the set targets. management throughout the process, covering
Register establish electronic registers to ensure the
electronic management registers for the entire
Management traceability and ease of querying of each batch
process of generation, storage, transfer, and
of hazardous waste.
Plant 1 of Jinan Production Base: ≥1% reduction in filter final disposal.
Targets residue per unit of pharmaceutical-grade HA product; Plant 2:
≥5% reduction in unit sewage sludge.
The Company continuously conducts waste management training and awareness campaigns to strengthen employees'
Plant 1 of Jinan Production Base: ≥6% actual reduction in awareness of "reduction, resource utilization, and harmlessness". Main production bases of the Company actively carry
Target Completion Status filter residue per unit of pharmaceutical-grade HA product; out various training sessions and practical activities to promote the implementation of waste management requirements.
Plant 2: ≥10% actual reduction in unit sewage sludge.
Waste Training Sessions and Practical Activities of Bloomage Biotech (Selected)
The Company strengthens waste management control measures, ensuring standardized full-process waste management
Chaohu Production Base：conducted the "Training on Laboratory Waste Liquid Disposal Knowledge" to enhance laboratory
in terms of source reduction, collection by classification, standardized storage, compliant transportation and disposal, and
personnel's standardized operational capabilities in classification, storage, and disposal of waste liquids.
The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. During the reporting
period, the Company's improvements in environmental protection facilities and adjustments in production and operations resulted in significant
fluctuations in most pollutant emission data.
Bloomage Biotech 2025 Sustainability Report
Tianjin Production Base：regularly conducted specialized training on hazardous waste and general solid waste Water Conservation and
management to improve employees' compliance awareness and site management. Consumption Reduction Specific Practices
Strategies
Jinan Production Base：organized thematic awareness campaigns to enhance environmental management personnel's
cognitive and practical capabilities in solid waste reduction and resource utilization. Dongying Base: Newly installed a purified water distribution system to enhance water
utilization efficiency.
Hainan Base: Regularly inspected water supply pipelines to identify and eliminate water
Efficient Water Use
Waste Release of Bloomage Biotech 6 wastage such as water running overflowing, dripping and leaking.
Jinan Base: Launched a water conservation initiative to encourage all employees to save
Index Unit 2025 2024 2023 water.
Total waste discharged ton 7,102.82 12,204.44 10,923.55 Tianjin Base:
General industrial waste ton 5,492.61 10,521.68 9,599.45 ·Recycled primary concentrated water for reuse of purified water.
·Recovered steam generated during alcohol distillation and conveyed it as condensate to
Hazardous waste ton 87.94 144.22 85.01 Resource Recycling
workshops for recycling.
Domestic waste ton 889.10 1,184.42 581.09 Hainan Base: Modified purified water concentrate discharge to the cooling pond for water
resource reuse, reducing direct tap water consumption for cooling.
Food waste ton 633.17 354.12 658.00
Recycled waste ton 3,304.38 7,125.01 7,331.00
Case: Circulation Retrofit of Heat Medium Water Reduces Water Resource Consumption
ton/CNY 1 million
Hazardous waste emission intensity 0.02 0.03 0.01 After the drying phase in the "Three-in-One" production process of Bloomage Biotech, equipment needs to be cooled for
revenue
discharge. Before the retrofit, cooling involved discharging hot heat medium water and replenishing with cold water, consuming
Non-hazardous waste emission ton/CNY 1 million several tons of fresh water per operation and resulting in significant water wastage. To address this, the Company installed plate
intensity revenue heat exchangers in the heat medium water loop and interconnected them with the chilled water system within the plant. After
the retrofit, heat medium water circulated in a closed loop during cooling, exchanging heat with chilled water via plate heat
exchangers for cooling. The process needs no discharge and replenishment, thereby reducing fresh water consumption and
drainage losses during cooling. The project achieved closed-loop cooling without discharge or replenishment, lowering fresh
Resource Utilization and Circular Economy water usage, associated water costs and softening treatment expenses, and saving energy.
Case: Replacement of Water Softener Resin Enhances Water Production Efficiency, Conserves Resources and
Water Management Reduces Consumption
Relying on municipal water supply systems, Bloomage Biotech provides water for all office and production activities, Due to resin aging in water softeners of Bloomage Biotech, the water output capacity of the equipment decreased, increasing
covering production processes, cooling system replenishment, boiler water feeding, environmental protection facility regeneration frequency and causing additional water and chemical consumption. To address this issue, we replaced the resin
operation, and daily life needs. To strengthen water resource management, the Company has formulated and implemented material and performed restorative maintenance during the overhaul period. After the replacement, the operational efficiency of
the Regulations on Energy and Energy Conservation & Consumption Reduction Management, specifying hierarchical water the water softener improved, with regeneration frequency reduced by approximately 50% compared to pre-retrofit levels, saving
metering and strengthening whole-process monitoring and data support. The Energy Management Leading Group about 3,250m? of water annually and reducing water treatment costs by approximately CNY 19,700, while decreasing resource
organizes, manages, and coordinates water resource usage and energy conservation efforts. The Engineering Equipment consumption during equipment operation.
Department serves as the competent department for water management. At the production units of each level, the first
persons of departments, workshops, and teams responsible for production respectively act as responsible persons for
energy management at their respective levels, forming an energy management network covering the entire production Water Resource Consumption of Bloomage Biotech 7
base to ensure efficient water resource utilization and coordinated achievement of energy-saving targets. Index Unit 2025 2024 2023
In 2025, Bloomage Biotech set water conservation targets, defining improved water efficiency as the core direction. It
Total water consumption 10,000tons 182.588 163.83 149.33
continued to advance water conservation management by increasing the recycling rate of condensate, optimizing
production processes and taking other measures. All production bases systematically implemented water conservation and ton/CNY 1 million
Water use intensity 434.80 305.04 245.77
consumption reduction solutions centered on the principles of "rational metering, efficient water use, and resource recovery" revenue
to ensure effective achievement of targets. In the reporting year, the Company successfully achieved its water conservation
targets as scheduled. Packaging Material Management
Water Conservation Strategies and Consumption Reduction Practices of Bloomage Biotech (Selected) Bloomage Biotech strictly complies with domestic green packaging policy requirements including the Law of the People's
Water Conservation and
Republic of China on Product Quality, the Food Safety Law of the People's Republic of China, the Drug Administration Law
Consumption Reduction Specific Practices of the People's Republic of China, the Regulations on the Supervision and Administration of Cosmetics, the Regulations
Strategies on the Supervision and Administration of Medical Devices, and the Law of the People's Republic of China on the Prevention
and Control of Environmental Pollution by Solid Wastes. The Company keeps an eye on green packaging policies and
Hainan Base: Regularly monitored purified water source quality to ensure metering industry trends, and advances the management and improvement of packaging materials and design in line with business
accuracy.
characteristics.
Tianjin Base: Analyzed energy usage weekly and monthly to promptly address water
Rational Metering Guided by circular economy principles, the Company implements practices focused on packaging material reduction and
consumption fluctuations and losses.
Jinan Base: Monitored water balance, with metering and data analysis for each water recyclability while ensuring product safety, quality, and compliance requirements are met. We optimize packaging
consumption unit. structures and material usage, and enhance the adaptability of recyclable and reusable design. We also explore the
application of renewable and biodegradable materials where feasible, and pay attention to the full lifecycle impact of
The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. During the reporting The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China.
period, the Company's improvements in environmental protection facilities and adjustments in production and operations resulted in significant 8
During the reporting period, the Company's overall water consumption increased, primarily due to the commissioning of new production
fluctuations in most waste release data. capacity and the operation of newly constructed supporting facilities.
Bloomage Biotech 2025 Sustainability Report
packaging materials. With these measures, we progressively reduce the environmental burden of packaging. Case: Application of Low-Carbon Bubble Films in Cloud Warehouses Reduces Carbon Emissions from Packaging
Materials
To mitigate the environmental impact of packaging materials in e-commerce fulfillment, Bloomage Biotech piloted replacing
Reducing Packaging Material Usage Promoting Recycling and Circularity Applying Sustainable Materials protective inner packaging materials for C-end shipments in multiple cloud warehouses with a low-carbon eco-friendly bubble
While meeting functional requirements film (RW eco-formula). While meeting protective performance and usage requirements, this material reduces carbon emission
We design recyclable packaging to Considering product safety and intensity per unit of material compared to conventional solutions. During the reporting year, the low-carbon bubble film was
for product protection, compliance, user
improve packaging recyclability, while regulatory requirements, we explore the applied across multiple cloud warehouses and SKUs, achieving scaled implementation.
experience, etc., we optimize structures
trialing the use of recycled materials in use of alternative materials like
and specifications to reduce
packaging, such as recycled renewable and biodegradable options Case: Corrugated Lamination Process R&D Project Drives Single-use Packaging Lightweighting and Recyclability
unnecessary packaging material usage,
polyethylene terephthalate (rPET) and where feasible, gradually reducing Upgrade
thereby lowering resource consumption
recycled cartons, to promote resource reliance on virgin petroleum-based The Company initiated the development of a sustainable-based "corrugated lamination" packaging process upon approval,
and environmental impact at the
circularity. plastics. enabling the replacement of solid grayboards of traditional rigid boxes with high-strength corrugated core layers through material
source.
and structural innovation. This achieves lightweight and easy recyclability while meeting packaging protection and appearance
presentation requirements. The project prioritizes recyclable systems in material selection and enhances load-bearing
Reducing Packaging Material Usage performance through structural design. meanwhile, validation methods such as DOE optimization and environmental adaptability
testing are employed to ensure the new solution can be adapted to existing production lines for mass production. Within the
While ensuring packaging functionality, Bloomage Biotech continuously takes measures to mitigate the environmental
project scope, evaluations indicate this solution can reduce raw material usage per box by approximately 20%, decrease box
impact of packaging materials. By reducing packaging weight, optimizing packaging structures and processes, and utilizing
weight by about 10%-20%, and lower carbon emissions per box by around 20%, while maintaining required packaging
low-carbon materials, we are committed to advancing packaging material lightweighting to alleviate environmental pressure compression resistance.
of packaging at the source.
Case: Bloomage Biotech Implements Reusable Packaging Design to Establish Green Cycle for Cream Products
Bloomage Biotech actively practices green design concepts by introducing reusable packaging solutions for cream products.
·We advanced packaging lightweighting and material optimization to reduce
Through standardized design, the same outer box is compatible with refill cores for the entire cream series, extending packaging
resource consumption and environmental impact. By implementing reduced-layer lifespan and reducing frequent disposal of outer boxes due to product changes. Meanwhile, minimalist packaging is adopted for
packaging design, eliminating unnecessary intermediate layers or outer boxes, refill cores, significantly reducing the usage of single-use plastics and auxiliary materials.
and developing corrugated lamination processes, we effectively reduced
Currently, we have launched refill design for several flagship brands:
corrugated paper and paper usage by over 20% while ensuring protective
performance of packaging. This resulted in an annual reduction of approximately BIOHYALUX Elasticity Filler Anti-Wrinkle Essence Cream 50g (with refill)
packaging waste. BIOHYALUX INFIHA Barrier Repairing Nourishing Cream 50g (with refill)
·BIOHYALUX brand under Bloomage Biotech reduced raw material waste from
Packaging Structure Optimization and QuadHA Skin Dynamic Youth Cream 40g (Nourishing Version) (with refill)
custom mold development through standardized packaging molds, and adopted
Reduction QuadHA Skin Dynamic Youth Cream 40g (with refill)
lightweight acrylic materials to lower overall energy consumption during
warehousing and transportation, further reducing carbon emissions. QuadHA Energize Regenerating Eye Cream 20g (with refill)
MedRepair Multi-Element Concentrated Repair Essence Cream (with refill)
Optimization of BIOHYALUX Product Packaging
·In raw material production and packaging workshops, the replacement of
polyethylene plastic bags with material buffer tanks saved 12,251 polyethylene
plastic bags in 2025.
·We substituted plastic film sealing with dispensing methods in packaging to
Packaging Material Substitution
reduce plastic usage.
·We promoted the use of biodegradable or compostable plant fiber materials
(bagasse) for inserts of single-use boxes to replace traditional inner trays made
of plastic, reducing virgin plastic consumption by approximately 25 tons annually. Refill Packaging Design for Flagship Brands
·We updated 1ml plungers and boosters for pre-filled syringes by adopting hot Promoting Recycling and Circularity
runner molds. This project is expected to reduce PC injection molding waste by Upholding sustainable development principles, Bloomage Biotech fully considers post-consumer recycling scenarios during
about 1 ton annually, corresponding to a carbon emission reduction of packaging design, prioritizing easily recyclable mono-materials and upgrading packaging for multiple products.
Low-carbon Materials
approximately 3 tons of CO2 equivalent 9. Concurrently, the Company systematically advances recycling programs for discarded packaging and scrapped products
·We utilized biodegradable or compostable plant fiber materials for inserts of by category, gradually establishing more efficient recycling and resource utilization mechanisms to enhance the circularity
single-use boxes to decrease virgin plastic usage. of packaging materials and facilitate the implementation of a green closed-loop system.
We used lightweight penicillin bottles to achieve a 30% weight reduction Case: "Empty Single-use Ampoule Recycling Program" of BIOHYALUX Illuminates Beauty of Circularity
Packaging Reduction
compared to traditional products.
As a pioneer in China's single-use ampoule serum category, BIOHYALUX brand under Bloomage Biotech launched its "Empty
Single-use Ampoule Recycling Program" in 2020 to explore pathways for cosmetic packaging recycling. Collected empty
It is calculated based on a carbon footprint of approximately 3 tons of CO2 equivalent per ton of PC material.
Bloomage Biotech 2025 Sustainability Report
ampoules are sorted before sent to recycling plants, where they are transformed through resource utilization into recycled
products such as frisbees, flowerpots, and art installations. Currently, this recycling program has expanded to include empty
single-use ampoules from non-BIOHYALUX brands. Consumers can submit recycling applications via the "BIOHYALUX Official
Mall" mini-program and receive "Ampoule Credits" upon approval, redeemable for benefits including single-use serums, skincare
samples, and medical aesthetic treatments. During the reporting year, the program achieved 48,000 redemption instances,
recycling 6.4207 million BIOHYALUX ampoules (68.86% of the total) and 2.9033 million ampoules from other brands (31.14%
of the total). We recycled a total of 21.2767 million empty single-use ampoules from BIOHYALUX brand and 3.8527 million from
other brands, promoting packaging recycling and public engagement in low-carbon practices.
Outer Box of a Product of a Skincare Brand under Bloomage Biotech
Procurement of Packaging Materials by Bloomage Biotech
Indicator Unit 2025 10 2024 2023
Total purchase volume of
Ton 3,006.41 8,494.23 5,270.00
packaging materials
Annual Empty Single-use Ampoule Recycling Plan of BIOHYALUX Procurement volume of FSC-
certified paper packaging ton 160.72 1,635.00 846.00
Case: Empty Bottle Recycling Plan-Giving Bottles A "New" Life
materials
QuadHA brand under Bloomage Biotech partnered with offline stores for the "Empty Bottle Recycling Plan—Giving Bottles A
'New' Life" campaign, where consumers return empty bottles to stores to exchange for items, advancing packaging recycling
and circularity.
Biodiversity Assessment
Adhering to the bottom line of biodiversity conservation in its production and operations, Bloomage Biotech continuously
identifies, monitors, and mitigates potential impacts of its operational activities on the surrounding ecological environment.
The Company assesses potential risk sources by considering factors such as the scope of impact, probability of occurrence,
and severity of harm, and formulates and implements corresponding prevention and control measures. Meanwhile, it
integrates the concept of biodiversity conservation into product development, manufacturing, and raw material procurement
processes. Leveraging its technological advantages in synthetic biology, it strives to reduce the potential impact of products
throughout their life cycle on biodiversity and promote sustainable development.
Biodiversity Conservation Measures of Bloomage Biotech (Selected)
We conduct environmental impact assessments in accordance with the law
Project planning and design
and implement necessary ecological protection measures during
stage
construction.
Empty Bottle Recycling Plan—Giving Bottles A "New" Life We regularly assess biodiversity and investigate surrounding ecosystems
and species of flora and fauna. The Company has assessed biodiversity,
Bottom Line with results indicating no nature reserves, scenic areas, national and local
Applying Sustainable Materials Protection key protected wild plants, or rare or endangered wild animals within a 1 km
Bloomage Biotech continuously advances green packaging upgrades, prioritizing renewable and recyclable materials Measures Daily production and radius of the plant site. Provided that environmental protection facilities are
including Post-Consumer Recycled (PCR) plastics, molded pulp inserts, and FSC-certified paper to reduce the usage of operation stage operating properly and effectively, and measures such as the testing and
virgin petroleum-based plastics and reliance on fossil resources. disinfection of foreign items are implemented, the operational activities are
not expected to have significant negative impacts on biodiversity. The
Case: Skincare Brands Fully Adopt FSC-Certified Eco-Paper Company will continue to conduct relevant assessments and prudently
manage biodiversity risks.
Skincare brands under Bloomage Biotech use FSC-certified paper for outer boxes of products, ensuring traceable paper
sourcing from well-managed, ecologically friendly forests that deliver social benefits and economic sustainability. Sustainable
packaging is enhanced through prioritized use of renewable, traceable raw materials.
During the reporting year, the Company assessed biodiversity at its Jinan Production Base as a pilot initiative. The
assessment team investigated the ecological environment surrounding the area where the production base is located, and
assessed and controlled risk sources such as environmental pollution and invasive species, with no significant negative
impacts identified.
During the reporting year, the Company conducted systematic structural optimization focusing on its innovative transformation businesses in
dermatological science and nutritional science. As a result, the total procurement volume of packaging materials and the procurement volume of
FSC?certified paper packaging materials both decreased compared with previous years.
Bloomage Biotech 2025 Sustainability Report
enhance organizational stability.
·Lawful and Compliant Dismissal: Where termination of an employment contract is necessary, we
strictly comply with the Labor Contract Law of the People's Republic of China, and communicate with
employees in advance regarding the reasons for termination and subsequent arrangements. We
provide severance payment in accordance with the law, and support employees' reemployment
through career counseling, training recommendations, and internal transfer opportunities.
Talent Development and Community While maintaining the stability of our core teams, we actively fulfill our social responsibilities by exploring diverse
employment models and creating more job opportunities in emerging sectors. We continue to increase hiring in areas such
Engagement as livestreaming e-commerce, content marketing, and digital operations, creating a range of emerging roles including AI
Agent engineers, private domain operations specialists, and content operations specialists. Meanwhile, we actively explore
Bloomage Biotech adheres to a people-centered philosophy of sustainable development, viewing its responsibilities to diverse employment models and provide various forms of flexible employment opportunities. Through sound management
employees and to communities as an integrated whole that mutually reinforces one another. Internally, we are committed mechanisms, we safeguard the lawful rights and benefits of flexible workers and promote a virtuous cycle between
to creating an equal, diverse, inclusive, and safe workplace. Through a comprehensive, lifecycle-oriented development corporate development and job creation.
system, we support employees' lifelong growth while systematically managing occupational health and safety to safeguard As of the end of the reporting period, we employed 3,699 people, all of whom are covered by duly executed labor contracts.
their physical and mental well-being. Externally, we rely on the "In Cloud" public welfare campaign to actively fulfill our All employees were adults aged 18 or above. No incidents of child labor or forced labor occurred, and there were no cases
corporate citizenship responsibilities, integrating technology, art, and philanthropy to give back to society. Through involving debt bondage, human trafficking, or other practices that seriously violate human rights standards.
coordinated internal and external efforts, we strive to achieve synergistic progress in employee development, community
prosperity, and corporate sustainability. Diversity and Inclusion
We are committed to fostering a diverse, equitable, and inclusive work environment and firmly believe that differences in
Fair Employment and Employee Rights gender, ability, background, and experience enrich our teams with broader perspectives and creativity. We provide equal
opportunities for career development to all employees and actively leverage the unique strengths of our workforce's diverse
We strictly adhere to the principle of equal employment and place respect for and protection of human and labor rights at backgrounds in our operations.
the core of our operations and management. We adopt management measures, such as standardizing recruitment and In 2025, we further enhanced our diversity, inclusion, and anti-discrimination management system. Topics including
hiring practices, improving employment policies, and strictly upholding ethical standards to continuously safeguard the opposition to discrimination and harassment, and the prohibition of forced labor and abusive practices, have been
fundamental and lawful rights of all employees. incorporated into our Employee Onboarding Guide and induction training, ensuring that every new employee completes
relevant awareness training upon joining. With our policies and systems, we continuously strengthened targeted support
Compliant Employment and rights protection for various employee groups. We respected the ethnic cultures and religious beliefs of all staff, built a
We take the Universal Declaration of Human Rights as our guiding principle and strictly comply with labor laws and diversified talent system, and implemented non-discriminatory policies and measures, effectively safeguarding the equal
regulations in China and other regions where we operate, including the Labor Law of the People's Republic of China and rights and personal dignity of every employee.
the Labor Contract Law of the People's Republic of China. We also actively refer to international social responsibility
standards such as SA8000, ISO 26000, and the Ethical Trading Initiative (ETI), incorporating relevant requirements into
our Employee Handbook and internal management policies. We treat all employees fairly and equitably regardless of race, ·We fully respect the cultural traditions and dietary habits of employees from different ethnic
social status, nationality, gender, age, disability, marital status, religious belief, cultural background, or other differences. backgrounds, and actively integrate this respect into our daily operations and employee care
We strictly prohibit child labor, forced labor, and any form of discrimination, harassment, or abuse, and are committed to initiatives. For example, our cafeterias offer a variety of dining options designed to accommodate
Multicultural
fostering a safe, equal, and respectful workplace. diverse dietary needs.
Integration
·We embrace an open and inclusive employment philosophy, actively attracting international talent to
In recruitment and separation management, including termination and resignation, we implement standardized
enhance organizational vitality and strengthen our global perspective. As of 2025, we employed 11
management practices, including but not limited to the following measures:
expatriate staff from various countries.
Support for Post- ·We have established the Management Regulations on Post-Retirement Rehiring, providing a platform
·Openness and Fairness: We conduct all recruitment activities in accordance with our Recruitment retirement for experienced senior professionals to continue contributing their expertise. In 2025, we had 2 post-
Management System, adhering to the principles of openness and fairness. We strictly prohibit any Rehiring retirement rehired employees.
form of discrimination or favoritism based on ethnicity, religion, disability, gender, marital status, or
any other factor. ·Our recruitment practices explicitly prohibit discrimination. We continuously create suitable job
·Standardized and Transparent Procedures: We have established a comprehensive recruitment Employment opportunities for persons with disabilities and improve accessibility facilities to safeguard their
process covering job requisition submission, approval, job posting, resume screening, interviews and Promotion for legitimate rights and interests. In 2025, we employed 11 employees with disabilities. We ensured that
Employee Persons with their compensation exceed the local minimum wage standard, and we provided them with all statutory
assessments, background checks, and hiring decisions to ensure a standardized and transparent
Recruitment Disabilities social benefits in compliance with national regulations, including pension, medical, unemployment,
process and merit-based recruitment.
·Rigorous and Compliant Review: With the informed consent of candidates, we strictly verify their work-related injury, and maternity insurance, as well as a housing provident fund.
identity information to prevent child labor, identity fraud, and potential conflicts of interest.
·Flexible and Controlled Mechanism: For urgent, unplanned, or specialized talent needs, we
implement a strictly supervised special approval process to ensure controlled procedures while
enabling timely recruitment and appropriate job fit. Headcount in 2025
Indicator Proportion (%)
(persons)
·Respect for Voluntary Resignation: In cases where employees voluntarily terminate their labor
Male 1,961 53.01%
Employee contracts, we fully respect their decision and handle resignation procedures in accordance with Gender Structure
Separation relevant regulations. Female 1,738 46.99%
Management ·Priority for Internal Placement: During workforce adjustments, we prioritize internal reassignment
Age Structure Aged 30 or below 1,588 42.93%
and job transfers to retain talent to the greatest extent possible, reduce employee turnover, and
Bloomage Biotech 2025 Sustainability Report
Headcount in 2025 Employee Rights and Interests
Indicator Proportion (%)
(persons) We place high importance on and resolutely safeguard the legitimate rights and interests of all employees. We strictly
prohibit all forms of forced labor and protect employees' rights to rest and leave, participate in trade unions, freedom of
Aged 31 to 50 2,041 55.18%
association, and collective bargaining. Through open, inclusive, and transparent internal communication mechanisms, we
Aged 51 or above 70 1.89% continuously enhance our employees' sense of fulfillment.
Ordinary employees 3,532 95.49% We explicitly prohibit any form of forced labor or abusive practices, including sexual coercion, sexual assault, threats, body
searches, mistreatment, humiliation, exploitation, or harassment. Through our policies, we clearly define employee rights
Job Level Middle management 162 4.37%
and delineate boundaries for manager conduct. We have established grievance mechanisms, with dedicated departments
Senior management 5 0.14% responsible for investigating and addressing concerns and conducting ongoing supervision to ensure fair and compliant
handling.
Below bachelor's degree 1,732 46.82%
In terms of working hours and leave management, we have formulated the Attendance and Leave Management System
Bachelor's degree 1,383 37.39% and strictly implement standard working hours and comprehensive working hour calculation systems. By implementing a
Education Background
Master's degree 552 14.92% well-designed multi-shift system covering different time periods, and based on different job functions, we flexibly configure
standard working hours, comprehensive working hours, and flexible working arrangements such as staggered shifts. This
Doctoral degree 32 0.87% approach effectively balances operational needs with employees' personal lifestyles, safeguarding employees' legitimate
rights to rest and leave while maintaining business and production order.
We are committed to fostering a transparent, efficient, and diversified organizational communication environment. Through
Key Performance
institutionalized feedback channels, normalized democratic participation, and robust protection of employee rights, we
·In 2025, the proportions of female employees at Bloomage Biotech were as follows: continuously enhance organizational health and employees' sense of belonging. To ensure orderly and efficient
·Proportion of female employees of the total number of employees: 46.99% communication, we have established both online and offline daily communication channels and clearly defined
·Proportion of female employees in senior management: 20.00% communication conduct guidelines:
·Proportion of female employees in middle management: 41.36%
·Proportion of female employees in R&D staff: 61.98% ·We follow the principle of "prioritizing communication within the reporting line, supplemented
Standardized by cross-level communication". For daily work matters, employees should first communicate
Communication with their direct supervisor. If an issue remains unresolved or requires escalation, employees
Employee Compensation and Rights Channels may communicate through written formats such as email or Feishu, ensuring clear and
traceable processes.
We continuously refine our employee compensation and benefits systems. By establishing robust policies, providing
favorable working conditions, and maintaining open channels for communication and grievance reporting, we foster a work ·We advocate a communication culture based on mutual respect and factual accuracy,
environment built on respect, fairness, and collaboration. Healthy Communication prohibiting any form of offensive language, personal attacks, or dissemination of false
Environment information. When raising work-related concerns, employees must base their feedback on facts
Employee Compensation
and provide constructive suggestions.
We adhere to the principle of equal pay for equal work and continuously enhance our Compensation Management System
and Performance Management System. Our compensation practices are guided by the principles of paying for the position ·We require that all information shared through our communication channels is accurate,
and performance, and maintaining openness, fairness, and transparency. We ensure that salaries are paid in full and on complete, and timely. Concealing key information or maliciously creating information
Responsible Information
time, and we provide each employee with a detailed payroll statement, enabling them to clearly understand their salary asymmetry is strictly prohibited. Individuals who cause adverse consequences due to
Sharing
composition, bonuses, and various benefits. information concealment or misrepresentation will be held accountable in accordance with
relevant regulations.
Our compensation structure consists of a fixed base salary, with performance-linked variable pay as the core incentive.
Overtime wages are paid in accordance with legal requirements. We have also established a range of allowances and
subsidies to effectively respond to employees' daily and special needs. Furthermore, each year, considering current rates We have established a multi-tiered employee feedback mechanism, encompassing face-to-face communication channels
in the job market and the overall compensation budget, we implement dynamic salary adjustments based on employee such as employee meetings and departmental gatherings, as well as various feedback channels including email and online
performance ratings. This process is moderately weighted in favor of high-performing and high-potential talent, continuously suggestion boxes, enabling two-way communication. We conduct regular anonymous employee satisfaction surveys to
enhancing our compensation competitiveness and organizational vitality. systematically understand employee perceptions and needs across five dimensions: job responsibilities, management
To enhance the motivational function of compensation, we will continue to optimize our income distribution structure, processes, work environment, career development, and compensation and benefits. At the same time, we actively involve
ensuring that pay is closely aligned with employee contributions and performance outcomes. We have established a employees in shaping our policies and procedures. Important policies are published on internal platforms for broad
cascading mechanism that translates strategic goals into organizational performance metrics, which are then cascaded employee consultation, safeguarding employees' right to information and participation.
down to individual employee performance objectives. This ensures a clear line of sight from strategy to execution, driving We fully respect and protect, in accordance with the law, employees' legitimate rights to freedom of association and
effective implementation. In terms of performance appraisal, we have developed a robust indicator system grounded in collective bargaining. Without prejudice to legality, we do not interfere with the establishment, operation, or management
principles of fairness, compliance, and incentive. Organizational performance focuses on key business indicators, strategic of collective bargaining, facilitating communication between labor and management. Trade unions have been established
initiatives, and exceptional items, while employee performance focuses on business targets, personal development goals, in accordance with the law at all our production bases and operate in compliance with the Trade Union Management
and corresponding bonus or deduction items, forming a systematic performance management system with clear direction. System. These unions actively represent employee voices, participate in democratic management, and safeguard
We set differentiated appraisal cycles based on the characteristics of different roles. For example, R&D positions are employees' legitimate rights and interests. Through various welfare and care initiatives, they contribute to building
assessed through a combination of project-based and annual reviews, while supply chain positions undergo quarterly and harmonious and stable labor relations.
annual reviews, enhancing the rationality and effectiveness of evaluations.
Reporting and Complaints
To ensure that our incentive mechanisms are precisely aligned with the Company's strategy and business development
needs, we updated the bonus incentive plans for our front-line business and R&D platforms during the year. This initiative To safeguard the legitimate rights and privacy of our employees, we have established strictly confidential and anonymous
strengthens the relevance and effectiveness of our incentives, fully stimulating the creativity and execution of our core channels for reporting complaints and concerns. Employees can safely and anonymously report issues such as policy
teams. At the same time, we maintain an equity incentive plan to attract and retain outstanding talent, promoting the long- violations, workplace misconduct, and safety hazards. All reports shall be investigated and handled independently and
term, shared development of both the Company and the employees. impartially. Whistleblower information is strictly protected, and all forms of retaliation are prohibited.
Bloomage Biotech 2025 Sustainability Report
Additionally, in our Code of Business Conduct for Employees, we explicitly require employees to protect the Company's ·We conduct a series of training programs for newly hired employees. By developing an onboarding
interests. If employees become aware of any conduct that violates company policies or may harm the Company's interests, learning roadmap, we help new employees gain a comprehensive and in-depth understanding of our
they can promptly report the matter to their direct supervisor, department head, responsible executive, or the relevant Training for New business operations and immerse themselves in our corporate culture. Training sessions include
functional departments. Employees policy briefings and hands-on system training, with aim to enhance work efficiency and help new
Complaint Channel colleagues integrate quickly into their teams. In 2025, over 400 sessions were attended by newly hired
regular employees.
E-mail address: hr@bloomagebiotech.com
·Based on the competency requirements for managers and business development needs, we have
Employee Development and Growth Training for
designed and implemented development programs for managers at different levels, as well as
programs for developing potential future leaders. Courses include Leadership and Role Awareness,
At Bloomage Biotech, we regard our people as the core driver of corporate growth. We continuously enhance our career Managers Task Planning and Execution, Coaching and Developing Employees, and Team Building and
development pathways, training systems, and performance incentive mechanisms to provide comprehensive support for Succession Planning, systematically enhancing managers' leadership skills and change management
employee growth. capabilities.
·In line with the professional competency requirements for each function and role, we have developed
Talent Acquisition and Assessment Training for corresponding learning roadmaps, establishing a progressive capability-building system from
We have planned talent development from a strategic perspective and established an efficient talent recruitment and Professional/R&D foundational to advanced levels. Through weekly online professional knowledge sharing sessions
management mechanism. Through data-driven forecasting of talent needs and strategic partnerships with external Staff (with an average weekly participation of 354 employees in 2025), we continuously cultivate the skills of
recruitment agencies, we have built a talent pool of qualified candidates covering technical, managerial and other core talent across various professional domains.
professional fields.
·Guided by the core principles of "precise selection, support for growth, emphasis on practical
Our recruitment strategy integrates both online and offline channels, leveraging internal and external resources. Online, application, and role-readiness", we have built a closed-loop, full-cycle development system. This
we utilize major job platforms, our corporate website, and university partnerships to attract talent broadly, engaging with Training for process involves identifying critical positions across the Company, defining talent criteria for these
graduating students through virtual career fairs and interactive sessions. Offline, we actively participate in campus Employees in positions, conducting talent reviews to determine development priorities and objectives, designing
recruitment events and industry seminars to expand our reach. Critical Positions customized development plans, and performing talent assessments to ensure readiness for
We have established long-term strategic partnerships with leading academic institutions including Peking University, placement. Through these phased steps, we systematically nurture and deploy talent for critical
Tsinghua University, and Jiangnan University. Through initiatives such as university-industry collaboration bases, we positions.
secure early access to outstanding young talent. Meanwhile, we encourage employee referrals and continuously activate
and nurture our candidate pool through ongoing database management.
Employee Training Overview 2025 of Bloomage Biotech11
Our assessment process employs a diversified approach to talent selection. We have developed a comprehensive
Indicator Unit 2025 2024 2023
evaluation system combining professional assessments, situational simulations, and multi-round interviews to thoroughly
evaluate candidate capabilities, ensuring strong alignment with our strategic talent needs. Average training hours of employees hour 34.72 22.83 26.61
General staff hour 35.96 25.84 18.49
Talent Development and Growth Average training hours by rank
The Management hour 23.46 32.52 38.52
We view our people as the core driver of organizational development and are committed to building a systematic and Male hour 41.28 29.17 22.19
diversified talent development and growth system. Guided by the strategic principles of "tiered development, career-long Average training hours by gender
Female hour 23.37 24.16 23.15
support, and multi-channel career pathways", we provide employees across different functions and levels with clear career
progression opportunities and sustained growth support through structured promotion and rotation mechanisms,
customized development programs, and integrated online and offline learning platforms. Meanwhile, we actively leverage and integrate high-quality external resources, maintaining stable partnerships with
renowned universities, professional training institutions, and industry think tanks. We regularly introduce cutting-edge
programs and support employees in participating in external certifications and high-level industry exchange activities,
We have established differentiated development systems tailored to junior, middle, and senior broadening their professional perspectives and industry insights. In 2025, we continued to invest resources in enhancing
By Rank
managers, as well as key professional talent. workforce capabilities, with total annual employee training expenditure reaching CNY 598,100 and an employee training
We have defined clear career pathways across various functions, including R&D, professional tracks, coverage rate of 100%.
By Function
and management.
Career Development Pathways and Promotion Mechanism
Through targeted initiatives such as key position talent development programs and internal promotion During the reporting period, we formulated the Employee Development and Promotion Mechanism, systematically
By Execution mechanisms, we are building a sustainable talent pipeline to ensure a robust supply of talent to support upgrading our employee promotion and talent rotation systems. The upgrading focus on building diversified career
the Company's long-term development. pathways, establishing precise evaluation systems, facilitating horizontal talent mobility, and ensuring fairness and
transparency. These initiatives aim to address the limitations of traditional single-path management promotions, one-
dimensional talent assessment methods, and constrained development approaches, creating a more flexible and equitable
Employee Training talent development ecosystem.
We have established a tiered and function-specific training system covering all employees across their entire career journey.
We have established three career development tracks for employees, i.e., the management track, the professional track,
Focusing on key areas including corporate culture and policies, general skills, professional capabilities, and leadership, we
and the R&D track. Employees may pursue vertical progression within their chosen tracks or horizontal rotation across
have designed differentiated development programs and learning pathways for four key groups: new hires, managers,
different tracks, providing multiple development pathways that align employee growth with our strategic objectives as
professional/R&D staff, and employees in critical positions. This approach aims to provide systematic learning resources
closely as possible. At the same time, we have implemented a standardized promotion process covering nomination, review,
to enhance the managerial and professional skills of employees at all levels, supporting talent development aligned with
approval, public notification, and a 3 to 6-month probationary assessment period. Promotion results are publicly announced
job requirements and empowering the Company's growth.
within appropriate scopes based on rank, ensuring process transparency and openness.
In terms of talent development, we have established a multi-dimensional cultivation system incorporating mentorship
Due to statistical scope and data availability constraints, only data related to AI training and new employee training are disclosed during the
reporting period.
Bloomage Biotech 2025 Sustainability Report
guidance, rotational assignments, and individual advancement support, continuously refining our employee development for all regular employees. For care and wellness, we offer commercial insurance and annual physical examinations,
model. complemented by supplementary health insurance and online physician consultation services. These benefits effectively
alleviate employees' difficulties in accessing medical care and addressing medication queries. They can also guide
appropriate specialist selection and provide health counseling to help relieve physical and mental stress. For financial
·Mentorship Program: We have established an internal coaching mechanism, providing benefits, we provide transportation subsidies, assistance with work residence permit applications, and discounts on
employees with professional advisory and guidance support. company products, supporting work-life balance of employees on all fronts.
Mentorship and Guidance ·Regular Knowledge Sharing: We conduct regular meetings to encourage communication
We regularly organize activities such as holiday celebrations, employee appreciation events, and team-building events, as
and learning among employees, facilitate the sharing of best practices, and enable well as continue to enhance the comfort of office environment through human-centered design to create a good
employees to independently access required training resources.
organizational atmosphere that is dynamic, enjoyable, and harmonious.
·On-the-job Training: Employees are matched with positions suited to their individual
Case: Celebrating 25 Years of Shared Journey - Bloomage Biotech Holds 25th Anniversary Events
capabilities to accumulate practical skills and management experience through hands-on
work. In August 2025, to celebrate our 25th anniversary and strengthen team cohesion, Bloomage Biotech held a series of anniversary
Experiential and Practical events. Through interactive activities such as puzzle challenges and ring toss games, the events effectively stimulated team
·Job Rotation Mechanism: Based on the characteristics of job category transition, priorities
Learning vitality and collaborative spirit. The subsequent "Two-Line Tour of Jinan City" facilitated cross-departmental interaction, fostering
for horizontal rotation, and qualification requirements for various positions, employees may
pursue transition and development within their career development paths, with no fixed a harmonious atmosphere and creating vibrant shared memories for this significant corporate milestone.
duration for rotation assignments.
·Personal Development: We provide learning subsidies to encourage employees to pursue
Support for Learning advanced degrees or professional certifications, supporting their efforts to obtain relevant
qualifications and credentials.
To support continuous learning and career development, we adhere to our internal Benefits Management System, providing
professional qualification training programs and educational advancement opportunities for all employees (including part-
time and contract workers). The system clearly defines reimbursement provisions for academic advancement and subsidy
support for obtaining professional certifications, offering learning subsidies at varying amounts based on rank to
comprehensively motivate employees to enhance their professional capabilities and educational qualifications. In 2025, we
invested a total of CNY 313,100 in subsidies for academic degrees and professional certifications. This year, in recognition
of our ongoing exploration and development of talent pathways, we received several prestigious accolades in talent
development and employer branding:
Employee Care and Benefits
Adhering to a people-centered approach, we have established a comprehensive benefits system that includes both
statutory benefits and supplementary ones. Through diverse care initiatives, we strive to enhance our employees' sense of
fulfillment, happiness, and belonging. All major production bases have signed Collective Labor Agreements with enterprise
trade unions, covering fundamental principles such as diversity and anti-discrimination and anti-harassment. These
agreements also address matters including working hours, wages, occupational safety and health, women's rights,
employee insurance and benefits, and staff training, providing institutional support for the protection of employee rights and
interests.
In terms of statutory benefits, we strictly comply with national laws and regulations. In accordance with our Leave and
Attendance Management System and Benefits Management System, we make full contributions on behalf of employees Case: Responding to Employee Needs with Care and Commitment
to social insurance (including medical, pension, unemployment, work-related injury, and maternity insurance), and the To understand the perspectives and development needs of young employees, the Jinan Production Base of Bloomage Biotech
housing provident fund. Additionally, employees enjoy various statutory leave benefits, including paid annual leave, sick launched the evening school program themed with "Bloomage Biotech Night Talks" in mid-October, organizing no fewer than
leave, marriage leave, maternity leave, parental leave, nursing leave, paternity leave, and bereavement leave. four themed sessions monthly. Through diverse and engaging activities, the program creates an interactive platform for young
In terms of supplementary benefits, to enhance employee welfare and satisfaction, we provide a range of additional benefits employees, enriching their spare time. Through ongoing communication, we promptly address concerns and resolve questions,
Bloomage Biotech 2025 Sustainability Report
enabling young employees to feel the sincere care of the Party organization within the Company's development journey. Key Performance
·In 2025, the coverage rate stood at 100% for supplementary medical insurance and physical examinations provided by the
Company for employees
·In 2025, 176 family members of employees were covered under the supplementary commercial medical insurance
Work Safety and Occupational Health Protection
Bloomage Biotech strictly complies with relevant national laws and regulations, including the Work Safety Law of the
People's Republic of China and the Law of the People's Republic of China on Prevention and Control of Occupational
Diseases. We have established and continuously improved a systematic, standardized environmental, health, and safety
(EHS) management system. Through robust governance structures, effective prevention mechanisms, efficient emergency
response, and rigorous closed-loop improvement processes, we safeguard employee safety and health in all aspects.
Work Safety Management System
We prioritize the health and safety of our employees, contractors, and related parties. Adhering to the principles of
"prevention with continuous improvement", we have built a safety management system with clear accountabilities and
effective operations, ensuring the comprehensive implementation of all occupational health and safety requirements.
During the reporting period, in alignment with the latest compliance requirements, we updated and released several core
policies, including the Emergency Rescue Management System, the EHS Inspection and Hazard Investigation and
Management System, the EHS Training and Education Management System, and the Contractor EHS Management
System. These updates ensure that safety management is governed by clear guidelines, further enhancing the
completeness and adaptability of our policy framework. As of the end of the reporting period, all production bases in Jinan,
Tianjin, and Dongying had obtained ISO 45001 Occupational Health and Safety Management System certification. Regular
internal audits and management reviews are conducted to ensure the effective operation of the system.
Each production base has established a Work Safety Committee, chaired by the base director. These committees are
"Bloomage Biotech Night Talks" Themed Event responsible for coordinating safety management at their respective bases, setting safety objectives and priorities, and
monitoring implementation. We have also established a centralized Safety and Environmental Protection Management
Case: Responding to Employee Needs with Care and Commitment
Center, responsible for developing, maintaining, and supervising the EHS management system.
To address the practical needs of employees' families, the Jinan Production Base launched a family parenting consultation
program, inviting professionals to conduct over 20 guidance sessions on parent-child relationships. For employees whose We have implemented a comprehensive work safety management system covering contractors, suppliers, and dispatched
children are preparing for the senior high school or college entrance examinations, the base thoughtfully organized the study workers. All production bases are required to conduct rigorous qualification reviews during contractor onboarding and sign
tour program themed with "Bloomage Biotech Kids". Employees' children were invited to step into the R&D center and production safety management agreements. Upon entering the facility, all personnel must conduct on-site operations in accordance
workshops, experiencing firsthand the corporate culture and technological innovation. Customized gifts were presented to the with our Special Operations Management System and other relevant policies, undergo standardized safety training and
children, further enhancing their sense of involvement, strengthening employees' sense of belonging, and aligning them with the assessments, and receive safety briefings before commencing work. During operations, we designate safety supervisors,
Company's goals for growth. implement safety measures, and require the operation supervisor, responsible departments and the Safety and
Environmental Protection Department to conduct multi-level on-site supervision, ensuring consistent safety management
standards across all bases and establishing closed-loop safety control from start to finish.
All production bases have implemented an entire personnel responsibility system for work safety, which decomposes
annual safety objectives level by level to subsidiaries, departments, workshops and individuals. Its implementation is
promoted through regular meetings, and coordination & performance appraisals. Through safety culture initiatives, ongoing
monitoring, and regular internal and external audits, we consolidate and validate safety management outcomes. We also
conduct post-incident reviews and analyses to drive continuous improvement of the management system.
Key Performance
·In 2025, Bloomage Biotech's total investment in work safety and occupational health amounted12 to CNY 8.0427 million.
Investment in employee work safety liability insurance was CNY 98,400, and the coverage rate of work safety liability insurance
for relevant positions13 reached 100%.
·In 2025, the purchase rate reached 100% for work-related injury insurance for employees at all production bases of Bloomage
"Bloomage Biotech Kids" Themed Study Tour Program Biotech.
Key Performance
· In 2025, the coverage rate reached 100% for statutory social insurance and housing provident fund contributions for Work Safety and Emergency Response
employees We have systematically established and operated a dual prevention mechanism comprising safety risk classification &
·In 2025, the coverage rate reached 100% for annual physical examinations for employees control and hazard identification & elimination. With ongoing work safety training and annual internal & external safety
audits, we continuously update our risk registers and implement control measures, achieving standardized closed-loop
The statistical scope covers Bloomage Biotech Group, including all expenditures on occupational health and safety. These expenditures This item is not a mandatory requirement for the industry to which Bloomage Biotech belongs.
include safety-related expenditures, physical examinations for employees, occupational health examinations, testing of occupational disease
hazards, and investment in employee work safety liability insurance and work-related injury insurance.
Bloomage Biotech 2025 Sustainability Report
management across all production processes. Through these systematic management initiatives throughout the year, we briefings and training before entering the premises. Training content is closely aligned with actual production activities,
fulfilled all work safety objectives. covering areas including laws and regulations, operating procedures, hazard identification, emergency response, and
Work Safety Management safety considerations for new processes, technologies, materials, and equipment. Training is delivered through diverse
formats, including expert lectures, case study analyses, online learning, and hands-on practical exercises. We have
Through hazard identification, assessment, and implementation of control measures, we continuously conduct hazard established a rigorous training evaluation mechanism that incorporates attendance and pass rates into performance
investigations to reduce work safety risks, prevent personal injury and health damage incidents, and effectively safeguard assessments, fostering a shift in employee safety mindset from "safety required of me" to "safety wanted by me".
employee safety and health.
In terms of emergency response capabilities, we conduct annual emergency drills across all production bases and office
We strictly adhere to process safety design standards, closely monitoring parameters including temperature, pressure, and locations in accordance with safety emergency plans, helping employees translate safety knowledge into practical on-the-
flow rates throughout production operations, and conducting regular maintenance and inspection of process equipment to job skills. In conjunction with "Work Safety Month" activities, we organize themed publicity and education campaigns
ensure safe operation. During the year, we further strengthened upstream control and on-site protection throughout the centered on the principle of "prioritizing safety, emphasizing prevention, and taking an integrated approach to risk
equipment lifecycle. When acquiring new equipment, we prioritized inherently safer designs that incorporated safety management". Through initiatives such as digital display promotions, educational video screenings, and targeted
features like interlocks, emergency stops, and audible-visual alarms. In view of mechanical injury risks such as collision, discussion sessions, we continuously cultivate a safety culture. Additionally, we engage fire safety and industry experts to
entanglement and clamping of moving equipment, special assessments were carried out and protective devices were conduct specialized skills training, organizing hands-on drills with fire extinguishers, fire blankets, and fire hydrants to
improved accordingly. We also identified risk points across job-specific workplace scenarios and optimized tooling and effectively enhance employees' practical response capabilities. These activities also encourage employees to participate
work methods, for example, by adding protective covers and improving feeding platforms. These measures reduced in identifying workplace hazards, promoting the implementation of safety responsibilities and the cultivation of safe
personnel exposure risks while improving operational efficiency and convenience. For special operations such as hot work behaviors.
and confined space operations, we strictly enforced pre-operation approval requirements and on-site monitoring during
operations. Operators must hold valid special operation certifications and complete specialized safety training. Emergency In 2025, a total of 847 safety training and education sessions were conducted across all production bases, reaching 18,162
supplies were equipped on site, and the "Three Nos" operations (operations conducted without approval, certification, or participants.
monitoring) are strictly prohibited.
In terms of laboratory safety management, we have formulated and strictly implemented a series of policies including the
Laboratory Management Measures for the Company-wide R&D Platforms, which specify standard operating procedures
for chemicals, biological materials and experimental equipment. To reduce laboratory safety risk exposure, we have taken
the following measures including risk identification and control, proper segregation and compliant disposal of hazardous
chemicals, provision and supervision of personal protective equipment, regular maintenance of laboratory equipment, and
the appointment of safety officers to formulate emergency plans and organize drills.
Regular Hazard Identification and Control
All production bases of Bloomage Biotech have established the dual prevention mechanism and conduct annual reviews
to ensure its effectiveness. Specific measures include maintaining risk registers and hazard identification records, and
conducting regular inspections covering comprehensive, seasonal, special, holiday, and routine checks. Hazards identified
are promptly assessed and rectified in accordance with the Management System for Safety Inspections and the
Investigation and Treatment of Hidden Dangers. Rectification progress is notified to employees via our internal OA (Office
Automation) system to ensure process transparency and full participation. For the safety management of contractors and
suppliers, we strictly enforce the Contractor EHS Management System, implementing closed-loop management covering
qualification review, pre-entry safety briefings and training, and whole-process supervision of operations to mitigate risks
associated with external personnel. In 2025, the Safety and Environmental Protection Management Center organized two
rounds of safety audits and inspections across all production bases and R&D platforms.
Emergency Response Mechanism
To effectively respond to emergencies, we have established standardized EHS incident classification and response Safety Drills at Production Bases
procedures, covering categories including workplace accidents, occupational disease incidents, on-site traffic accidents,
food poisoning, and unexpected environmental incidents. The department involved must report incidents to the Safety and
Environmental Protection Management Center immediately after occurrence, and activate the corresponding emergency Occupational Health and Safety Incident Reporting
response plan according to the incident level. We have also established an Emergency Leadership Group and a standing We have established multiple accessible reporting channels for occupational health and safety incidents. All production
Emergency Management Office, with on-site emergency response coordination teams established within each business bases utilize digital tools including Feishu's Snap feature, suggestion boxes, and work group platforms, to enhance
unit, ensuring unified command, rapid response, and effective handling during emergencies to minimize losses. reporting efficiency. Formal procedures, such as the Safety Reporting and Whistleblowing Management System, support
For occured EHS incidents, we have established a full-process closed-loop management process from investigation to both named and anonymous reporting. All employees may report directly to their line managers or on-site HSE officers
rectification and implementation. We adhere to the "Four No Releases" incident handling principle. An investigation team, (Health, Safety and Environment). Every report received is subject to standardized documentation and investigation
led by the Safety and Environmental Protection Management Center or the department with EHS responsibilities, procedures, with corresponding incentive and accountability measures implemented to ensure corrective actions are taken.
completes investigations within specified timeframes and issues reports analyzing root causes and defining responsibilities
and corrective measures. The department involved must implement all corrective requirements, with the Safety and
Environmental Protection Management Center responsible for tracking and verification. Upon completion of the rectification, Occupational Health and Safety Overview 2025 for Bloomage Biotech Employees
the Center shall establish incident files containing investigation reports, rectification reports, and training records. Regular Index Unit 2025 2024 2023
incident statistical analysis is conducted, transforming lessons learned into continuous optimization of management Number of work-related deaths person 0 0 0
systems, truly achieving closed-loop EHS management and long-term improvement.
Number of work-related injuries incidents 4 0 3
Safety Training and Emergency Drills Workdays lost due to work-related injuries day 392 0 53
In accordance with the EHS Training and Education Management System, we have established a tiered and function- Lost Time Injury Frequency Rate (LTIFR) % 0.52 0 0.32
specific safety training system covering all employees. We strictly implement a three-tier safety education program at the
company, department, and team levels, ensuring that new employees, contractors, and visitors receive appropriate safety
Bloomage Biotech 2025 Sustainability Report
Chemical Safety Management and Control Equipment (PPE) safety helmets, masks, and gas masks, and supervise proper usage.
We strictly comply with relevant laws and regulations such as the Work Safety Law of the People's Republic of China, and Provision and ·We conduct regular and ongoing inspections and maintenance of PPE, with damaged or
the Regulations on the Safety Administration of Hazardous Chemicals. We have established and continuously improved Management ineffective items promptly replaced and records properly retained.
internal systems including the Hazard Identification and Assessment System, the Highly Toxic Chemicals Management ·For high-risk positions, we enhance protection by optimizing operation methods and
System, the Chemicals Management System, and the Precursor Chemicals and Explosive-Prone Chemicals Management reasonably shortening exposure duration, reducing occupational health risks at the source.
System. We require that all activities involving chemicals at our production bases (including procurement, storage,
·We organize regular specialized occupational health training for all employees, disseminating
requisition, use, handling, and disposal, as well as operations involving precursor and explosive chemicals) must strictly
knowledge on occupational disease prevention and enhancing employees' health protection
adhere to these policies and be subject to standardized controls. Furthermore, we implement rigorous chemical risk
Occupational Health awareness and self-care capabilities. For employees exposed to occupational disease hazards,
identification, assessment, and emergency management procedures, integrating them into daily operations to minimize the Training and Education pre-job, on-the-job and post-employment occupational health examinations are conducted.
consequences of any incidents. Employees are informed of the examination results and health recommendations, enabling
dynamic monitoring of health changes.
·Basic Chemical Risk Identification: We collect complete information on all chemicals used, ·We strengthen mechanical equipment safety management, conducting planned maintenance
Equipment and
including specific components, physicochemical properties, and clear hazard information and condition inspections (e.g., quarterly maintenance) to reduce occupational health risks
Operational Safety
(e.g., health hazards such as skin corrosion/irritation, respiratory irritation, and environmental such as noise and leakage caused by equipment abnormalities, thereby improving on-site
Support
hazards such as toxicity to aquatic life). safety.
·Environmental Risk Assessment: We conduct specialized assessments in accordance
with the HJ 611-2011 Technical Guidelines for Environmental Impact Assessment of
Risk Identification and
Pharmaceutical Construction Projects. This encompasses identification of hazardous Beyond traditional occupational disease prevention, we also address musculoskeletal disorders resulting from repetitive
Assessment
substances and major hazard installations, investigation of incidents at similar facilities, operations. We continuously promote automation initiatives to replace manual labor and the application of auxiliary handling
determination of risk sources, risk prediction, development of targeted prevention and control equipment at all production bases. For example, we have introduced robotic arms for palletizing operations in Chaohu and
measures, and preparation of comprehensive emergency plans. Hainan, and utilize AGVs (Automated Guided Vehicles) or manual carts to replace manual heavy lifting, reducing
·Biological Evaluation: In accordance with the GB/T 16886 series of standards, we conduct employees' physical strain and repetitive operation risks.
physicochemical information collection for medical devices/components, data gap analysis, In 2025, we achieved our annual occupational health protection objectives, with overall performance meeting expectations
and toxicological risk assessment, performing equivalence assessments when necessary. and demonstrating positive progress. Key achievements include:
·Chemical Spill Response: In the event of a spill, all non-essential personnel are
·Compliance rate for occupational hazard factor testing: 100%
immediately evacuated. Emergency responders must wear appropriate professional
protective equipment, including positive-pressure respirators and acid/alkali-resistant ·Occupational health examination coverage: 100%
protective clothing. ·Completion rate for the design, construction, and commissioning of occupational disease prevention facilities in new, modified,
·Emergency Response for Personnel Health: We have developed detailed health first-aid and expanded projects: 100%
protocols covering emergency procedures for different exposure scenarios, ensuring sound
and effective responses.
Emergency Response
·Incident Reporting and Drills: Following an incident, responsible personnel at the second
Procedures
and third-tier departments must immediately report to their superior department and the Risk
Community Care and Contribution
Control Management Department. We also conduct regular hazardous chemical emergency Bloomage Biotech firmly believes that a company's sustainable development is inseparable from the prosperity of the
drills to enhance employees' ability to respond to emergencies. communities in which it operates. Through our long-standing "In Cloud" public welfare campaign, we continuously explore
·Post-incident Evaluation and Improvement: Upon conclusion of each incident response, opportunities in rural revitalization, healthcare access, and cultural preservation. We are committed to empowering local
we organize dedicated post-incident reviews to analyze causes and evaluate response industries through technology, enhancing community well-being, and improving the lives of rural residents.
effectiveness. Based on these reviews, we update emergency plans, optimize protective
resource allocation, and refine training content, forming a closed-loop management process. Case: Supporting Rural Revitalization with Technology - the Chinese Pear Story
Bloomage Biotech, taking the Chinese pear (Pyrus ussuriensis Maxim) – a species endemic to Linxia Prefecture, Gansu Province
– as the core link, completed five years of dedicated R&D efforts and launched Runlanxin, a science-based skincare brand, in
Occupational Health Protection 2025 leveraging synthetic biology technology.
We firmly believe that excellent safety performance and comprehensive employee well-being stem not only from systematic The story of this brand began with the Company's attention to the Chinese pear (Pyrus ussuriensis Maxim), a unique plateau
safety assurance but also from a strong safety culture and proactive health management. We integrate systematic fruit native to Linxia, during a public welfare project. This ancient species is not only a key carrier of Linxia's regional farming
culture, but also demonstrates remarkable resilience in the harsh plateau environment of drought and intense UV radiation. Yet
occupational health protection with safety culture development, safeguarding employees' physical and mental well-being
it has long faced the dilemma of insufficient development and utilization, a short industrial chain, and low added value, with its
through policies, personal protection, and health care initiatives.
resource advantages never effectively translated into industrial value. To address this challenge, the Company actively
We strictly comply with relevant laws and regulations, including the Law of the People's Republic of China on the Prevention responded to the national rural revitalization strategy and explored a sustainable development path of "Technology
and Control of Occupational Diseases, and have developed the Occupational Health Management System and the Empowerment + Industry-Driven Farmer Support". Through in-depth development of the Chinese pear via microbial biomimetic
Management System for Personal Protective Equipment. Additionally, we conduct regular identification and assessment of fermentation technology, the Company successfully developed the highly active ingredient "Chinese Pear Ferment Extract",
occupational hazard factors in the workplace, and engage qualified third-party agencies for on-site sampling and testing to which significantly enhances the concentration and diversity of the fruit's natural active components, transforming this
continuously verify the effectiveness of hazard control measures, ensuring that employees work in a safe and healthy characteristic plateau agricultural product into a high value-added biotech raw material.
environment. In terms of the implementation of industrial transformation, two cosmetic ingredients developed from the Chinese pear have
completed filing with the National Medical Products Administration (NMPA), namely Pyrus ussuriensis Maxim Powder (NMPA
Filing No. 20250042) and Hanseniaspora uvarum/Pyrus ussuriensis Maxim Ferment Filtrate (NMPA Filing No. 20250051).
·We employ a combination of engineering measures including isolation, segregated operations, Leveraging the core antioxidant and anti-photoaging properties of these ingredients, the Company developed the Runlanxin
Engineering Controls ventilation, dust removal, noise reduction, and enclosed and piped production equipment, to brand with the core philosophy of "Rooted in Place, in Sync with Nature", created targeted skincare solutions tailored to the arid,
reduce employee exposure to occupational hazard factors. high-UV environment of Northwest China, and brought Linxia's distinctive plateau resources into the public consumer market
through science-based skincare products.
Personal Protective ·We provide employees with PPE that meets national standards, including earplugs/earmuffs,
Leveraging a multi-faceted framework of "Cultural Promotion, Technology Empowerment and Industrial Transformation", the
Bloomage Biotech 2025 Sustainability Report
Company has developed a sustainable cooperation model of "R&D in the East, Transformation in the West" and "Markets in the
East, Bases in the West", pioneering an innovative approach to technology-enabled rural revitalization. This model has effectively
addressed the widespread challenge facing unique local resources in remote regions: high-quality produce fails to command
premium prices, paired with underdeveloped deep processing capabilities. With industrial development as its core vehicle, the
initiative has not only driven the broad spread of Linxia’s distinctive local culture and intangible cultural heritage, but also
delivered a step-change in agricultural product added value via biotechnology. This has spurred the upgrading of local industries
and steady income growth for farming households, ultimately delivering the coordinated development of cultural preservation
and economic revitalization, and forging a replicable, sustainable path for business for good and inclusive common development.
Jinan Production Base Donates to Linxia and Establishes Charitable Fund
Case: QuadHA Champions Sports & Wellness Initiatives with Professional Care
QuadHA, a brand under Bloomage Biotech, actively champions sports and wellness initiatives while advancing public health
literacy. By supporting athletic events and implementing health-focused programs, it promotes an active lifestyle and advocates
for scientifically grounded health concepts. In the realm of sports and wellness, it has sponsored a total of 28 outdoor events,
Runlanxin Product Line placing "energy" at the core of its mission, empowering athletes to push their limits and encouraging science-based approaches
to fitness and healthy living. On the health and professional front, it focuses on health advocacy and industry knowledge sharing.
Case: 15 Years of "In Cloud" Public Welfare Campaign: A Longstanding Commitment from Cultural Preservation to It has contributed over 340,600 product units to hospital health services, industry association exchanges, and public health
Industrial Synergy experience initiatives. Through these efforts, the brand leverages its professional expertise to champion health aesthetics and
In December 2025, "In Cloud" public welfare campaign, a public welfare brand of Bloomage Biotech, celebrated its fifteenth elevate public health awareness.
anniversary milestone with the charity exhibition and performance themed with "Discover Gansu: The Bloom of Life" at the
Beijing Times Art Museum. The event brought together intangible cultural heritage inheritors from across Gansu, presenting
over a dozen forms of indigenous art. Through a stage language combining strength with subtlety, the performances captured
Gansu's unique cultural character, at once majestic and delicate. Since its launch in 2011, this campaign has covered a
cumulative total of over 170,000 kilometers through its on-the-ground operations. It has built deep connections with more than
intangible cultural heritage art, the campaign has continuously raised public awareness and recognition of the preservation and
inheritance of China's ethnic culture.
QuadHA Supports Sports & Wellness Activities and Public Science Education
Case: Caring Through Innovation: Bloomage Biotech's Support for Persons with Disabilities
Bloomage Biotech has long believed that a company's value derives from society and should be returned to society. On
occasions such as the National Day of Helping Persons with Disabilities and the International Day of Persons with Disabilities,
we have carried out a series of care activities in local communities, translating our professional health expertise into genuine
warm support for persons with disabilities. At these events, the attentive service and sincere interactions of our volunteer
teams were widely appreciated by individuals with disabilities and their families within the community.
Charity Exhibition and Performance Themed with "Discover Gansu: The Bloom of Life"
Beyond our business operations, we are deeply committed to public welfare initiatives and social responsibility. We actively
engage in community care, rural revitalization, support for women and children, promotion of sports and wellness, and
public education in science, delivering meaningful social impact through diverse, professionally executed programs that
reflect our commitment to giving back.
Case: Multi-Faceted Public Welfare Initiatives Drive Community Development at Jinan Production Base
In 2025, Bloomage Biotech actively fulfilled our corporate citizenship responsibilities through sustained investment in social
welfare initiatives, including material donations, establishment of special funds, and charitable activities. In response to the
national call for East-West collaboration, we donated over CNY 1.0213 million in materials to the Women's Federations of Linxia
Prefecture and Linxia County in Gansu Province. These funds are dedicated to supporting local women's and children's
development, strengthening the development of community-level women's federation organizations, and enabling care services.
For localized public welfare efforts, our Jinan Production Base, under the guidance of the Jinan High-tech Zone Charity
Federation, established the "Bloomage Special Charitable Fund" focusing on key areas such as educational support and rural
Bloomage Biotech participated in the "Care Without Limits" Public Welfare Initiative Series
revitalization, planning and implementing a series of charitable programs. Throughout the year, the base also organized four
"Charity Sale" events, encouraging employee participation and channeling collective goodwill toward positive impact. Case: Bringing Warmth to Neighbors in Need: Bloomage Biotech's Winter Charity Initiative
Bloomage Biotech 2025 Sustainability Report
Bloomage Biotech actively participated in the community care initiative organized by the Wangjing Sub-district Disability Persons' Dimension Disclosure Topics Section/Index
Federation in Beijing's Chaoyang District. Our employee volunteers visited local communities, delivering thoughtfully prepared
care packages to families with special needs. Each package contained not only practical daily essentials but also our signature Supply Chain Security Sustainable Supply Chain Management
wellness products, offering tangible care tailored to residents' winter needs. Through face-to-face conversations and warm During the period, the Company's
interactions, our volunteers shared health knowledge and genuine concern, demonstrating corporate social responsibility
balance of accounts payable (including
through meaningful action and contributing to a more compassionate and inclusive community.
notes payable) remained under CNY 30
Equal Treatment of Small and Medium-sized billion, accounting for less than 50% of
Enterprises total assets. Furthermore, no instances
of overdue payments to SMEs were
identified. Therefore, this topic is not
applicable.
Quality Management,
Pharmacovigilance and Adverse
Bloomage Biotech Winter Charity Initiative for Persons with Disabilities Product and Service Safety and Quality Reactions, Chemical Ingredient
Management, Customer Services and
Rights Protection
Intelligent Technology Empowerment
Data Security and Client Privacy Protection
and AI Security
Fair Employment and Employee Rights,
Employee Development and Growth,
Employees Employee Care and Benefits, Work
Safety and Occupational Health
Supported Employment Base Protection
National Employment Assistance Month
Establishment & Chinese New
& Chinese New Year Charity Disability Employment Support Initiative Sustainable Development Management
Year Appreciation Event
Event Organized at Bajiao Sub- Organized at Guangwai Sub- Due Diligence Investigation System, Compliance and Internal
Organized at Yanshan Xingcheng
district, Shijingshan District, district, Xicheng District, Beijing Control Risk Management
Sub-district, Fangshan District,
Beijing Beijing Governance Related
to Sustainable Stakeholder Engagement and Double
Stakeholder Engagement
Employment Support Initiatives of Bloomage Biotech Development Materiality Assessment
Anti-Commercial Bribery and Anti-Corruption Business Ethics
Anti-Unfair Competition Business Ethics
Index of Indicators
SSE Sustainability Report Disclosure Guidelines
GRI Index
Dimension Disclosure Topics Section/Index
GRI Standard Disclosure Section
Response to Climate Change and
Response to climate change About This Report, About Bloomage
Energy Management 2-1 Organizational details
Biotech
Pollutant Emissions and Waste
Pollutant Emissions 2-2 Entities included in the
Management About This Report
organization's sustainability reporting
Pollutant Emissions and Waste
Waste Management 2-3 Reporting period, frequency and
Management About This Report
contact point
Environmental Ecosystem and Biodiversity Conservation Biodiversity Assessment
Response to Climate Change and
Energy Utilization 2-5 External assurance /
Energy Management
GRI 2: General Disclosures 2-6 Activities, value chain and other About This Report, Sustainable Supply
Resource Utilization and Circular
Water Utilization business relationships Chain Management
Economy
Resource Utilization and Circular Fair Employment and Employee Rights,
Circular Economy Employee Development and Growth,
Economy
Rural Revitalization Community Care and Contribution Safety and Occupational Health
Protection
Social Contribution Community Care and Contribution
Social Work Safety and Occupational Health
Innovation-Driven Development R&D Innovation
Ethics in Technology R&D Innovation Management
Bloomage Biotech 2025 Sustainability Report
GRI Standard Disclosure Section GRI Standard Disclosure Section
Corporate Governance
composition Security and Data Privacy, R&D
Innovation, Quality Management,
Environmental Compliance
highest governance body
Management, Response to Climate
body Pollutant Emissions and Waste
Management, Work Safety and
body in overseeing the management of
impacts Corporate Governance, Sustainable
Development Management System,
managing impacts 2-27 Compliance with laws and Management, Business Ethics, Network
body in sustainability reporting System Environmental Compliance
Management, Employee Development
concerns Materiality Assessment 2-28 Membership associations
Materiality Assessment
Corporate Governance
highest governance body engagement Materiality Assessment
the highest governance body
remuneration GRI 3: Material Topics 3-2 List of material topics
Materiality Assessment
Materiality Assessment
development strategy System 201-1 Direct economic value generated
Economic Performance
and distributed
Corporate Governance, Sustainable
Development Management System, 201-2 Financial implications and other
Compliance and Internal Control Risk Response to Climate Change and
risks and opportunities due to climate
Management, Business Ethics, Network Energy Management
Information Security and Data Privacy,
Environmental Compliance 201-3 Defined benefit plan obligations
Employee Care and Benefits
Management, Employee Development and other retirement plans
and Growth 201-4 Financial assistance received
/
Corporate Governance, Sustainable from government
Development Management System, 202-1 Ratios of standard entry level
Compliance and Internal Control Risk Fair Employment and Employee Rights,
wage by gender compared to local
Management, Business Ethics, Network Social Performance
Information Security and Data Privacy,
Environmental Compliance 202-2 Proportion of senior management Corporate Governance, Fair
Management, Employee Development hired from the local community Employment and Employee Rights
and Growth
/
Compliance and Internal Control Risk services supported
Management, Network Information GRI 203: Indirect Economic Impacts
Security and Data Privacy, R&D Community Care and Contribution
impacts
Innovation, Quality Management,
GRI 204: Procurement Practices /
impacts Management, Response to Climate suppliers
Change and Energy Management,
Pollutant Emissions and Waste Business Ethics
related to corruption
Management, Work Safety and GRI 205: Anti-corruption
Occupational Health Protection 205-2 Communication and training
Business Ethics
about anti-corruption policies and
Bloomage Biotech 2025 Sustainability Report
GRI Standard Disclosure Section GRI Standard Disclosure Section
procedures 304-4 IUCN Red List species and Biodiversity Assessment
national conservation list species with
Business Ethics habitats in areas affected by operations
and actions taken
Response to Climate Change and
Energy Management
GRI 206: Anti-Competitive Behavior behavior, anti-trust, and monopoly Business Ethics
practices 305-2 Energy indirect (Scope 2) GHG Response to Climate Change and
emissions Energy Management
emissions Energy Management
management
GRI 207: Tax Response to Climate Change and
GRI 305: Emissions Energy Management
management of concerns related to tax
Response to Climate Change and
Energy Management
volume Economy /
substances (ODS)
Resource Utilization and Circular
GRI 301: Materials 301-2 Recycled input materials used 305-7 Nitrogen oxides (NOx), sulfur
Economy Pollutant Emissions and Waste
oxides (SOx), and other significant air
Management
packaging materials Economy
Response to Climate Change and waste-related impacts Management
Energy Management, Resource
organization 306-2 Management of significant waste- Pollutant Emissions and Waste
Utilization and Circular Economy
related impacts Management
Response to Climate Change and
Energy Management, Resource GRI 306: Waste 306-3 Waste generated
the organization Management
Utilization and Circular Economy
Pollutant Emissions and Waste
Response to Climate Change and 306-4 Waste diverted from disposal
Management
GRI 302: Energy 302-3 Energy intensity Energy Management, Resource
Utilization and Circular Economy Pollutant Emissions and Waste
Management
Response to Climate Change and
Sustainable Supply Chain Management
Utilization and Circular Economy GRI 308: Supplier Environmental screened using environmental criteria
Response to Climate Change and Assessment 308-2 Negative environmental impacts Sustainable Supply Chain
Energy Management, Resource in the supply chain and actions taken Management
requirements of products and services
Utilization and Circular Economy
Social Performance
shared resource Economy
GRI 401: Employment
related impacts Management temporary or part-time employees
Resource Utilization and Circular 401-3 Parental leave Employee Care and Benefits
GRI 303: Water and Effluents 303-3 Water withdrawal
Economy
GRI 402: Labor/Management Relations /
Pollutant Emissions and Waste regarding operational changes
Management
Resource Utilization and Circular management system Protection
Economy
managed in, or adjacent to, protected GRI 403: Occupational Health and
Biodiversity Assessment Safety Work Safety and Occupational Health
areas and areas of high biodiversity 403-3 Occupational health services
Protection
value outside protected areas
GRI 304: Biodiversity
consultation, and communication on
products and services on biodiversity Protection
occupational health and safety
Bloomage Biotech 2025 Sustainability Report
GRI Standard Disclosure Section GRI Standard Disclosure Section
health and safety Protection
GRI 415: Public Policy 415-1 Political contributions /
Work Safety and Occupational Health
Protection Customer Services and Rights
safety impacts of product and service
Protection
Work Safety and Occupational Health GRI 416: Customer Health and Safety
occupational health and safety impacts
Protection 416-2 Incidents of non-compliance Customer Services and Rights
directly linked by business relationships
concerning the health and safety Protection
Work Safety and Occupational Health
occupational health and safety
Protection 417-1 Requirements for product and Customer Services and Rights
management system
service information and labeling Protection
Work Safety and Occupational Health
Protection
GRI 417: Marketing and Labeling concerning product and service Protection
Work Safety and Occupational Health information and labeling
Protection
Employee Development and Growth
year per employee
skills and transition assistance privacy and losses of customer data
GRI 404: Training and Education
programs
receiving regular performance and IFRS S2 Recommended Disclosure Index
career development reviews
Fair Employment and Employee Rights Suggested Disclosure Section
GRI 405: Diversity and Equal and employees
Opportunity The governance body (which can Response to Climate Change and
Fair Employment and Employee Rights include the board of directors, a Energy Management
remuneration of women to men
committee, or an equivalent governing
GRI 406: Non-discrimination Fair Employment and Employee Rights overseeing climate-related risks and
corrective actions taken
Governance opportunities
GRI 407: Freedom of Association and which the right to freedom of The role of the Management in the Response to Climate Change and
Fair Employment and Employee Rights governance processes, controls, and
Collective Bargaining association and collective bargaining Energy Management
may be at risk procedures for monitoring, managing,
and overseeing climate-related risks
GRI 408: Child Labor significant risk for incidents of child Management, Fair Employment and
labor Employee Rights Climate-related risks and opportunities Response to Climate Change and
that could reasonably be expected to Energy Management
GRI 409: Forced or Compulsory Labor significant risk for incidents of forced or Management, Fair Employment and
compulsory labor Employee Rights The current and anticipated effects of Response to Climate Change and
climate-related risks and opportunities Energy Management
GRI 410: Security Practices
human rights policies or procedures Protection value chain
GRI 411: Rights of Indigenous Peoples /
rights of indigenous peoples opportunities on the entity's strategy Energy Management
Strategy and decision-making, including
engagement, impact assessment, and Community Care and Contribution information about its climate-related
development programs transition plan
GRI 413: Local Communities
and potential negative impacts on local Community Care and Contribution opportunities on the entity's financial Energy Management
communities position, financial performance, and
cash flows for the reporting period, and
Sustainable Supply Chain Management
GRI 414: Supplier Social Assessment screened using social criteria financial position, financial performance,
Bloomage Biotech 2025 Sustainability Report
Suggested Disclosure Section
and long term, with considerations
given to how climate-related risks and
opportunities are included in the entity's
financial planning
The resilience of the entity's strategy Response to Climate Change and
and its business model to climate- Energy Management
related changes, developments, and
uncertainties, with consideration given
to the climate-related risks and
opportunities identified by the entity
The processes and related policies Response to Climate Change and
used by the entity for identifying, Energy Management
assessing, prioritizing, and monitoring
climate-related risks
The processes used by the entity for Response to Climate Change and
identifying, assessing, prioritizing, and Energy Management
monitoring climate-related opportunities,
including information on whether and
how the entity uses climate-related
Risk Management
scenario analysis to identify climate-
related opportunities
The extent to which the processes for Response to Climate Change and
identifying, assessing, prioritizing, and Energy
monitoring climate-related risks and
opportunities are integrated into the
entity's overall risk management
process, and how they are integrated
and communicated
Information related to cross-industry Environmental Performance
metric categories
Industry-specific metrics related to Environmental Performance
specific business models, activities, or
other common characteristics of the
industries in which the entity operates
Metrics and Targets The goals set by the entity to mitigate or Environmental Performance
adapt to climate-related risks or
capitalize on climate-related
opportunities, and any goals required
by law or regulation, including the
metrics used by the governance body or
the Management to measure progress
against these goals
Bloomage Biotech 2025 Sustainability Report
GHG Verification Statement
Bloomage Biotech 2025 Sustainability Report
ESG Key Performance Tables Indicators Unit 2025 2024 2023
Purchased heat from
GJ 119,107.91 153,263.05 38,282.69
Environmental Performance14 biomass fuel
Total energy tons of standard
consumption17 coal
Indicators Unit 2025 2024 2023
Including: Clean tons of standard
Total Location- energy consumption coal
tCO2e 103,971.11 113,510.99 100,902.09
GHG based
emissions tons of standard
Total energy
(Scopes 1 Market- coal/CNY 1 9.12 7.96 6.06
consumption intensity
and 2) tCO2e 97,392.40 109,785.94 / million revenue
based
Total water
consumption
GHG Location- tCO2e/CNY 1 Water 18
emissions based million ton/CNY 10,000
per unit of Water use intensity 434.80 305.04 245.77
revenue
GHG 15 revenue Market- tCO2e/CNY 1
(Scopes 1 based 23.19 20.44 / Total purchase volume
million ton 3,006.41 8,494.23 5,270.00
and 2) of packaging materials
Packaging
Scope 1 emissions tCO2e 25,904.30 37,412.27 43,554.73 Materials19 Purchase volume of
FSC-certified paper ton 160.72 1,635.00 846.00
Location- packaging materials
tCO2e 78,066.81 76,098.72 57,347.36
Scope 2 based
Total waste
emissions Market- ton 7,102.82 12,204.44 10,923.55
tCO2e 71,488.11 72,373.66 / discharged
based
General industrial
Scope 3 emissions tCO2e 91,546.37 183,852.39 / ton 5,492.61 10,521.68 9,599.45
waste
Natural gas cubic meter 10,060,451 13,073,453 15,686,836 Hazardous waste ton 87.94 144.22 85.01
Gasoline litre 24,018 30,112 21,706 Domestic waste ton 889.10 1,184.42 581.09
Waste20
Diesel oil litre 8,871 7,934 8,939 Food waste ton 633.17 354.12 658.00
Purchased electricity Recycled waste ton 3,304.38 7,125.01 7,331.00
kWh 65,968,824 77,625,771 66,931,210
(thermal power)
Non-hazardous waste ton/CNY 1 million
Purchased renewable 1.67 2.25 1.78
kWh 21,220,592 13,375,618 / emission intensity revenue
electricity
Hazardous waste ton/CNY 1 million
Total 0.02 0.03 0.01
Energy 16
kWh 2,963,495 3,745,485 3,521,913 emission intensity revenue
amount
Sulfur oxides ton 2.05 1.75 2.32
Self- Photovoltaic
generated electricity kWh 2,277,254 2,312,192 2,401,725 Exhaust Nitrogen oxides ton 3.91 6.22 7.46
renewable generation Gas21
Volatile organic
electricity ton 1.66 3.05 3.30
Biogas compounds
electricity kWh 686,241 1,433,293 1,120,188 Total volume of
generation wastewater 10,000 tons 174.60 171.54 123.85
Wastewater discharged
Purchased heat from
GJ 282,215.92 245,503.80 174,331.73
fossil fuels Chemical oxygen ton 86.53 102.52 54.01
The scope of statistics includes all wholly-owned operational production bases of Bloomage Biotech located within China. "/" indicates not During the reporting period, the Company optimized the accounting caliber of this indicator. Based on the statistics of the original fossil fuel
applicable. consumption within the production and operation boundary, the Company additionally included the consumption of clean energy within the same
Scope 1 and Scope 2 greenhouse gas emissions include emissions from the consumption of natural gas, diesel, gasoline, fugitive methane
from wastewater, refrigerant charging, fire extinguishers, purchased electricity and purchased heat. Scope 3 emissions include emissions from 2023 and 2024 in accordance with the unified caliber for 2025.
purchased goods and services, capital goods, fuel and energy-related activities, upstream transportation and distribution, waste generated in During the reporting period, the Company's overall water consumption increased, primarily due to the commissioning of new production
operations, business trips, and transportation and distribution of sold products. The accounting was conducted in accordance with the GHG capacity and the operation of newly constructed supporting facilities.
Protocol: Corporate Accounting and Reporting Standard for Greenhouse Gases and ISO 14064-1:2018 Greenhouse Gases—Part 1: 19
During the reporting year, the Company conducted systematic structural optimization focusing on its innovative transformation businesses in
Specification with Guidance at the Organization Level for Quantification and Reporting of Greenhouse Gas Emissions or Removals. dermatological science and nutritional science. As a result, the total procurement volume of packaging materials and the procurement volume of
During the reporting period, the total Scope 3 greenhouse gas emissions decreased year-on-year, mainly due to the systematic structural FSC?certified paper packaging materials both decreased compared with previous years.
optimization carried out by the Company around its dermatological science innovation and transformation business and nutritional science 20
During the reporting period, the Company's improvements in environmental protection facilities and adjustments in production and operations
innovation and transformation business. Meanwhile, the Company is carrying out low-carbon supply chain management, which has also had an
resulted in significant fluctuations in most waste emission data.
impact on relevant greenhouse gas emissions. 21
During the reporting period, the Company continued to optimize its energy mix. Meanwhile, driven by adjustments in production and
resulted in significant fluctuations in most exhaust gas emission data.
operational activities, the consumption of natural gas, gasoline, and purchased electricity decreased significantly.
Bloomage Biotech 2025 Sustainability Report
Indicators Unit 2025 2024 2023 Indicators Unit 2025 2024 2023
demand (COD) employees employees
Ammonia nitrogen ton 1.11 0.80 2.03 Number of female
person 533 577 576
R&D employees
Total phosphorus ton 1.28 1.04 0.79
Proportion of female
Total nitrogen ton 8.64 11.23 10.10 % 61.98 62.72 62.20
R&D employees
Training on Number of training
times 31 53 43 Number of General staff person 3,688 4,427 4,643
Environmental sessions
employees by
Protection physical
Number of employees Disabled employees person 11 17 12
and Pollution participants 1,604 2,987 3,622 condition
trained
Prevention
and Control Total training duration hour 926 4,806 3,313 Number of
employees of ethnic person 104 120 131
Number of minorities
employees by
Social Performance 22 ethnic group Number of
employees of non- person 3,595 4,324 4,524
ethnic minorities
Indicators Unit 2025 2024 2023 Doctor's degree and
person 32 43 36
Professor
Total number of employees Number of
person 3,699 4,444 4,655 Master's degree person 552 633 654
employees by
education Bachelor's degree person 1,383 1,699 1,712
Number of Male person 1,961 2,268 2,344
background
employees by
Female person 1,738 2,176 2,311 Below bachelor's
gender person 1,732 2,069 2,253
degree
Aged 30 or below person 1,588 2,205 2,568
Number of Total employee turnover rate % 29.30 28.75 28.46
employees by Aged 31 to 50 person 2,041 2,172 2,017 Male % 24.92 26.80 -
age Turnover rate
Aged 51 or above person 70 67 70 by gender Female % 34.03 30.76 -
Employment Senior management person 5 8 8
Number of Aged 30 or below % 33.85 38.51 -
employees by Middle management person 162 193 663 Turnover rate
Aged 31 to 50 % 25.40 18.00 -
rank Employee by age
General staff person 3,532 4,243 3,984
Turnover Rate Aged 51 or above % 23.36 17.52 -
Mainland China person 3,688 4,428 4,637
Mainland China % 29.28 28.75 -
Number of Regions or countries
employees by outside Mainland Regions or countries
Turning rate by outside Mainland
geographic China (including person 11 16 18 region China (including % 37.04 29.41 -
location Hong Kong, Macao,
Hong Kong, Macao,
and Taiwan)
and Taiwan)
Female senior
Average Male hour 41.28 29.17 22.19
management person 1 4 4
training hours
(executives) Female hour 23.37 24.16 23.15
by gender
Proportion of women Average The Management hour 23.46 32.52 38.52
Number and in senior % 20.00 50.00 50.00
proportion of training hours
management Employee General staff hour 35.96 25.84 18.49
women in by rank
Training
management Female middle
Employee Total number of employees trained % 100 100 100
management (above person 67 80 328
Diversity the manager level) Average training hours of employees hour 34.72 22.83 26.61
Proportion of women Total investment in employee CNY
in middle % 41.36 41.45 49.47 training 10,000
management
Employee Proportion of employees receiving
% 100 100 100
Number and Number of R&D Development performance appraisals
person 860 920 926
proportion of employees
Internal Total number of promotions person 231 322 /
R&D Proportion of R&D % 23.25 20.70 19.87
The symbol "-" indicates that the item is not counted, while the symbol "/" indicates that the item is not applicable.
Bloomage Biotech 2025 Sustainability Report
Indicators Unit 2025 2024 2023 Indicators Unit 2025 2024 2023
Promotion Internal promotion rate % 6.24 7.25 / occupational health
and safety training
Number of male
employees promoted person 118 114 / Number of work-
incidents 4 0 3
internally related injuries
Proportion of male Number of work-
person 0 0 0
employees promoted % 51.08 35.40 / related deaths
Number of internally Work-related Number of working
promotions by
Number of female injury incidents days lost due to day 392 0 53
gender
employees promoted person 113 208 / work-related injuries
internally
Lost time injury
Proportion of female frequency rate % 0.52 0 0.32
employees promoted % 48.92 64.60 / (LTIFR)
internally
CNY
Investment in Total investment 804.27 1,082.22 935.05
senior management person 2 4 / 10,000
occupational
Proportion of senior health and Investment in
CNY
management % 0.87 1.24 / safety employee safety 9.84 13.52 13.76
Number of 10,000
promoted internally liability insurance
promotions by
rank Middle management person 9 25 / Internal safety audit
% 100 100 100
rate
Proportion of middle Safety audit
management % 3.90 7.76 / Rectification rate of
% 100 100 100
promoted internally safety audit
Aged 30 or below person 88 172 / Cumulative number
Number of of invention patents item 464 392 296
promotions by Aged 31 to 50 person 142 147 / authorized
age
Aged 51 or above person 1 3 / Cumulative number
Unadjusted average gender pay of design patents item 96 73 58
% -8.75 -7.71 - authorized
gap 23
Employee
Compensation Ratio of average wages by gender % 91.96 92.84 - Cumulative number
of utility model item 131 122 98
Median wage ratio by gender % 77.07 78.46 - patents authorized
Cumulative
Proportion of employees' social number of Cumulative number
% 100 100 100 intellectual
security contributions of trademark rights item 5,569 5,057 4,346
property rights authorized
Employee Supplementary medical insurance
% 100 100 100
Benefits coverage rate for regular employees Cumulative number
of software and
Physical examination coverage rate Intellectual item 121 113 100
% 100 100 100 copyright
for regular employees Property
authorizations
Number of
Cumulative number
occupational health
times 839 1,755 640 of invention patents
and safety training item 464 392 296
applied to main
sessions
business
Number of
Cumulative number
Employee Occupational employees trained
participants 18,105 34,080 16,675 of domestic patent item 667 572 445
Health and health and on occupational
Cumulative authorizations
Safety safety training health and safety
number of
Cumulative number
Safety education intellectual
of overseas patent item 24 15 7
coverage rate for property
% 100 100 100 authorizations
suppliers, authorizations
contractors, etc. by region Cumulative number
of domestic item 4,538 4,180 3,749
Total hours of hour 2,810 36,629 23,533
trademark
Unadjusted average gender pay gap = (average male pay - average female pay) ÷ average male pay x 100%. Ratio of average wages by
gender is the difference in average hourly wages between full-time male employees and full-time female employees, expressed as a ratio of employees, expressed as a ratio of male/female.
Bloomage Biotech 2025 Sustainability Report
Indicators Unit 2025 2024 2023 Indicators Unit 2025 2024 2023
authorizations CNY
Social Welfare Total investment in public welfare 102.13 960.96 /
Cumulative number
of overseas
item 1,031 877 597 Governance Performance
trademark
authorizations
Annual number of Indicators Unit 2025 2024 2023
invention patent item 72 96 87
authorizations Number of directors person 9 9 9
Annual number of Number of female directors
person 2 3 3
design patent item 23 15 16 in the Board
authorizations Proportion of female
% 22.22 33.33 33.33
Annual number of directors in the Board
utility model patent item 9 24 12 Number of independent
authorizations person 3 3 3
directors in the Board
Annual number Annual number of Proportion of independent
of intellectual trademark right item 512 711 585 % 33.33 33.33 33.33
directors in the Board
property rights authorizations
Number of directors with
Annual number of industry experience in the person 2 5 5
software and work Board
item 8 13 17
copyright
authorizations Number of directors with risk
management experience in person 2 6 6
Annual number of the Board
invention patents
authorized for main item 72 96 87 Number of directors with
business financial management person 4 3 3
experience in the Board
Board
Annual number Composition Proportion of independent
authorizations of Items 95 127 112 and directors in the Audit % 66.67 100 100 24
domestic patent Governance Committee
Overview Proportion of independent
Annual number Annual number of
overseas patent Items 9 8 3 directors in the Nomination % 66.67 66.67 66.67
of property
authorizations Committee
intellectual
property Annual number of Proportion of independent
authorizations domestic trademark Items 358 431 530 directors in the
by region % 66.67 66.67 66.67
authorizations Remuneration and
Assessment Committee
Annual number of
overseas trademark Items 154 280 55 Proportion of independent
authorizations directors in the Strategy % 20 20 20
Committee
Total number of suppliers entities 489 1,339 712
Proportion of independent
Mainland China entities 480 1,333 601 directors in the ESG % 66.67 66.67 66.67
Number of Hong Kong, Macao, Committee
entities 1 1 2
suppliers by and Taiwan, China Number of the Board
Suppliers region times 8 5 6
Overseas countries meetings held
entities 8 5 109
or regions Number of the shareholders'
times 2 2 1
Signing rate of compliance meetings held
commitment letters of suppliers of % 100 100 94 Number of meetings of each
production materials times 13 10 7
committee
Cybersecurity Network and data security violations incidents 0 0 0 Special Number of compliance
times 9 3 6
Training on training sessions
On December 29, 2023, the Company held the 10th Meeting of the Second Board of Directors and approved the Proposal on Adjusting
Members of the Audit Committee of the Second Board of Directors. Upon adjustment, 100% of the Audit Committee members are independent
directors.
Bloomage Biotech 2025 Sustainability Report
Indicators Unit 2025 2024 2023
Corporate Rate of personnel in key
Governance positions covered by % 100 100 100
compliance training
Number of anti-bribery
times 1 4 2
training sessions
Rate of personnel in key
positions covered by anti- % 100 100 100
bribery training
Economic Performance
Indicators Unit 2025 2024 2023
CNY 100
Operating revenue 41.99 53.71 60.76
million
CNY 100
Net income attributable to parent 2.92 1.74 5.93
million
CNY 100
Total R&D investment 4.72 4.66 4.46
million
Proportion of R&D investment in operating
% 11.24 8.68 7.35
revenue
首页
微信公众号
证券之星APP
